[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQxVuBuRO6CJSpl4v5z0w31tVBcY66Tqjj9q4TofDmU4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":8,"truncated":9,"activeTrials":10,"phase3Count":11,"totalEnrollment":12,"activePrograms":13,"nonDrugCount":14,"topConditions":15,"upcomingReadouts":39,"phaseBuckets":40,"rows":47},"Allergan",[4,6,7],"Allergan Medical","Allergan S.A. DE C.V..",517,false,1,130,319701,0,113,[16,19,22,25,28,31,34,36],{"name":17,"count":18},"Ocular Hypertension",74,{"name":20,"count":21},"Glaucoma",32,{"name":23,"count":24},"Glaucoma, Open-Angle",31,{"name":26,"count":27},"Dry Eye Syndromes",29,{"name":29,"count":30},"Macular Edema",21,{"name":32,"count":33},"Muscle Spasticity",17,{"name":35,"count":33},"Overactive Bladder",{"name":37,"count":38},"Migraine Disorders",15,[],[41,42,43,44,45,46],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[48,180,278,379,439,493,553,614,654,702,734,778,815,837,870,903,931,966,995,1029,1065,1100,1122,1156,1178,1213,1249,1285,1309,1327,1345,1363,1381,1406,1424,1448,1471,1495,1513,1536,1561,1579,1597,1615,1633,1651,1669,1693,1711,1738,1756,1774,1792,1810,1834,1852,1870,1888,1906,1930,1948,1966,1984,2007,2025,2043,2065,2083,2107,2132,2150,2168,2186,2204,2227,2252,2270,2288,2306,2328,2350,2368,2391,2409,2432,2450,2468,2486,2510,2528,2554,2572,2590,2615,2633,2657,2742,2803,2859,2922,2984,3033,3080,3119,3166,3208,3246,3294,3326,3369,3413,3435,3469,3491,3524,3554,3593,3625,3647,3682,3704,3726,3748,3781,3813,3842,3864,3896,3928,3950,3972,3996,4014,4032,4050,4075,4093,4119,4137,4161,4179,4197,4222,4240,4264,4282,4300,4322,4349,4367,4385,4403,4421,4439,4457,4482,4500,4518,4542,4566,4594,4612,4639,4657,4675,4693,4711,4729,4754,4772,4790,4808,4826,4847,4865,4883,4908,4926,4949,4967,4991,5009,5036,5054,5072,5090,5114,5132,5150,5168,5186,5212,5230,5254,5272,5295,5313,5335,5357,5415,5462,5503,5529,5559,5585,5611,5651,5677,5717,5754,5776,5809,5834,5856,5878,5900,5922,5944,5966,5988,6010,6032,6063,6085,6110,6128,6152,6170,6188,6206,6224,6242,6267,6285,6303,6321,6339,6357,6375,6393,6418,6436,6454,6485,6503,6521,6539,6557,6575,6593,6611,6629,6655,6673,6696,6720,6738,6762,6780,6798,6816,6834,6852,6870,6888,6911,6929,6947,6972,6990,7008,7026,7044,7070,7088,7113,7131,7156,7177,7200,7218,7236,7258,7286,7304,7322,7340,7358,7384,7402,7420,7438,7456,7474,7498,7516,7538,7565,7583,7601,7624,7653,7671,7693,7718,7742,7765,7783,7801,7827,7845,7863,7907,7929,7951,7973,8002,8020,8038,8056,8074,8092,8113,8136,8157,8182,8200,8218,8236,8254,8277,8295,8313,8337,8355,8373,8391,8409,8427,8445,8463,8488,8506,8529,8547,8565,8583,8601,8619,8637,8661,8679,8697,8715,8733,8751,8769,8787,8805,8830,9271,9450,9626,9712,9779,9827,9874,9914,9942,9977,10010,10043,10065,10095,10117,10147,10174,10198,10220,10242,10265,10283,10306,10328,10346,10370,10392,10416,10440,10462,10486,10504,10528,10550,10572,10590,10608,10630,10652,10674,10692,10714,10732,10755,10779],{"intervention":49,"totalTrials":50,"cells":51},"ranibizumab",11,{"EARLY_PHASE1":52,"PHASE1":54,"PHASE2":56,"PHASE3":142,"PHASE4":165,"NA":178},{"trials":53,"activeCount":13},[],{"trials":55,"activeCount":13},[],{"trials":57,"activeCount":13},[58,72,84,95,104,113,123,135],{"nctId":59,"briefTitle":60,"status":61,"phases":62,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":70},"NCT00775411","Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)","COMPLETED",[43],"2009-11","2010-04","2008-11",44,[68,69],"Choroidal Neovascularization","Age-Related Maculopathy",[71,49],"dexamethasone",{"nctId":73,"briefTitle":74,"status":75,"phases":76,"primaryCompletion":77,"completion":77,"start":78,"enrollment":79,"conditions":80,"interventions":82},"NCT01122511","Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration","TERMINATED",[43],"2011-05","2010-08",4,[81,69],"Subfoveal Choroidal Neovascularization",[83,49],"700 ug dexamethasone",{"nctId":85,"briefTitle":86,"status":61,"phases":87,"primaryCompletion":88,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":93},"NCT02181504","A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration",[43],"2015-12","2014-09",25,[92],"Macular Degeneration",[94,49],"abicipar pegol",{"nctId":96,"briefTitle":97,"status":61,"phases":98,"primaryCompletion":99,"completion":99,"start":100,"enrollment":101,"conditions":102,"interventions":103},"NCT00511706","Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)",[43],"2009-03-01","2007-11-01",243,[68,69],[71,49],{"nctId":105,"briefTitle":106,"status":61,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT02186119","A Study of Abicipar Pegol in Patients With Diabetic Macular Edema",[43],"2015-06","2014-07",151,[29],[94,49],{"nctId":114,"briefTitle":115,"status":61,"phases":116,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":121},"NCT01492400","Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema",[43],"2014-02-13","2012-03-09",363,[29],[122,49],"dexamethasone Intravitreal Implant",{"nctId":124,"briefTitle":125,"status":61,"phases":126,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},"NCT01397409","Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)",[43],"2014-03-31","2014-04-30","2011-09-01",271,[132],"Age-related Macular Degeneration",[134,49],"AGN-150998",{"nctId":136,"briefTitle":137,"status":61,"phases":138,"primaryCompletion":139,"completion":139,"start":109,"enrollment":90,"conditions":140,"interventions":141},"NCT02181517","A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration",[43],"2015-03",[92],[94,49],{"trials":143,"activeCount":13},[144,156],{"nctId":145,"briefTitle":146,"status":61,"phases":147,"primaryCompletion":148,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":153},"NCT02462928","A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration",[44],"2018-04-18","2019-06-19","2015-06-25",939,[92],[154,155],"Abicipar Pegol","Ranibizumab",{"nctId":157,"briefTitle":158,"status":61,"phases":159,"primaryCompletion":160,"completion":161,"start":150,"enrollment":162,"conditions":163,"interventions":164},"NCT02462486","Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration",[44],"2018-04-12","2019-06-06",949,[92],[154,155],{"trials":166,"activeCount":13},[167],{"nctId":168,"briefTitle":169,"status":61,"phases":170,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":176},"NCT01427751","Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion",[45],"2014-11-04","2011-10-11",307,[175,29],"Retinal Vein Occlusion",[177,49],"dexamethasone intravitreal implant",{"trials":179,"activeCount":13},[],{"intervention":181,"totalTrials":182,"cells":183},"Vehicle",8,{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":233,"PHASE4":263,"NA":276},{"trials":185,"activeCount":13},[],{"trials":187,"activeCount":13},[],{"trials":189,"activeCount":13},[190,200,211,222],{"nctId":191,"briefTitle":192,"status":75,"phases":193,"primaryCompletion":194,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":198},"NCT02013791","Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease",[43],"2017-04-12","2014-04-29",55,[26],[181,199],"Cyclosporine New Ophthalmic Formulation",{"nctId":201,"briefTitle":202,"status":61,"phases":203,"primaryCompletion":77,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":209},"NCT01109056","Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium",[43],"2011-06","2010-06",115,[208],"Pterygium",[210,181],"cyclosporine ophthalmic emulsion 0.05%",{"nctId":212,"briefTitle":213,"status":214,"phases":215,"primaryCompletion":216,"completion":216,"start":217,"enrollment":13,"conditions":218,"interventions":220},"NCT05393089","Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia","WITHDRAWN",[43],"2023-04-04","2022-06-09",[219],"Presbyopia",[221,181],"AGN-190584",{"nctId":223,"briefTitle":224,"status":61,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"NCT02479139","Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis",[43],"2016-02-29","2015-06-03",145,[230],"Hyperhidrosis",[181,232],"ANT-1207",{"trials":234,"activeCount":13},[235,245,253],{"nctId":236,"briefTitle":237,"status":75,"phases":238,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":243},"NCT02815293","Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye",[44],"2017-06-21","2016-09-30",36,[26],[244,181],"AGN-195263",{"nctId":246,"briefTitle":237,"status":75,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":252},"NCT02965846",[44],"2017-06-13","2016-12-13",43,[26],[244,181],{"nctId":254,"briefTitle":255,"status":61,"phases":256,"primaryCompletion":257,"completion":257,"start":258,"enrollment":259,"conditions":260,"interventions":261},"NCT04983589","A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily",[44],"2022-02-11","2021-09-02",230,[219],[262,181],"Pilocarpine HCl",{"trials":264,"activeCount":13},[265],{"nctId":266,"briefTitle":267,"status":61,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":274},"NCT00243542","Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency",[45],"2006-10","2005-11",64,[273],"Acne Vulgaris",[275,181],"ACZONE Gel, 5%",{"trials":277,"activeCount":13},[],{"intervention":279,"totalTrials":280,"cells":281},"bimatoprost ophthalmic solution 0.03%",7,{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":336,"PHASE4":338,"NA":377},{"trials":283,"activeCount":13},[],{"trials":285,"activeCount":13},[],{"trials":287,"activeCount":13},[288,303,315,328],{"nctId":289,"briefTitle":290,"status":61,"phases":291,"primaryCompletion":77,"completion":204,"start":205,"enrollment":292,"conditions":293,"interventions":295},"NCT01110499","Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",[43],163,[17,294],"Primary Open-Angle Glaucoma",[296,297,298,299,300,301,302,279],"AGN-210961 Formulation 1","AGN-210961 Formulation 2","AGN-210961 Formulation 3","AGN-210961 Formulation 4","AGN-210961 Formulation 5","AGN-210961 Formulation 6","AGN-210961 Formulation 7",{"nctId":304,"briefTitle":305,"status":61,"phases":306,"primaryCompletion":307,"completion":307,"start":308,"enrollment":309,"conditions":310,"interventions":312},"NCT01064882","Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence",[43],"2010-07","2010-03",104,[311],"Eyelash Hypotrichosis",[313,314,279],"bimatoprost ophthalmic solution 0.005%","bimatoprost ophthalmic solution 0.015%",{"nctId":316,"briefTitle":317,"status":61,"phases":318,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":323},"NCT00809848","Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma",[42,43],"2009-05","2009-02",172,[17,20],[324,325,326,279,327],"AGN-210669 ophthalmic solution, 0.075%","AGN-210669 ophthalmic solution, 0.05%","AGN-210669 ophthalmic solution, 0.025%","AGN-210669 vehicle ophthalmic solution",{"nctId":329,"briefTitle":330,"status":61,"phases":331,"primaryCompletion":64,"completion":64,"start":63,"enrollment":332,"conditions":333,"interventions":334},"NCT01001195","Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution",[43],165,[23,17],[335,324,325,279],"AGN-210669 ophthalmic solution, 0.1%",{"trials":337,"activeCount":13},[],{"trials":339,"activeCount":13},[340,351,363],{"nctId":341,"briefTitle":342,"status":61,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":349},"NCT01448525","Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence",[45],"2012-04","2011-10",88,[348],"Hypotrichosis",[279,350],"bimatoprost vehicle solution",{"nctId":352,"briefTitle":353,"status":61,"phases":354,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":361},"NCT01023841","Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children",[45],"2012-11-02","2012-11-30","2010-06-01",71,[311,360],"Alopecia Areata",[279,362],"Vehicle Sterile Solution",{"nctId":364,"briefTitle":365,"status":61,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":375},"NCT02176356","Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)",[45],"2015-05-03","2014-06-30",116,[371,372,373,374],"Facial Rhytides","Crow's Feet Lines","Glabellar Lines","Nasolabial Fold",[376,279],"onabotulinumtoxinA",{"trials":378,"activeCount":13},[],{"intervention":350,"totalTrials":380,"cells":381},5,{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":412,"PHASE4":431,"NA":437},{"trials":383,"activeCount":13},[],{"trials":385,"activeCount":13},[],{"trials":387,"activeCount":13},[388,403],{"nctId":389,"briefTitle":390,"status":61,"phases":391,"primaryCompletion":392,"completion":393,"start":204,"enrollment":173,"conditions":394,"interventions":398},"NCT01325337","Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia",[43],"2012-08","2012-09",[395,396,397],"Alopecia","Alopecia, Androgenetic","Baldness",[399,400,401,350,402],"bimatoprost Formulation A","bimatoprost Formulation B","bimatoprost Formulation C","minoxidil 5% solution",{"nctId":404,"briefTitle":405,"status":61,"phases":406,"primaryCompletion":407,"completion":393,"start":204,"enrollment":408,"conditions":409,"interventions":410},"NCT01325350","Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss",[43],"2012-07",306,[395,397],[399,400,401,350,411],"minoxidil 2% solution",{"trials":413,"activeCount":13},[414,424],{"nctId":415,"briefTitle":416,"status":61,"phases":417,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":422},"NCT01391273","Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis",[44],"2012-05-19","2011-07-01",173,[311],[423,350],"bimatoprost solution 0.03%",{"nctId":425,"briefTitle":426,"status":61,"phases":427,"primaryCompletion":428,"completion":428,"start":419,"enrollment":241,"conditions":429,"interventions":430},"NCT01391286","Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis",[44],"2012-05-25",[311],[423,350],{"trials":432,"activeCount":13},[433],{"nctId":341,"briefTitle":342,"status":61,"phases":434,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":435,"interventions":436},[45],[348],[279,350],{"trials":438,"activeCount":13},[],{"intervention":440,"totalTrials":79,"cells":441},"trospium chloride",{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":491},{"trials":443,"activeCount":13},[],{"trials":445,"activeCount":13},[446],{"nctId":447,"briefTitle":448,"status":61,"phases":449,"primaryCompletion":63,"completion":63,"start":450,"enrollment":66,"conditions":451,"interventions":453},"NCT00986401","Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects",[42],"2009-10",[452],"Healthy",[454,455],"Trospium Chloride","Metformin hydrochloride",{"trials":457,"activeCount":13},[],{"trials":459,"activeCount":13},[],{"trials":461,"activeCount":13},[462,472,483],{"nctId":463,"briefTitle":464,"status":61,"phases":465,"primaryCompletion":466,"completion":466,"start":78,"enrollment":467,"conditions":468,"interventions":469},"NCT01178827","Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial",[45],"2011-03",20,[35],[440,470,471],"oxybutynin IR","oxybutynin IR placebo",{"nctId":473,"briefTitle":474,"status":61,"phases":475,"primaryCompletion":476,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":482},"NCT00863551","Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial",[45],"2009-08","2009-04",12,[480,481,35],"Elderly","Pharmacokinetics",[454],{"nctId":484,"briefTitle":485,"status":61,"phases":486,"primaryCompletion":487,"completion":487,"start":308,"enrollment":488,"conditions":489,"interventions":490},"NCT01089751","Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily",[45],"2012-06",322,[35],[440],{"trials":492,"activeCount":13},[],{"intervention":494,"totalTrials":79,"cells":495},"bimatoprost ophthalmic solution 0.01%",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":515,"PHASE4":517,"NA":551},{"trials":497,"activeCount":13},[],{"trials":499,"activeCount":13},[],{"trials":501,"activeCount":13},[502],{"nctId":503,"briefTitle":504,"status":61,"phases":505,"primaryCompletion":506,"completion":506,"start":507,"enrollment":508,"conditions":509,"interventions":510},"NCT01863953","A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension",[43],"2013-12","2013-06",112,[20,17],[511,512,513,514],"Fixed-Combination Bimatoprost\u002FBrimonidine","Bimatoprost Ophthalmic Solution 0.01%","Vehicle Ophthalmic Solution","Brimonidine Tartrate Ophthalmic Solution 0.2%",{"trials":516,"activeCount":13},[],{"trials":518,"activeCount":13},[519,529,540],{"nctId":520,"briefTitle":521,"status":61,"phases":522,"primaryCompletion":345,"completion":345,"start":523,"enrollment":524,"conditions":525,"interventions":526},"NCT01253902","Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension",[45],"2010-12",164,[23,17],[494,527,528],"travoprost ophthalmic solution 0.004%","latanoprost ophthalmic solution 0.005%",{"nctId":530,"briefTitle":531,"status":61,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":538},"NCT02863705","Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)",[45],"2018-07-25","2016-07-05",118,[23,537],"Normal Tension Glaucoma",[539,494],"brimonidine tartrate\u002Ftimolol malate Ophthalmic Solution",{"nctId":541,"briefTitle":542,"status":61,"phases":543,"primaryCompletion":544,"completion":544,"start":545,"enrollment":546,"conditions":547,"interventions":548},"NCT01547598","Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction",[45],"2013-07","2011-12",135,[23,17],[527,549,550],"travoprost 0.004% \u002F timolol 0.5% combination ophthalmic solution","Bimatoprost ophthalmic solution 0.01%",{"trials":552,"activeCount":13},[],{"intervention":554,"totalTrials":79,"cells":555},"Bimatoprost 0.03% Ophthalmic Solution",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":587,"PHASE4":599,"NA":612},{"trials":557,"activeCount":13},[],{"trials":559,"activeCount":13},[],{"trials":561,"activeCount":13},[562,573],{"nctId":563,"briefTitle":564,"status":61,"phases":565,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":570},"NCT00651859","Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension",[43],"2004-01","2002-11",111,[20,17],[571,554,572],"Bimatoprost 0.01% Ophthalmic Solution","Bimatoprost Vehicle Ophthalmic Solution",{"nctId":574,"briefTitle":575,"status":61,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT00652496","Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension",[43],"2005-05","2005-01",249,[20,17],[582,583,584,585,586],"Bimatoprost 0.01% ophthalmic solution","Bimatoprost 0.015% formulation 1 ophthalmic solution","Bimatoprost 0.015% formulation 2 ophthalmic solution","Bimatoprost 0.02% ophthalmic solution","Bimatoprost 0.03% ophthalmic solution",{"trials":588,"activeCount":13},[589],{"nctId":590,"briefTitle":591,"status":61,"phases":592,"primaryCompletion":593,"completion":593,"start":594,"enrollment":595,"conditions":596,"interventions":597},"NCT01099774","Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",[44],"2011-04-29","2010-05-01",597,[20,17],[598,554],"Bimatoprost 0.03% Formulation B Ophthalmic Solution",{"trials":600,"activeCount":13},[601],{"nctId":602,"briefTitle":603,"status":61,"phases":604,"primaryCompletion":605,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":609},"NCT01298700","Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",[45],"2016-12-06","2011-05-31",806,[20,17],[610,611],"bimatoprost 0.01% ophthalmic solution","bimatoprost 0.03% ophthalmic solution",{"trials":613,"activeCount":13},[],{"intervention":615,"totalTrials":616,"cells":617},"vehicle sterile solution",3,{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":638,"NA":652},{"trials":619,"activeCount":13},[],{"trials":621,"activeCount":13},[],{"trials":623,"activeCount":13},[],{"trials":625,"activeCount":13},[626],{"nctId":627,"briefTitle":628,"status":61,"phases":629,"primaryCompletion":630,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":636},"NCT00693420","Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence",[44],"2007-10","2007-12","2007-04",278,[635],"Eyelashes",[637,615],"Bimatoprost 0.03% sterile solution",{"trials":639,"activeCount":13},[640,648],{"nctId":641,"briefTitle":642,"status":61,"phases":643,"primaryCompletion":307,"completion":78,"start":63,"enrollment":644,"conditions":645,"interventions":646},"NCT00958035","Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis",[45],89,[348],[647,615],"bimatoprost ophthalmic 0.03% solution",{"nctId":352,"briefTitle":353,"status":61,"phases":649,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":650,"interventions":651},[45],[311,360],[279,362],{"trials":653,"activeCount":13},[],{"intervention":655,"totalTrials":616,"cells":656},"Usual Care",{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":663,"PHASE4":676,"NA":700},{"trials":658,"activeCount":13},[],{"trials":660,"activeCount":13},[],{"trials":662,"activeCount":13},[],{"trials":664,"activeCount":13},[665],{"nctId":666,"briefTitle":667,"status":61,"phases":668,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":674},"NCT02873221","An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine",[44],"2018-08-02","2016-09-13",1254,[673],"Migraine, With or Without Aura",[675,655],"Ubrogepant",{"trials":677,"activeCount":13},[678,689],{"nctId":679,"briefTitle":680,"status":61,"phases":681,"primaryCompletion":682,"completion":682,"start":683,"enrollment":684,"conditions":685,"interventions":687},"NCT02961764","Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)",[45],"2019-03-29","2016-11-29",313,[686],"Acute Bacterial Skin and Skin Structure Infections",[655,688],"Dalbavancin",{"nctId":690,"briefTitle":691,"status":61,"phases":692,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":696,"interventions":699},"NCT03233438","Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)",[45],"2018-10-30","2017-07-24",91,[697,698],"Bacterial Infections","Acute Bacterial Skin and Skin Structure Infection",[688,655],{"trials":701,"activeCount":13},[],{"intervention":688,"totalTrials":616,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":720,"PHASE4":722,"NA":732},{"trials":705,"activeCount":13},[],{"trials":707,"activeCount":13},[],{"trials":709,"activeCount":13},[710],{"nctId":711,"briefTitle":712,"status":75,"phases":713,"primaryCompletion":714,"completion":714,"start":715,"enrollment":10,"conditions":716,"interventions":718},"NCT03091439","Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis",[43],"2017-08-31","2017-05-15",[717],"Osteomyelitis",[688,719],"Standard of Care",{"trials":721,"activeCount":13},[],{"trials":723,"activeCount":13},[724,728],{"nctId":679,"briefTitle":680,"status":61,"phases":725,"primaryCompletion":682,"completion":682,"start":683,"enrollment":684,"conditions":726,"interventions":727},[45],[686],[655,688],{"nctId":690,"briefTitle":691,"status":61,"phases":729,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":730,"interventions":731},[45],[697,698],[688,655],{"trials":733,"activeCount":13},[],{"intervention":735,"totalTrials":616,"cells":736},"sodium hyaluronate 0.18%",{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":745,"NA":776},{"trials":738,"activeCount":13},[],{"trials":740,"activeCount":13},[],{"trials":742,"activeCount":13},[],{"trials":744,"activeCount":13},[],{"trials":746,"activeCount":13},[747,757,765],{"nctId":748,"briefTitle":749,"status":61,"phases":750,"primaryCompletion":307,"completion":751,"start":63,"enrollment":752,"conditions":753,"interventions":755},"NCT00987727","Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye",[45],"2010-09",82,[26,754],"Keratoconjunctivitis Sicca",[756,735],"carboxymethylcellulose 0.5% , glycerin 0.9%",{"nctId":758,"briefTitle":759,"status":61,"phases":760,"primaryCompletion":761,"completion":761,"start":761,"enrollment":358,"conditions":762,"interventions":763},"NCT00938704","Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms",[45],"2009-06",[26],[764,735],"carboxymethylcellulose 0.5% +glycerin 0.9%",{"nctId":766,"briefTitle":767,"status":61,"phases":768,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":774},"NCT02117687","A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye",[45],"2015-01-27","2015-03-17","2014-05-14",80,[26,754],[775,735],"carboxymethylcellulose 0.5%\u002Fglycerin 0.9%",{"trials":777,"activeCount":13},[],{"intervention":779,"totalTrials":780,"cells":781},"timolol 0.5%",2,{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":790,"NA":813},{"trials":783,"activeCount":13},[],{"trials":785,"activeCount":13},[],{"trials":787,"activeCount":13},[],{"trials":789,"activeCount":13},[],{"trials":791,"activeCount":13},[792,803],{"nctId":793,"briefTitle":794,"status":61,"phases":795,"primaryCompletion":796,"completion":796,"start":507,"enrollment":797,"conditions":798,"interventions":799},"NCT01881126","An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension",[45],"2014-10",93,[20,17],[800,801,779,802],"bimatoprost 0.01%","travatan 0.004%","hypromellose 0.3%",{"nctId":804,"briefTitle":805,"status":61,"phases":806,"primaryCompletion":807,"completion":807,"start":808,"enrollment":809,"conditions":810,"interventions":811},"NCT02097719","Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension",[45],"2014-12","2014-05",100,[20,17],[800,812,779,802],"travoprost 0.004%",{"trials":814,"activeCount":13},[],{"intervention":802,"totalTrials":780,"cells":816},{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":825,"NA":835},{"trials":818,"activeCount":13},[],{"trials":820,"activeCount":13},[],{"trials":822,"activeCount":13},[],{"trials":824,"activeCount":13},[],{"trials":826,"activeCount":13},[827,831],{"nctId":793,"briefTitle":794,"status":61,"phases":828,"primaryCompletion":796,"completion":796,"start":507,"enrollment":797,"conditions":829,"interventions":830},[45],[20,17],[800,801,779,802],{"nctId":804,"briefTitle":805,"status":61,"phases":832,"primaryCompletion":807,"completion":807,"start":808,"enrollment":809,"conditions":833,"interventions":834},[45],[20,17],[800,812,779,802],{"trials":836,"activeCount":13},[],{"intervention":838,"totalTrials":780,"cells":839},"bimatoprost 0.03% eye drops",{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":846,"PHASE4":848,"NA":868},{"trials":841,"activeCount":13},[],{"trials":843,"activeCount":13},[],{"trials":845,"activeCount":13},[],{"trials":847,"activeCount":13},[],{"trials":849,"activeCount":13},[850,859],{"nctId":851,"briefTitle":852,"status":61,"phases":853,"primaryCompletion":630,"completion":630,"start":854,"enrollment":855,"conditions":856,"interventions":857},"NCT00440011","Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%",[45],"2006-08",266,[20,17],[838,858],"travoprost 0.004% eye drops",{"nctId":860,"briefTitle":861,"status":61,"phases":862,"primaryCompletion":863,"completion":863,"start":631,"enrollment":864,"conditions":865,"interventions":866},"NCT00541242","Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension",[45],"2008-08",586,[17,20],[838,867],"latanoprost 0.005% eye drops",{"trials":869,"activeCount":13},[],{"intervention":871,"totalTrials":780,"cells":872},"fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution",{"EARLY_PHASE1":873,"PHASE1":875,"PHASE2":877,"PHASE3":879,"PHASE4":881,"NA":901},{"trials":874,"activeCount":13},[],{"trials":876,"activeCount":13},[],{"trials":878,"activeCount":13},[],{"trials":880,"activeCount":13},[],{"trials":882,"activeCount":13},[883,893],{"nctId":884,"briefTitle":885,"status":61,"phases":886,"primaryCompletion":887,"completion":887,"start":888,"enrollment":889,"conditions":890,"interventions":891},"NCT00811564","An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%\u002F Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects",[45],"2010-01","2008-12",148,[20,17],[871,892],"latanoprost 0.005%",{"nctId":894,"briefTitle":895,"status":61,"phases":896,"primaryCompletion":897,"completion":897,"start":888,"enrollment":38,"conditions":898,"interventions":899},"NCT00811850","Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow",[45],"2009-12",[20],[871,900],"fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution",{"trials":902,"activeCount":13},[],{"intervention":892,"totalTrials":780,"cells":904},{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":913,"NA":929},{"trials":906,"activeCount":13},[],{"trials":908,"activeCount":13},[],{"trials":910,"activeCount":13},[],{"trials":912,"activeCount":13},[],{"trials":914,"activeCount":13},[915,919],{"nctId":884,"briefTitle":885,"status":61,"phases":916,"primaryCompletion":887,"completion":887,"start":888,"enrollment":889,"conditions":917,"interventions":918},[45],[20,17],[871,892],{"nctId":920,"briefTitle":921,"status":61,"phases":922,"primaryCompletion":897,"completion":897,"start":923,"enrollment":924,"conditions":925,"interventions":926},"NCT00735449","Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects",[45],"2008-07",204,[20,17],[927,928,892],"Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%","timolol maleate 0.5%",{"trials":930,"activeCount":13},[],{"intervention":932,"totalTrials":780,"cells":933},"Botox",{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":947,"PHASE3":949,"PHASE4":951,"NA":964},{"trials":935,"activeCount":13},[],{"trials":937,"activeCount":13},[938],{"nctId":939,"briefTitle":940,"status":61,"phases":941,"primaryCompletion":942,"completion":942,"start":943,"enrollment":321,"conditions":944,"interventions":946},"NCT04631588","Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines",[42],"2021-11-03","2020-11-16",[945],"Facial Fine Lines",[932],{"trials":948,"activeCount":13},[],{"trials":950,"activeCount":13},[],{"trials":952,"activeCount":13},[953],{"nctId":954,"briefTitle":955,"status":61,"phases":956,"primaryCompletion":957,"completion":957,"start":958,"enrollment":271,"conditions":959,"interventions":962},"NCT04609020","Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment",[45],"2024-05-10","2023-02-15",[371,960,961],"Skin Folds","Loss of Volume and Skin Quality",[963],"BOTOX",{"trials":965,"activeCount":13},[],{"intervention":867,"totalTrials":780,"cells":967},{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":974,"PHASE4":976,"NA":993},{"trials":969,"activeCount":13},[],{"trials":971,"activeCount":13},[],{"trials":973,"activeCount":13},[],{"trials":975,"activeCount":13},[],{"trials":977,"activeCount":13},[978,982],{"nctId":860,"briefTitle":861,"status":61,"phases":979,"primaryCompletion":863,"completion":863,"start":631,"enrollment":864,"conditions":980,"interventions":981},[45],[17,20],[838,867],{"nctId":983,"briefTitle":984,"status":61,"phases":985,"primaryCompletion":923,"completion":986,"start":987,"enrollment":988,"conditions":989,"interventions":991},"NCT00539526","Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues",[45],"2008-09","2007-09",106,[990,17],"Open Angle Glaucoma",[992,812,867],"Bimatoprost 0.03%",{"trials":994,"activeCount":13},[],{"intervention":996,"totalTrials":780,"cells":997},"Brimonidine 0.2%\u002FTimolol 0.5% Fixed Combination Ophthalmic Solution",{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1015,"NA":1027},{"trials":999,"activeCount":13},[],{"trials":1001,"activeCount":13},[],{"trials":1003,"activeCount":13},[],{"trials":1005,"activeCount":13},[1006],{"nctId":1007,"briefTitle":1008,"status":61,"phases":1009,"primaryCompletion":1010,"completion":1010,"start":270,"enrollment":1011,"conditions":1012,"interventions":1013},"NCT00651612","Study to Evaluate Safety of Brimonidine\u002FTimolol Fixed Combination in Glaucoma or Ocular Hypertension Patients",[44],"2007-01",604,[20,17],[996,1014],"Concurrent brimonidine 0.2% and 0.5% timolol",{"trials":1016,"activeCount":13},[1017],{"nctId":1018,"briefTitle":1019,"status":75,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":63,"enrollment":33,"conditions":1022,"interventions":1024},"NCT01151904","Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients",[45],"2012-02",[1023],"Glaucoma, Angle-Closure",[1025,1026],"brimonidine 0.2%\u002Ftimolol 0.5% fixed combination ophthalmic solution","latanoprost",{"trials":1028,"activeCount":13},[],{"intervention":1030,"totalTrials":780,"cells":1031},"latanoprost 0.005% ophthalmic solution",{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1040,"NA":1063},{"trials":1033,"activeCount":13},[],{"trials":1035,"activeCount":13},[],{"trials":1037,"activeCount":13},[],{"trials":1039,"activeCount":13},[],{"trials":1041,"activeCount":13},[1042,1054],{"nctId":1043,"briefTitle":1044,"status":61,"phases":1045,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":1048,"conditions":1049,"interventions":1050},"NCT01525173","A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension",[45],"2012-10","2012-01",137,[20,17],[1051,1052,1053,1030],"0.1% brimonidine tartrate ophthalmic solution","0.01% bimatoprost ophthalmic solution","0.2% hypromellose lubricant eye drops",{"nctId":1055,"briefTitle":1056,"status":61,"phases":1057,"primaryCompletion":1058,"completion":1058,"start":357,"enrollment":1059,"conditions":1060,"interventions":1061},"NCT01243567","Safety and Efficacy of Bimatoprost\u002FTimolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated",[45],"2012-02-14",81,[23],[1062,1030],"bimatoprost 0.03%\u002Ftimolol 0.5% combination ophthalmic solution",{"trials":1064,"activeCount":13},[],{"intervention":1066,"totalTrials":780,"cells":1067},"tazarotene cream 0.1%",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1083,"PHASE3":1085,"PHASE4":1087,"NA":1098},{"trials":1069,"activeCount":13},[],{"trials":1071,"activeCount":13},[1072],{"nctId":1073,"briefTitle":1074,"status":61,"phases":1075,"primaryCompletion":139,"completion":139,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1079},"NCT02218034","Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris",[42],"2014-08",78,[273],[1080,1081,1082,1066],"AGN-190168 Formulation 1","AGN-190168 Formulation 2","tazarotene gel 0.1%",{"trials":1084,"activeCount":13},[],{"trials":1086,"activeCount":13},[],{"trials":1088,"activeCount":13},[1089],{"nctId":1090,"briefTitle":1091,"status":75,"phases":1092,"primaryCompletion":1093,"completion":1093,"start":630,"enrollment":332,"conditions":1094,"interventions":1095},"NCT00829049","Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris",[45],"2008-10",[273],[1096,1097],"Tazarotene Cream 0.1%","Adapalene",{"trials":1099,"activeCount":13},[],{"intervention":527,"totalTrials":780,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1110,"NA":1120},{"trials":1103,"activeCount":13},[],{"trials":1105,"activeCount":13},[],{"trials":1107,"activeCount":13},[],{"trials":1109,"activeCount":13},[],{"trials":1111,"activeCount":13},[1112,1116],{"nctId":520,"briefTitle":521,"status":61,"phases":1113,"primaryCompletion":345,"completion":345,"start":523,"enrollment":524,"conditions":1114,"interventions":1115},[45],[23,17],[494,527,528],{"nctId":541,"briefTitle":542,"status":61,"phases":1117,"primaryCompletion":544,"completion":544,"start":545,"enrollment":546,"conditions":1118,"interventions":1119},[45],[23,17],[527,549,550],{"trials":1121,"activeCount":13},[],{"intervention":1123,"totalTrials":780,"cells":1124},"Eluxadoline",{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1131,"PHASE4":1133,"NA":1154},{"trials":1126,"activeCount":13},[],{"trials":1128,"activeCount":13},[],{"trials":1130,"activeCount":13},[],{"trials":1132,"activeCount":13},[],{"trials":1134,"activeCount":13},[1135,1145],{"nctId":1136,"briefTitle":1137,"status":61,"phases":1138,"primaryCompletion":1139,"completion":1139,"start":1140,"enrollment":1141,"conditions":1142,"interventions":1144},"NCT03441581","Eluxadoline Bile Acid Malabsorption (BAM) Study",[45],"2020-04-28","2018-02-23",24,[1143],"Irritable Bowel Syndrome With Diarrhea",[1123],{"nctId":1146,"briefTitle":1147,"status":61,"phases":1148,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":1152,"interventions":1153},"NCT02959983","Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use",[45],"2018-01-22","2016-10-25",346,[1143],[1123],{"trials":1155,"activeCount":13},[],{"intervention":812,"totalTrials":780,"cells":1157},{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1164,"PHASE4":1166,"NA":1176},{"trials":1159,"activeCount":13},[],{"trials":1161,"activeCount":13},[],{"trials":1163,"activeCount":13},[],{"trials":1165,"activeCount":13},[],{"trials":1167,"activeCount":13},[1168,1172],{"nctId":983,"briefTitle":984,"status":61,"phases":1169,"primaryCompletion":923,"completion":986,"start":987,"enrollment":988,"conditions":1170,"interventions":1171},[45],[990,17],[992,812,867],{"nctId":804,"briefTitle":805,"status":61,"phases":1173,"primaryCompletion":807,"completion":807,"start":808,"enrollment":809,"conditions":1174,"interventions":1175},[45],[20,17],[800,812,779,802],{"trials":1177,"activeCount":13},[],{"intervention":1179,"totalTrials":780,"cells":1180},"Cyclosporine 0.05% Ophthalmic Emulsion",{"EARLY_PHASE1":1181,"PHASE1":1183,"PHASE2":1185,"PHASE3":1187,"PHASE4":1189,"NA":1211},{"trials":1182,"activeCount":13},[],{"trials":1184,"activeCount":13},[],{"trials":1186,"activeCount":13},[],{"trials":1188,"activeCount":13},[],{"trials":1190,"activeCount":13},[1191,1200],{"nctId":1192,"briefTitle":1193,"status":61,"phases":1194,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":1197,"conditions":1198,"interventions":1199},"NCT02554981","Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®",[45],"2016-03-24","2015-07-21",51,[26],[1179],{"nctId":1201,"briefTitle":1202,"status":61,"phases":1203,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":1207,"interventions":1208},"NCT02121847","Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy",[45],"2014-09-23","2014-04-03",40,[26],[1209,1210],"cyclosporine 0.05% ophthalmic emulsion","carboxymethylcellulose-based lubricant eye drops",{"trials":1212,"activeCount":13},[],{"intervention":1214,"totalTrials":780,"cells":1215},"dextran 70 0.1%\u002Fhydroxypropyl methylcellulose 0.3%",{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1222,"PHASE4":1224,"NA":1247},{"trials":1217,"activeCount":13},[],{"trials":1219,"activeCount":13},[],{"trials":1221,"activeCount":13},[],{"trials":1223,"activeCount":13},[],{"trials":1225,"activeCount":13},[1226,1238],{"nctId":1227,"briefTitle":1228,"status":61,"phases":1229,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":1233,"interventions":1235},"NCT01732757","A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis",[45],"2012-12","2012-11",157,[1234],"Conjunctivitis, Allergic",[1236,1237,1214],"Alcaftadine 0.25%","Olopatadine 0.2%",{"nctId":1239,"briefTitle":1240,"status":61,"phases":1241,"primaryCompletion":545,"completion":545,"start":345,"enrollment":1242,"conditions":1243,"interventions":1244},"NCT01470118","A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis",[45],127,[1234],[1245,1246,1214],"alcaftadine 0.25% ophthalmic solution","olopatadine 0.2% ophthalmic solution",{"trials":1248,"activeCount":13},[],{"intervention":1250,"totalTrials":780,"cells":1251},"BELKYRA®",{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1256,"PHASE3":1258,"PHASE4":1260,"NA":1283},{"trials":1253,"activeCount":13},[],{"trials":1255,"activeCount":13},[],{"trials":1257,"activeCount":13},[],{"trials":1259,"activeCount":13},[],{"trials":1261,"activeCount":13},[1262,1273],{"nctId":1263,"briefTitle":1264,"status":61,"phases":1265,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":1268,"conditions":1269,"interventions":1271},"NCT03712449","A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment",[45],"2020-07-29","2019-01-22",59,[1270],"Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality",[1272,1250],"BOTOX Cosmetic®",{"nctId":1274,"briefTitle":1275,"status":61,"phases":1276,"primaryCompletion":1277,"completion":1277,"start":1278,"enrollment":1279,"conditions":1280,"interventions":1282},"NCT03425253","Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour",[45],"2019-12-05","2018-02-02",58,[1281],"Contour",[1250],{"trials":1284,"activeCount":13},[],{"intervention":1286,"totalTrials":10,"cells":1287},"bimatoprost 0.03% plus timolol 0.5%",{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1292,"PHASE3":1294,"PHASE4":1296,"NA":1307},{"trials":1289,"activeCount":13},[],{"trials":1291,"activeCount":13},[],{"trials":1293,"activeCount":13},[],{"trials":1295,"activeCount":13},[],{"trials":1297,"activeCount":13},[1298],{"nctId":1299,"briefTitle":1300,"status":61,"phases":1301,"primaryCompletion":1302,"completion":1302,"start":1303,"enrollment":1304,"conditions":1305,"interventions":1306},"NCT02571712","Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension",[45],"2018-06-21","2015-11-10",750,[23,17],[1286],{"trials":1308,"activeCount":13},[],{"intervention":801,"totalTrials":10,"cells":1310},{"EARLY_PHASE1":1311,"PHASE1":1313,"PHASE2":1315,"PHASE3":1317,"PHASE4":1319,"NA":1325},{"trials":1312,"activeCount":13},[],{"trials":1314,"activeCount":13},[],{"trials":1316,"activeCount":13},[],{"trials":1318,"activeCount":13},[],{"trials":1320,"activeCount":13},[1321],{"nctId":793,"briefTitle":794,"status":61,"phases":1322,"primaryCompletion":796,"completion":796,"start":507,"enrollment":797,"conditions":1323,"interventions":1324},[45],[20,17],[800,801,779,802],{"trials":1326,"activeCount":13},[],{"intervention":858,"totalTrials":10,"cells":1328},{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1337,"NA":1343},{"trials":1330,"activeCount":13},[],{"trials":1332,"activeCount":13},[],{"trials":1334,"activeCount":13},[],{"trials":1336,"activeCount":13},[],{"trials":1338,"activeCount":13},[1339],{"nctId":851,"briefTitle":852,"status":61,"phases":1340,"primaryCompletion":630,"completion":630,"start":854,"enrollment":855,"conditions":1341,"interventions":1342},[45],[20,17],[838,858],{"trials":1344,"activeCount":13},[],{"intervention":470,"totalTrials":10,"cells":1346},{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1353,"PHASE4":1355,"NA":1361},{"trials":1348,"activeCount":13},[],{"trials":1350,"activeCount":13},[],{"trials":1352,"activeCount":13},[],{"trials":1354,"activeCount":13},[],{"trials":1356,"activeCount":13},[1357],{"nctId":463,"briefTitle":464,"status":61,"phases":1358,"primaryCompletion":466,"completion":466,"start":78,"enrollment":467,"conditions":1359,"interventions":1360},[45],[35],[440,470,471],{"trials":1362,"activeCount":13},[],{"intervention":471,"totalTrials":10,"cells":1364},{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1371,"PHASE4":1373,"NA":1379},{"trials":1366,"activeCount":13},[],{"trials":1368,"activeCount":13},[],{"trials":1370,"activeCount":13},[],{"trials":1372,"activeCount":13},[],{"trials":1374,"activeCount":13},[1375],{"nctId":463,"briefTitle":464,"status":61,"phases":1376,"primaryCompletion":466,"completion":466,"start":78,"enrollment":467,"conditions":1377,"interventions":1378},[45],[35],[440,470,471],{"trials":1380,"activeCount":13},[],{"intervention":1382,"totalTrials":10,"cells":1383},"Topiramate",{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1392,"NA":1404},{"trials":1385,"activeCount":13},[],{"trials":1387,"activeCount":13},[],{"trials":1389,"activeCount":13},[],{"trials":1391,"activeCount":13},[],{"trials":1393,"activeCount":13},[1394],{"nctId":1395,"briefTitle":1396,"status":61,"phases":1397,"primaryCompletion":1398,"completion":1399,"start":1400,"enrollment":1401,"conditions":1402,"interventions":1403},"NCT02191579","Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults",[45],"2017-05-09","2017-09-01","2014-08-05",282,[37],[376,1382],{"trials":1405,"activeCount":13},[],{"intervention":275,"totalTrials":10,"cells":1407},{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1412,"PHASE3":1414,"PHASE4":1416,"NA":1422},{"trials":1409,"activeCount":13},[],{"trials":1411,"activeCount":13},[],{"trials":1413,"activeCount":13},[],{"trials":1415,"activeCount":13},[],{"trials":1417,"activeCount":13},[1418],{"nctId":266,"briefTitle":267,"status":61,"phases":1419,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":1420,"interventions":1421},[45],[273],[275,181],{"trials":1423,"activeCount":13},[],{"intervention":1425,"totalTrials":10,"cells":1426},"Eflornithine hydrochloride",{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1431,"PHASE3":1433,"PHASE4":1435,"NA":1446},{"trials":1428,"activeCount":13},[],{"trials":1430,"activeCount":13},[],{"trials":1432,"activeCount":13},[],{"trials":1434,"activeCount":13},[],{"trials":1436,"activeCount":13},[1437],{"nctId":1438,"briefTitle":1439,"status":61,"phases":1440,"completion":1441,"start":1442,"enrollment":1077,"conditions":1443,"interventions":1445},"NCT00152048","Evaluation of Eflornithine on Facial and Forearm Skin",[45],"2005-10-31","2004-11-30",[1444],"Hirsutism",[1425],{"trials":1447,"activeCount":13},[],{"intervention":1449,"totalTrials":10,"cells":1450},"0.15% Brimonidine Tartrate",{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1457,"PHASE4":1459,"NA":1469},{"trials":1452,"activeCount":13},[],{"trials":1454,"activeCount":13},[],{"trials":1456,"activeCount":13},[],{"trials":1458,"activeCount":13},[],{"trials":1460,"activeCount":13},[1461],{"nctId":1462,"briefTitle":1463,"status":61,"phases":1464,"primaryCompletion":1465,"completion":1465,"start":307,"enrollment":1466,"conditions":1467,"interventions":1468},"NCT02003534","A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension",[45],"2013-02",376,[23,17],[1449],{"trials":1470,"activeCount":13},[],{"intervention":1472,"totalTrials":10,"cells":1473},"latanoprost 0.005% eye drops and brimonidine 0.1% eye drops",{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1480,"PHASE4":1482,"NA":1493},{"trials":1475,"activeCount":13},[],{"trials":1477,"activeCount":13},[],{"trials":1479,"activeCount":13},[],{"trials":1481,"activeCount":13},[],{"trials":1483,"activeCount":13},[1484],{"nctId":1485,"briefTitle":1486,"status":61,"phases":1487,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1206,"conditions":1490,"interventions":1491},"NCT00440141","Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%",[45],"2007-03","2006-07",[20,17],[1472,1492],"latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops",{"trials":1494,"activeCount":13},[],{"intervention":1492,"totalTrials":10,"cells":1496},{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1503,"PHASE4":1505,"NA":1511},{"trials":1498,"activeCount":13},[],{"trials":1500,"activeCount":13},[],{"trials":1502,"activeCount":13},[],{"trials":1504,"activeCount":13},[],{"trials":1506,"activeCount":13},[1507],{"nctId":1485,"briefTitle":1486,"status":61,"phases":1508,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":1206,"conditions":1509,"interventions":1510},[45],[20,17],[1472,1492],{"trials":1512,"activeCount":13},[],{"intervention":1514,"totalTrials":10,"cells":1515},"brimonidine 0.1%",{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1534},{"trials":1517,"activeCount":13},[],{"trials":1519,"activeCount":13},[],{"trials":1521,"activeCount":13},[],{"trials":1523,"activeCount":13},[],{"trials":1525,"activeCount":13},[1526],{"nctId":1527,"briefTitle":1528,"status":61,"phases":1529,"primaryCompletion":320,"completion":320,"start":1530,"enrollment":38,"conditions":1531,"interventions":1533},"NCT00457795","24-hour IOP-lowering Effect of Brimonidine 0.1%",[45],"2006-12",[1532,17],"Open-angle Glaucoma",[1514],{"trials":1535,"activeCount":13},[],{"intervention":1537,"totalTrials":10,"cells":1538},"A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®",{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1545,"PHASE4":1547,"NA":1559},{"trials":1540,"activeCount":13},[],{"trials":1542,"activeCount":13},[],{"trials":1544,"activeCount":13},[],{"trials":1546,"activeCount":13},[],{"trials":1548,"activeCount":13},[1549],{"nctId":1550,"briefTitle":1551,"status":61,"phases":1552,"primaryCompletion":1553,"completion":1553,"start":1554,"enrollment":1555,"conditions":1556,"interventions":1557},"NCT00761202","Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms",[45],"2008-06","2007-08",50,[26],[1537,1558],"Sodium hyaluronate",{"trials":1560,"activeCount":13},[],{"intervention":1558,"totalTrials":10,"cells":1562},{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1569,"PHASE4":1571,"NA":1577},{"trials":1564,"activeCount":13},[],{"trials":1566,"activeCount":13},[],{"trials":1568,"activeCount":13},[],{"trials":1570,"activeCount":13},[],{"trials":1572,"activeCount":13},[1573],{"nctId":1550,"briefTitle":1551,"status":61,"phases":1574,"primaryCompletion":1553,"completion":1553,"start":1554,"enrollment":1555,"conditions":1575,"interventions":1576},[45],[26],[1537,1558],{"trials":1578,"activeCount":13},[],{"intervention":1051,"totalTrials":10,"cells":1580},{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1587,"PHASE4":1589,"NA":1595},{"trials":1582,"activeCount":13},[],{"trials":1584,"activeCount":13},[],{"trials":1586,"activeCount":13},[],{"trials":1588,"activeCount":13},[],{"trials":1590,"activeCount":13},[1591],{"nctId":1043,"briefTitle":1044,"status":61,"phases":1592,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":1048,"conditions":1593,"interventions":1594},[45],[20,17],[1051,1052,1053,1030],{"trials":1596,"activeCount":13},[],{"intervention":1052,"totalTrials":10,"cells":1598},{"EARLY_PHASE1":1599,"PHASE1":1601,"PHASE2":1603,"PHASE3":1605,"PHASE4":1607,"NA":1613},{"trials":1600,"activeCount":13},[],{"trials":1602,"activeCount":13},[],{"trials":1604,"activeCount":13},[],{"trials":1606,"activeCount":13},[],{"trials":1608,"activeCount":13},[1609],{"nctId":1043,"briefTitle":1044,"status":61,"phases":1610,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":1048,"conditions":1611,"interventions":1612},[45],[20,17],[1051,1052,1053,1030],{"trials":1614,"activeCount":13},[],{"intervention":1053,"totalTrials":10,"cells":1616},{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1621,"PHASE3":1623,"PHASE4":1625,"NA":1631},{"trials":1618,"activeCount":13},[],{"trials":1620,"activeCount":13},[],{"trials":1622,"activeCount":13},[],{"trials":1624,"activeCount":13},[],{"trials":1626,"activeCount":13},[1627],{"nctId":1043,"briefTitle":1044,"status":61,"phases":1628,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":1048,"conditions":1629,"interventions":1630},[45],[20,17],[1051,1052,1053,1030],{"trials":1632,"activeCount":13},[],{"intervention":900,"totalTrials":10,"cells":1634},{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1641,"PHASE4":1643,"NA":1649},{"trials":1636,"activeCount":13},[],{"trials":1638,"activeCount":13},[],{"trials":1640,"activeCount":13},[],{"trials":1642,"activeCount":13},[],{"trials":1644,"activeCount":13},[1645],{"nctId":894,"briefTitle":895,"status":61,"phases":1646,"primaryCompletion":897,"completion":897,"start":888,"enrollment":38,"conditions":1647,"interventions":1648},[45],[20],[871,900],{"trials":1650,"activeCount":13},[],{"intervention":528,"totalTrials":10,"cells":1652},{"EARLY_PHASE1":1653,"PHASE1":1655,"PHASE2":1657,"PHASE3":1659,"PHASE4":1661,"NA":1667},{"trials":1654,"activeCount":13},[],{"trials":1656,"activeCount":13},[],{"trials":1658,"activeCount":13},[],{"trials":1660,"activeCount":13},[],{"trials":1662,"activeCount":13},[1663],{"nctId":520,"briefTitle":521,"status":61,"phases":1664,"primaryCompletion":345,"completion":345,"start":523,"enrollment":524,"conditions":1665,"interventions":1666},[45],[23,17],[494,527,528],{"trials":1668,"activeCount":13},[],{"intervention":1670,"totalTrials":10,"cells":1671},"dexamethasone implant",{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1678,"PHASE4":1680,"NA":1691},{"trials":1673,"activeCount":13},[],{"trials":1675,"activeCount":13},[],{"trials":1677,"activeCount":13},[],{"trials":1679,"activeCount":13},[],{"trials":1681,"activeCount":13},[1682],{"nctId":1683,"briefTitle":1684,"status":61,"phases":1685,"primaryCompletion":1686,"completion":1687,"start":1688,"enrollment":358,"conditions":1689,"interventions":1690},"NCT01903720","A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion",[45],"2014-09-24","2015-03-30","2013-07-16",[29,175],[1670],{"trials":1692,"activeCount":13},[],{"intervention":756,"totalTrials":10,"cells":1694},{"EARLY_PHASE1":1695,"PHASE1":1697,"PHASE2":1699,"PHASE3":1701,"PHASE4":1703,"NA":1709},{"trials":1696,"activeCount":13},[],{"trials":1698,"activeCount":13},[],{"trials":1700,"activeCount":13},[],{"trials":1702,"activeCount":13},[],{"trials":1704,"activeCount":13},[1705],{"nctId":748,"briefTitle":749,"status":61,"phases":1706,"primaryCompletion":307,"completion":751,"start":63,"enrollment":752,"conditions":1707,"interventions":1708},[45],[26,754],[756,735],{"trials":1710,"activeCount":13},[],{"intervention":1712,"totalTrials":10,"cells":1713},"brimonidine tartrate 0.2%\u002Ftimolol maleate 0.5% fixed combination",{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1718,"PHASE3":1720,"PHASE4":1722,"NA":1736},{"trials":1715,"activeCount":13},[],{"trials":1717,"activeCount":13},[],{"trials":1719,"activeCount":13},[],{"trials":1721,"activeCount":13},[],{"trials":1723,"activeCount":13},[1724],{"nctId":1725,"briefTitle":1726,"status":61,"phases":1727,"primaryCompletion":1728,"completion":1728,"start":577,"enrollment":1729,"conditions":1730,"interventions":1732},"NCT00822055","Comparison of the Fixed Combinations of Brimonidine\u002FTimolol and Dorzolamide\u002FTimolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension",[45],"2006-11",140,[1731,17],"Open-Angle Glaucoma",[1712,1733,1734,1735],"dorzolamide hcl 2%\u002Ftimolol maleate 0.5% fixed combination","brimonidine tartrate 0.2%\u002Ftimolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy","dorzolamide hcl 2%\u002Ftimolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy",{"trials":1737,"activeCount":13},[],{"intervention":1733,"totalTrials":10,"cells":1739},{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1746,"PHASE4":1748,"NA":1754},{"trials":1741,"activeCount":13},[],{"trials":1743,"activeCount":13},[],{"trials":1745,"activeCount":13},[],{"trials":1747,"activeCount":13},[],{"trials":1749,"activeCount":13},[1750],{"nctId":1725,"briefTitle":1726,"status":61,"phases":1751,"primaryCompletion":1728,"completion":1728,"start":577,"enrollment":1729,"conditions":1752,"interventions":1753},[45],[1731,17],[1712,1733,1734,1735],{"trials":1755,"activeCount":13},[],{"intervention":1734,"totalTrials":10,"cells":1757},{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1762,"PHASE3":1764,"PHASE4":1766,"NA":1772},{"trials":1759,"activeCount":13},[],{"trials":1761,"activeCount":13},[],{"trials":1763,"activeCount":13},[],{"trials":1765,"activeCount":13},[],{"trials":1767,"activeCount":13},[1768],{"nctId":1725,"briefTitle":1726,"status":61,"phases":1769,"primaryCompletion":1728,"completion":1728,"start":577,"enrollment":1729,"conditions":1770,"interventions":1771},[45],[1731,17],[1712,1733,1734,1735],{"trials":1773,"activeCount":13},[],{"intervention":1735,"totalTrials":10,"cells":1775},{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1782,"PHASE4":1784,"NA":1790},{"trials":1777,"activeCount":13},[],{"trials":1779,"activeCount":13},[],{"trials":1781,"activeCount":13},[],{"trials":1783,"activeCount":13},[],{"trials":1785,"activeCount":13},[1786],{"nctId":1725,"briefTitle":1726,"status":61,"phases":1787,"primaryCompletion":1728,"completion":1728,"start":577,"enrollment":1729,"conditions":1788,"interventions":1789},[45],[1731,17],[1712,1733,1734,1735],{"trials":1791,"activeCount":13},[],{"intervention":539,"totalTrials":10,"cells":1793},{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1800,"PHASE4":1802,"NA":1808},{"trials":1795,"activeCount":13},[],{"trials":1797,"activeCount":13},[],{"trials":1799,"activeCount":13},[],{"trials":1801,"activeCount":13},[],{"trials":1803,"activeCount":13},[1804],{"nctId":530,"briefTitle":531,"status":61,"phases":1805,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":1806,"interventions":1807},[45],[23,537],[539,494],{"trials":1809,"activeCount":13},[],{"intervention":1811,"totalTrials":10,"cells":1812},"Ketorolac 0.4%",{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1817,"PHASE3":1819,"PHASE4":1821,"NA":1832},{"trials":1814,"activeCount":13},[],{"trials":1816,"activeCount":13},[],{"trials":1818,"activeCount":13},[],{"trials":1820,"activeCount":13},[],{"trials":1822,"activeCount":13},[1823],{"nctId":1824,"briefTitle":1825,"status":61,"phases":1826,"primaryCompletion":476,"completion":476,"start":65,"enrollment":1827,"conditions":1828,"interventions":1830},"NCT00791323","Efficacy of Ketorolac 0.4% in Prostaglandin Suppression",[45],9,[1829],"Inflammation",[1811,1831],"Lubricating Eye Drop",{"trials":1833,"activeCount":13},[],{"intervention":1831,"totalTrials":10,"cells":1835},{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1840,"PHASE3":1842,"PHASE4":1844,"NA":1850},{"trials":1837,"activeCount":13},[],{"trials":1839,"activeCount":13},[],{"trials":1841,"activeCount":13},[],{"trials":1843,"activeCount":13},[],{"trials":1845,"activeCount":13},[1846],{"nctId":1824,"briefTitle":1825,"status":61,"phases":1847,"primaryCompletion":476,"completion":476,"start":65,"enrollment":1827,"conditions":1848,"interventions":1849},[45],[1829],[1811,1831],{"trials":1851,"activeCount":13},[],{"intervention":1026,"totalTrials":10,"cells":1853},{"EARLY_PHASE1":1854,"PHASE1":1856,"PHASE2":1858,"PHASE3":1860,"PHASE4":1862,"NA":1868},{"trials":1855,"activeCount":13},[],{"trials":1857,"activeCount":13},[],{"trials":1859,"activeCount":13},[],{"trials":1861,"activeCount":13},[],{"trials":1863,"activeCount":13},[1864],{"nctId":1018,"briefTitle":1019,"status":75,"phases":1865,"primaryCompletion":1021,"completion":1021,"start":63,"enrollment":33,"conditions":1866,"interventions":1867},[45],[1023],[1025,1026],{"trials":1869,"activeCount":13},[],{"intervention":647,"totalTrials":10,"cells":1871},{"EARLY_PHASE1":1872,"PHASE1":1874,"PHASE2":1876,"PHASE3":1878,"PHASE4":1880,"NA":1886},{"trials":1873,"activeCount":13},[],{"trials":1875,"activeCount":13},[],{"trials":1877,"activeCount":13},[],{"trials":1879,"activeCount":13},[],{"trials":1881,"activeCount":13},[1882],{"nctId":641,"briefTitle":642,"status":61,"phases":1883,"primaryCompletion":307,"completion":78,"start":63,"enrollment":644,"conditions":1884,"interventions":1885},[45],[348],[647,615],{"trials":1887,"activeCount":13},[],{"intervention":764,"totalTrials":10,"cells":1889},{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1896,"PHASE4":1898,"NA":1904},{"trials":1891,"activeCount":13},[],{"trials":1893,"activeCount":13},[],{"trials":1895,"activeCount":13},[],{"trials":1897,"activeCount":13},[],{"trials":1899,"activeCount":13},[1900],{"nctId":758,"briefTitle":759,"status":61,"phases":1901,"primaryCompletion":761,"completion":761,"start":761,"enrollment":358,"conditions":1902,"interventions":1903},[45],[26],[764,735],{"trials":1905,"activeCount":13},[],{"intervention":1907,"totalTrials":10,"cells":1908},"Dapsone",{"EARLY_PHASE1":1909,"PHASE1":1911,"PHASE2":1913,"PHASE3":1915,"PHASE4":1917,"NA":1928},{"trials":1910,"activeCount":13},[],{"trials":1912,"activeCount":13},[],{"trials":1914,"activeCount":13},[],{"trials":1916,"activeCount":13},[],{"trials":1918,"activeCount":13},[1919],{"nctId":1920,"briefTitle":1921,"status":61,"phases":1922,"primaryCompletion":1923,"completion":1923,"start":888,"enrollment":1924,"conditions":1925,"interventions":1926},"NCT00834210","Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris",[45],"2009-09",171,[273],[1907,1927],"Tazarotene",{"trials":1929,"activeCount":13},[],{"intervention":1927,"totalTrials":10,"cells":1931},{"EARLY_PHASE1":1932,"PHASE1":1934,"PHASE2":1936,"PHASE3":1938,"PHASE4":1940,"NA":1946},{"trials":1933,"activeCount":13},[],{"trials":1935,"activeCount":13},[],{"trials":1937,"activeCount":13},[],{"trials":1939,"activeCount":13},[],{"trials":1941,"activeCount":13},[1942],{"nctId":1920,"briefTitle":1921,"status":61,"phases":1943,"primaryCompletion":1923,"completion":1923,"start":888,"enrollment":1924,"conditions":1944,"interventions":1945},[45],[273],[1907,1927],{"trials":1947,"activeCount":13},[],{"intervention":1236,"totalTrials":10,"cells":1949},{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1956,"PHASE4":1958,"NA":1964},{"trials":1951,"activeCount":13},[],{"trials":1953,"activeCount":13},[],{"trials":1955,"activeCount":13},[],{"trials":1957,"activeCount":13},[],{"trials":1959,"activeCount":13},[1960],{"nctId":1227,"briefTitle":1228,"status":61,"phases":1961,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":1962,"interventions":1963},[45],[1234],[1236,1237,1214],{"trials":1965,"activeCount":13},[],{"intervention":1237,"totalTrials":10,"cells":1967},{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1974,"PHASE4":1976,"NA":1982},{"trials":1969,"activeCount":13},[],{"trials":1971,"activeCount":13},[],{"trials":1973,"activeCount":13},[],{"trials":1975,"activeCount":13},[],{"trials":1977,"activeCount":13},[1978],{"nctId":1227,"briefTitle":1228,"status":61,"phases":1979,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":1980,"interventions":1981},[45],[1234],[1236,1237,1214],{"trials":1983,"activeCount":13},[],{"intervention":1985,"totalTrials":10,"cells":1986},"Dapsone Gel",{"EARLY_PHASE1":1987,"PHASE1":1989,"PHASE2":1991,"PHASE3":1993,"PHASE4":1995,"NA":2005},{"trials":1988,"activeCount":13},[],{"trials":1990,"activeCount":13},[],{"trials":1992,"activeCount":13},[],{"trials":1994,"activeCount":13},[],{"trials":1996,"activeCount":13},[1997],{"nctId":1998,"briefTitle":1999,"status":61,"phases":2000,"primaryCompletion":2001,"completion":89,"start":506,"enrollment":2002,"conditions":2003,"interventions":2004},"NCT02032407","A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris",[45],"2014-06",68,[273],[1985],{"trials":2006,"activeCount":13},[],{"intervention":1245,"totalTrials":10,"cells":2008},{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2017,"NA":2023},{"trials":2010,"activeCount":13},[],{"trials":2012,"activeCount":13},[],{"trials":2014,"activeCount":13},[],{"trials":2016,"activeCount":13},[],{"trials":2018,"activeCount":13},[2019],{"nctId":1239,"briefTitle":1240,"status":61,"phases":2020,"primaryCompletion":545,"completion":545,"start":345,"enrollment":1242,"conditions":2021,"interventions":2022},[45],[1234],[1245,1246,1214],{"trials":2024,"activeCount":13},[],{"intervention":1246,"totalTrials":10,"cells":2026},{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2033,"PHASE4":2035,"NA":2041},{"trials":2028,"activeCount":13},[],{"trials":2030,"activeCount":13},[],{"trials":2032,"activeCount":13},[],{"trials":2034,"activeCount":13},[],{"trials":2036,"activeCount":13},[2037],{"nctId":1239,"briefTitle":1240,"status":61,"phases":2038,"primaryCompletion":545,"completion":545,"start":345,"enrollment":1242,"conditions":2039,"interventions":2040},[45],[1234],[1245,1246,1214],{"trials":2042,"activeCount":13},[],{"intervention":2044,"totalTrials":10,"cells":2045},"Lubricant Eye Drops",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2052,"PHASE4":2054,"NA":2063},{"trials":2047,"activeCount":13},[],{"trials":2049,"activeCount":13},[],{"trials":2051,"activeCount":13},[],{"trials":2053,"activeCount":13},[],{"trials":2055,"activeCount":13},[2056],{"nctId":2057,"briefTitle":2058,"status":61,"phases":2059,"primaryCompletion":476,"completion":476,"start":986,"enrollment":1197,"conditions":2060,"interventions":2061},"NCT00756678","Efficacy and Acceptability of Two Lubricant Eye Drops",[45],[26],[2044,2062],"Lubricating Eye Drops",{"trials":2064,"activeCount":13},[],{"intervention":2062,"totalTrials":10,"cells":2066},{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2081},{"trials":2068,"activeCount":13},[],{"trials":2070,"activeCount":13},[],{"trials":2072,"activeCount":13},[],{"trials":2074,"activeCount":13},[],{"trials":2076,"activeCount":13},[2077],{"nctId":2057,"briefTitle":2058,"status":61,"phases":2078,"primaryCompletion":476,"completion":476,"start":986,"enrollment":1197,"conditions":2079,"interventions":2080},[45],[26],[2044,2062],{"trials":2082,"activeCount":13},[],{"intervention":2084,"totalTrials":10,"cells":2085},"OZURDEX",{"EARLY_PHASE1":2086,"PHASE1":2088,"PHASE2":2090,"PHASE3":2092,"PHASE4":2094,"NA":2105},{"trials":2087,"activeCount":13},[],{"trials":2089,"activeCount":13},[],{"trials":2091,"activeCount":13},[],{"trials":2093,"activeCount":13},[],{"trials":2095,"activeCount":13},[2096],{"nctId":2097,"briefTitle":2098,"status":61,"phases":2099,"primaryCompletion":2100,"completion":2100,"start":2101,"enrollment":2102,"conditions":2103,"interventions":2104},"NCT03908307","Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China",[45],"2021-09-26","2019-07-25",150,[29,175],[2084],{"trials":2106,"activeCount":13},[],{"intervention":2108,"totalTrials":10,"cells":2109},"moxifloxacin 0.5% HCI ophthalmic solution",{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2116,"PHASE4":2118,"NA":2130},{"trials":2111,"activeCount":13},[],{"trials":2113,"activeCount":13},[],{"trials":2115,"activeCount":13},[],{"trials":2117,"activeCount":13},[],{"trials":2119,"activeCount":13},[2120],{"nctId":2121,"briefTitle":2122,"status":61,"phases":2123,"primaryCompletion":1923,"completion":450,"start":2124,"enrollment":2125,"conditions":2126,"interventions":2128},"NCT00874887","A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms",[45],"2009-03",66,[2127],"Anti-biotic Resistance",[2108,2129],"gatifloxacin ophthalmic solution 0.3%",{"trials":2131,"activeCount":13},[],{"intervention":2129,"totalTrials":10,"cells":2133},{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2140,"PHASE4":2142,"NA":2148},{"trials":2135,"activeCount":13},[],{"trials":2137,"activeCount":13},[],{"trials":2139,"activeCount":13},[],{"trials":2141,"activeCount":13},[],{"trials":2143,"activeCount":13},[2144],{"nctId":2121,"briefTitle":2122,"status":61,"phases":2145,"primaryCompletion":1923,"completion":450,"start":2124,"enrollment":2125,"conditions":2146,"interventions":2147},[45],[2127],[2108,2129],{"trials":2149,"activeCount":13},[],{"intervention":1210,"totalTrials":10,"cells":2151},{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2158,"PHASE4":2160,"NA":2166},{"trials":2153,"activeCount":13},[],{"trials":2155,"activeCount":13},[],{"trials":2157,"activeCount":13},[],{"trials":2159,"activeCount":13},[],{"trials":2161,"activeCount":13},[2162],{"nctId":1201,"briefTitle":1202,"status":61,"phases":2163,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":2164,"interventions":2165},[45],[26],[1209,1210],{"trials":2167,"activeCount":13},[],{"intervention":927,"totalTrials":10,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2174,"PHASE3":2176,"PHASE4":2178,"NA":2184},{"trials":2171,"activeCount":13},[],{"trials":2173,"activeCount":13},[],{"trials":2175,"activeCount":13},[],{"trials":2177,"activeCount":13},[],{"trials":2179,"activeCount":13},[2180],{"nctId":920,"briefTitle":921,"status":61,"phases":2181,"primaryCompletion":897,"completion":897,"start":923,"enrollment":924,"conditions":2182,"interventions":2183},[45],[20,17],[927,928,892],{"trials":2185,"activeCount":13},[],{"intervention":928,"totalTrials":10,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2196,"NA":2202},{"trials":2189,"activeCount":13},[],{"trials":2191,"activeCount":13},[],{"trials":2193,"activeCount":13},[],{"trials":2195,"activeCount":13},[],{"trials":2197,"activeCount":13},[2198],{"nctId":920,"briefTitle":921,"status":61,"phases":2199,"primaryCompletion":897,"completion":897,"start":923,"enrollment":924,"conditions":2200,"interventions":2201},[45],[20,17],[927,928,892],{"trials":2203,"activeCount":13},[],{"intervention":2205,"totalTrials":10,"cells":2206},"0.03% Bimatoprost",{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2213,"PHASE4":2215,"NA":2225},{"trials":2208,"activeCount":13},[],{"trials":2210,"activeCount":13},[],{"trials":2212,"activeCount":13},[],{"trials":2214,"activeCount":13},[],{"trials":2216,"activeCount":13},[2217],{"nctId":2218,"briefTitle":2219,"status":61,"phases":2220,"primaryCompletion":1230,"completion":1230,"start":2221,"enrollment":2222,"conditions":2223,"interventions":2224},"NCT02020512","A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension",[45],"2011-07",87,[23,17],[2205],{"trials":2226,"activeCount":13},[],{"intervention":2228,"totalTrials":10,"cells":2229},"Androderm®",{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2234,"PHASE3":2236,"PHASE4":2238,"NA":2250},{"trials":2231,"activeCount":13},[],{"trials":2233,"activeCount":13},[],{"trials":2235,"activeCount":13},[],{"trials":2237,"activeCount":13},[],{"trials":2239,"activeCount":13},[2240],{"nctId":2241,"briefTitle":2242,"status":61,"phases":2243,"primaryCompletion":2244,"completion":2244,"start":2245,"enrollment":2246,"conditions":2247,"interventions":2249},"NCT04320745","A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants",[45],"2021-06-24","2020-05-19",168,[2248],"Hypogonadism",[2228],{"trials":2251,"activeCount":13},[],{"intervention":775,"totalTrials":10,"cells":2253},{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2258,"PHASE3":2260,"PHASE4":2262,"NA":2268},{"trials":2255,"activeCount":13},[],{"trials":2257,"activeCount":13},[],{"trials":2259,"activeCount":13},[],{"trials":2261,"activeCount":13},[],{"trials":2263,"activeCount":13},[2264],{"nctId":766,"briefTitle":767,"status":61,"phases":2265,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":2266,"interventions":2267},[45],[26,754],[775,735],{"trials":2269,"activeCount":13},[],{"intervention":1097,"totalTrials":10,"cells":2271},{"EARLY_PHASE1":2272,"PHASE1":2274,"PHASE2":2276,"PHASE3":2278,"PHASE4":2280,"NA":2286},{"trials":2273,"activeCount":13},[],{"trials":2275,"activeCount":13},[],{"trials":2277,"activeCount":13},[],{"trials":2279,"activeCount":13},[],{"trials":2281,"activeCount":13},[2282],{"nctId":1090,"briefTitle":1091,"status":75,"phases":2283,"primaryCompletion":1093,"completion":1093,"start":630,"enrollment":332,"conditions":2284,"interventions":2285},[45],[273],[1096,1097],{"trials":2287,"activeCount":13},[],{"intervention":1272,"totalTrials":10,"cells":2289},{"EARLY_PHASE1":2290,"PHASE1":2292,"PHASE2":2294,"PHASE3":2296,"PHASE4":2298,"NA":2304},{"trials":2291,"activeCount":13},[],{"trials":2293,"activeCount":13},[],{"trials":2295,"activeCount":13},[],{"trials":2297,"activeCount":13},[],{"trials":2299,"activeCount":13},[2300],{"nctId":1263,"briefTitle":1264,"status":61,"phases":2301,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":1268,"conditions":2302,"interventions":2303},[45],[1270],[1272,1250],{"trials":2305,"activeCount":13},[],{"intervention":2307,"totalTrials":10,"cells":2308},"Botulinum Toxin Type A 900kD",{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2313,"PHASE3":2315,"PHASE4":2317,"NA":2326},{"trials":2310,"activeCount":13},[],{"trials":2312,"activeCount":13},[],{"trials":2314,"activeCount":13},[],{"trials":2316,"activeCount":13},[],{"trials":2318,"activeCount":13},[2319],{"nctId":2320,"briefTitle":2321,"status":61,"phases":2322,"primaryCompletion":887,"completion":307,"start":630,"enrollment":2323,"conditions":2324,"interventions":2325},"NCT00549783","BOTOX® Economic Spasticity Trial (BEST)",[45],274,[32],[2307],{"trials":2327,"activeCount":13},[],{"intervention":2329,"totalTrials":10,"cells":2330},"Dapsone; Tretinoin",{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2335,"PHASE3":2337,"PHASE4":2339,"NA":2348},{"trials":2332,"activeCount":13},[],{"trials":2334,"activeCount":13},[],{"trials":2336,"activeCount":13},[],{"trials":2338,"activeCount":13},[],{"trials":2340,"activeCount":13},[2341],{"nctId":2342,"briefTitle":2343,"status":61,"phases":2344,"primaryCompletion":476,"completion":476,"start":888,"enrollment":292,"conditions":2345,"interventions":2346},"NCT00835198","Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris",[45],[273],[2329,2347],"Tretinoin",{"trials":2349,"activeCount":13},[],{"intervention":2347,"totalTrials":10,"cells":2351},{"EARLY_PHASE1":2352,"PHASE1":2354,"PHASE2":2356,"PHASE3":2358,"PHASE4":2360,"NA":2366},{"trials":2353,"activeCount":13},[],{"trials":2355,"activeCount":13},[],{"trials":2357,"activeCount":13},[],{"trials":2359,"activeCount":13},[],{"trials":2361,"activeCount":13},[2362],{"nctId":2342,"briefTitle":2343,"status":61,"phases":2363,"primaryCompletion":476,"completion":476,"start":888,"enrollment":292,"conditions":2364,"interventions":2365},[45],[273],[2329,2347],{"trials":2367,"activeCount":13},[],{"intervention":2369,"totalTrials":10,"cells":2370},"fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution",{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2377,"PHASE4":2379,"NA":2389},{"trials":2372,"activeCount":13},[],{"trials":2374,"activeCount":13},[],{"trials":2376,"activeCount":13},[],{"trials":2378,"activeCount":13},[],{"trials":2380,"activeCount":13},[2381],{"nctId":2382,"briefTitle":2383,"status":61,"phases":2384,"primaryCompletion":751,"completion":751,"start":897,"enrollment":2385,"conditions":2386,"interventions":2387},"NCT01170884","Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®",[45],121,[20,17],[2369,2388],"bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops",{"trials":2390,"activeCount":13},[],{"intervention":2388,"totalTrials":10,"cells":2392},{"EARLY_PHASE1":2393,"PHASE1":2395,"PHASE2":2397,"PHASE3":2399,"PHASE4":2401,"NA":2407},{"trials":2394,"activeCount":13},[],{"trials":2396,"activeCount":13},[],{"trials":2398,"activeCount":13},[],{"trials":2400,"activeCount":13},[],{"trials":2402,"activeCount":13},[2403],{"nctId":2382,"briefTitle":2383,"status":61,"phases":2404,"primaryCompletion":751,"completion":751,"start":897,"enrollment":2385,"conditions":2405,"interventions":2406},[45],[20,17],[2369,2388],{"trials":2408,"activeCount":13},[],{"intervention":2410,"totalTrials":10,"cells":2411},"Dapsone plus Adapalene",{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2430},{"trials":2413,"activeCount":13},[],{"trials":2415,"activeCount":13},[],{"trials":2417,"activeCount":13},[],{"trials":2419,"activeCount":13},[],{"trials":2421,"activeCount":13},[2422],{"nctId":2423,"briefTitle":2424,"status":61,"phases":2425,"primaryCompletion":204,"completion":204,"start":78,"enrollment":2426,"conditions":2427,"interventions":2428},"NCT01231334","A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne",[45],286,[273],[2410,2429],"Clindamycin\u002Fbenzoyl peroxide plus Adapalene",{"trials":2431,"activeCount":13},[],{"intervention":2429,"totalTrials":10,"cells":2433},{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2438,"PHASE3":2440,"PHASE4":2442,"NA":2448},{"trials":2435,"activeCount":13},[],{"trials":2437,"activeCount":13},[],{"trials":2439,"activeCount":13},[],{"trials":2441,"activeCount":13},[],{"trials":2443,"activeCount":13},[2444],{"nctId":2423,"briefTitle":2424,"status":61,"phases":2445,"primaryCompletion":204,"completion":204,"start":78,"enrollment":2426,"conditions":2446,"interventions":2447},[45],[273],[2410,2429],{"trials":2449,"activeCount":13},[],{"intervention":1062,"totalTrials":10,"cells":2451},{"EARLY_PHASE1":2452,"PHASE1":2454,"PHASE2":2456,"PHASE3":2458,"PHASE4":2460,"NA":2466},{"trials":2453,"activeCount":13},[],{"trials":2455,"activeCount":13},[],{"trials":2457,"activeCount":13},[],{"trials":2459,"activeCount":13},[],{"trials":2461,"activeCount":13},[2462],{"nctId":1055,"briefTitle":1056,"status":61,"phases":2463,"primaryCompletion":1058,"completion":1058,"start":357,"enrollment":1059,"conditions":2464,"interventions":2465},[45],[23],[1062,1030],{"trials":2467,"activeCount":13},[],{"intervention":549,"totalTrials":10,"cells":2469},{"EARLY_PHASE1":2470,"PHASE1":2472,"PHASE2":2474,"PHASE3":2476,"PHASE4":2478,"NA":2484},{"trials":2471,"activeCount":13},[],{"trials":2473,"activeCount":13},[],{"trials":2475,"activeCount":13},[],{"trials":2477,"activeCount":13},[],{"trials":2479,"activeCount":13},[2480],{"nctId":541,"briefTitle":542,"status":61,"phases":2481,"primaryCompletion":544,"completion":544,"start":545,"enrollment":546,"conditions":2482,"interventions":2483},[45],[23,17],[527,549,550],{"trials":2485,"activeCount":13},[],{"intervention":2487,"totalTrials":10,"cells":2488},"gatifloxacin",{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2497,"NA":2508},{"trials":2490,"activeCount":13},[],{"trials":2492,"activeCount":13},[],{"trials":2494,"activeCount":13},[],{"trials":2496,"activeCount":13},[],{"trials":2498,"activeCount":13},[2499],{"nctId":2500,"briefTitle":2501,"status":61,"phases":2502,"primaryCompletion":986,"completion":986,"start":2503,"enrollment":1924,"conditions":2504,"interventions":2506},"NCT00464438","A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis",[45],"2007-06",[2505],"Bacterial Conjunctivitis",[2487,2507],"moxifloxacin 0.5% eye drops",{"trials":2509,"activeCount":13},[],{"intervention":2507,"totalTrials":10,"cells":2511},{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2518,"PHASE4":2520,"NA":2526},{"trials":2513,"activeCount":13},[],{"trials":2515,"activeCount":13},[],{"trials":2517,"activeCount":13},[],{"trials":2519,"activeCount":13},[],{"trials":2521,"activeCount":13},[2522],{"nctId":2500,"briefTitle":2501,"status":61,"phases":2523,"primaryCompletion":986,"completion":986,"start":2503,"enrollment":1924,"conditions":2524,"interventions":2525},[45],[2505],[2487,2507],{"trials":2527,"activeCount":13},[],{"intervention":2529,"totalTrials":10,"cells":2530},"Sodium Carboxymethylcellulose",{"EARLY_PHASE1":2531,"PHASE1":2533,"PHASE2":2535,"PHASE3":2537,"PHASE4":2539,"NA":2552},{"trials":2532,"activeCount":13},[],{"trials":2534,"activeCount":13},[],{"trials":2536,"activeCount":13},[],{"trials":2538,"activeCount":13},[],{"trials":2540,"activeCount":13},[2541],{"nctId":2542,"briefTitle":2543,"status":61,"phases":2544,"primaryCompletion":2545,"completion":2545,"start":2221,"enrollment":2546,"conditions":2547,"interventions":2549},"NCT02028754","A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms",[45],"2013-05",180,[26,2548],"Cataract",[2529,2550,2551],"Levofloxacin","Prednisolone",{"trials":2553,"activeCount":13},[],{"intervention":2550,"totalTrials":10,"cells":2555},{"EARLY_PHASE1":2556,"PHASE1":2558,"PHASE2":2560,"PHASE3":2562,"PHASE4":2564,"NA":2570},{"trials":2557,"activeCount":13},[],{"trials":2559,"activeCount":13},[],{"trials":2561,"activeCount":13},[],{"trials":2563,"activeCount":13},[],{"trials":2565,"activeCount":13},[2566],{"nctId":2542,"briefTitle":2543,"status":61,"phases":2567,"primaryCompletion":2545,"completion":2545,"start":2221,"enrollment":2546,"conditions":2568,"interventions":2569},[45],[26,2548],[2529,2550,2551],{"trials":2571,"activeCount":13},[],{"intervention":2551,"totalTrials":10,"cells":2573},{"EARLY_PHASE1":2574,"PHASE1":2576,"PHASE2":2578,"PHASE3":2580,"PHASE4":2582,"NA":2588},{"trials":2575,"activeCount":13},[],{"trials":2577,"activeCount":13},[],{"trials":2579,"activeCount":13},[],{"trials":2581,"activeCount":13},[],{"trials":2583,"activeCount":13},[2584],{"nctId":2542,"briefTitle":2543,"status":61,"phases":2585,"primaryCompletion":2545,"completion":2545,"start":2221,"enrollment":2546,"conditions":2586,"interventions":2587},[45],[26,2548],[2529,2550,2551],{"trials":2589,"activeCount":13},[],{"intervention":2591,"totalTrials":10,"cells":2592},"Botulinum Toxin Type A 900kDa",{"EARLY_PHASE1":2593,"PHASE1":2595,"PHASE2":2597,"PHASE3":2599,"PHASE4":2601,"NA":2613},{"trials":2594,"activeCount":13},[],{"trials":2596,"activeCount":13},[],{"trials":2598,"activeCount":13},[],{"trials":2600,"activeCount":13},[],{"trials":2602,"activeCount":13},[2603],{"nctId":2604,"briefTitle":2605,"status":61,"phases":2606,"primaryCompletion":2607,"completion":2607,"start":1489,"enrollment":2608,"conditions":2609,"interventions":2611},"NCT00761592","Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm",[45],"2008-01",65,[2610],"Blepharospasm",[2591,2612],"Botulinum Toxin Type A 150kDa",{"trials":2614,"activeCount":13},[],{"intervention":2612,"totalTrials":10,"cells":2616},{"EARLY_PHASE1":2617,"PHASE1":2619,"PHASE2":2621,"PHASE3":2623,"PHASE4":2625,"NA":2631},{"trials":2618,"activeCount":13},[],{"trials":2620,"activeCount":13},[],{"trials":2622,"activeCount":13},[],{"trials":2624,"activeCount":13},[],{"trials":2626,"activeCount":13},[2627],{"nctId":2604,"briefTitle":2605,"status":61,"phases":2628,"primaryCompletion":2607,"completion":2607,"start":1489,"enrollment":2608,"conditions":2629,"interventions":2630},[45],[2610],[2591,2612],{"trials":2632,"activeCount":13},[],{"intervention":2634,"totalTrials":10,"cells":2635},"Trospium Chloride, Extended Release",{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2642,"PHASE4":2644,"NA":2655},{"trials":2637,"activeCount":13},[],{"trials":2639,"activeCount":13},[],{"trials":2641,"activeCount":13},[],{"trials":2643,"activeCount":13},[],{"trials":2645,"activeCount":13},[2646],{"nctId":2647,"briefTitle":2648,"status":61,"phases":2649,"primaryCompletion":545,"completion":545,"start":2650,"enrollment":1242,"conditions":2651,"interventions":2654},"NCT00932022","Trospium Chloride XR in Obese Female Patients With Overactive Bladder",[45],"2009-07",[2652,35,2653],"Obesity","Incontinence",[2634],{"trials":2656,"activeCount":13},[],{"intervention":2658,"totalTrials":1827,"cells":2659},"Dexamethasone",{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2695,"PHASE4":2738,"NA":2740},{"trials":2661,"activeCount":13},[],{"trials":2663,"activeCount":13},[],{"trials":2665,"activeCount":13},[2666,2670,2681,2691],{"nctId":59,"briefTitle":60,"status":61,"phases":2667,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":2668,"interventions":2669},[43],[68,69],[71,49],{"nctId":2671,"briefTitle":2672,"status":61,"phases":2673,"primaryCompletion":2674,"completion":2674,"start":2675,"enrollment":2676,"conditions":2677,"interventions":2679},"NCT00464685","Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema",[43],"2010-02-08","2007-05-01",253,[2678],"Diabetic Macular Edema",[2658,2680],"Sham",{"nctId":2682,"briefTitle":2683,"status":61,"phases":2684,"primaryCompletion":2685,"completion":2685,"start":2686,"enrollment":2687,"conditions":2688,"interventions":2690},"NCT00799227","Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema",[43],"2009-12-01","2009-01-01",56,[2678,2689],"Vitrectomy",[2658],{"nctId":96,"briefTitle":97,"status":61,"phases":2692,"primaryCompletion":99,"completion":99,"start":100,"enrollment":101,"conditions":2693,"interventions":2694},[43],[68,69],[71,49],{"trials":2696,"activeCount":13},[2697,2705,2714,2722,2729],{"nctId":2698,"briefTitle":2699,"status":75,"phases":2700,"primaryCompletion":1488,"completion":1488,"start":2701,"enrollment":380,"conditions":2702,"interventions":2704},"NCT00333996","A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis",[43,44],"2006-05",[2703],"Anterior Uveitis",[2658],{"nctId":2706,"briefTitle":2707,"status":61,"phases":2708,"primaryCompletion":2709,"completion":2709,"start":2710,"enrollment":2711,"conditions":2712,"interventions":2713},"NCT02121262","A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema",[44],"2019-11-01","2016-01-08",284,[29],[2658],{"nctId":2715,"briefTitle":2716,"status":61,"phases":2717,"primaryCompletion":2718,"completion":2718,"start":577,"enrollment":2719,"conditions":2720,"interventions":2721},"NCT00168337","A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema",[44],"2012-05",554,[2678],[2658],{"nctId":2723,"briefTitle":2716,"status":61,"phases":2724,"primaryCompletion":487,"completion":487,"start":2725,"enrollment":2726,"conditions":2727,"interventions":2728},"NCT00168389",[44],"2005-02",494,[2678],[2658],{"nctId":2730,"briefTitle":2731,"status":61,"phases":2732,"primaryCompletion":888,"completion":477,"start":2701,"enrollment":2733,"conditions":2734,"interventions":2737},"NCT00333814","A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis",[43,44],229,[2735,2736],"Intermediate Uveitis","Posterior Uveitis",[2658,71,2680],{"trials":2739,"activeCount":13},[],{"trials":2741,"activeCount":13},[],{"intervention":2743,"totalTrials":182,"cells":2744},"Abicipar pegol",{"EARLY_PHASE1":2745,"PHASE1":2747,"PHASE2":2766,"PHASE3":2789,"PHASE4":2799,"NA":2801},{"trials":2746,"activeCount":13},[],{"trials":2748,"activeCount":13},[2749,2758],{"nctId":2750,"briefTitle":2751,"status":61,"phases":2752,"primaryCompletion":2753,"completion":2753,"start":2754,"enrollment":2755,"conditions":2756,"interventions":2757},"NCT02859766","Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD",[42],"2017-10-20","2016-12-07",30,[92],[2743],{"nctId":2759,"briefTitle":2760,"status":61,"phases":2761,"primaryCompletion":2762,"completion":2762,"start":2763,"enrollment":50,"conditions":2764,"interventions":2765},"NCT03335852","Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD",[42],"2018-10-08","2017-11-28",[92],[2743],{"trials":2767,"activeCount":13},[2768,2777,2781,2785],{"nctId":2769,"briefTitle":2770,"status":61,"phases":2771,"primaryCompletion":2772,"completion":2772,"start":2773,"enrollment":2774,"conditions":2775,"interventions":2776},"NCT03539549","A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)",[43],"2019-02-27","2018-05-25",124,[92],[2743],{"nctId":85,"briefTitle":86,"status":61,"phases":2778,"primaryCompletion":88,"completion":88,"start":89,"enrollment":90,"conditions":2779,"interventions":2780},[43],[92],[94,49],{"nctId":105,"briefTitle":106,"status":61,"phases":2782,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":2783,"interventions":2784},[43],[29],[94,49],{"nctId":136,"briefTitle":137,"status":61,"phases":2786,"primaryCompletion":139,"completion":139,"start":109,"enrollment":90,"conditions":2787,"interventions":2788},[43],[92],[94,49],{"trials":2790,"activeCount":13},[2791,2795],{"nctId":145,"briefTitle":146,"status":61,"phases":2792,"primaryCompletion":148,"completion":149,"start":150,"enrollment":151,"conditions":2793,"interventions":2794},[44],[92],[154,155],{"nctId":157,"briefTitle":158,"status":61,"phases":2796,"primaryCompletion":160,"completion":161,"start":150,"enrollment":162,"conditions":2797,"interventions":2798},[44],[92],[154,155],{"trials":2800,"activeCount":13},[],{"trials":2802,"activeCount":13},[],{"intervention":2804,"totalTrials":380,"cells":2805},"MAP0004",{"EARLY_PHASE1":2806,"PHASE1":2808,"PHASE2":2835,"PHASE3":2845,"PHASE4":2855,"NA":2857},{"trials":2807,"activeCount":13},[],{"trials":2809,"activeCount":13},[2810,2818,2826],{"nctId":2811,"briefTitle":2812,"status":61,"phases":2813,"primaryCompletion":751,"completion":523,"start":308,"enrollment":1141,"conditions":2814,"interventions":2815},"NCT01089062","Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure",[42],[452],[2804,2816,2817],"IV Placebo","IV Dihydroergotamine Mesylate",{"nctId":2819,"briefTitle":2820,"status":61,"phases":2821,"primaryCompletion":78,"completion":78,"start":307,"enrollment":1141,"conditions":2822,"interventions":2823},"NCT01468558","Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole",[42],[452],[2804,2824,2825],"IV DHE","Ketoconazole",{"nctId":2827,"briefTitle":2828,"status":61,"phases":2829,"primaryCompletion":751,"completion":751,"start":78,"enrollment":2830,"conditions":2831,"interventions":2832},"NCT01191723","QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo",[42],54,[452],[2804,2833,2834],"Inhaler Placebo","Moxifloxacin",{"trials":2836,"activeCount":13},[2837],{"nctId":2838,"briefTitle":2839,"status":61,"phases":2840,"primaryCompletion":64,"completion":64,"start":887,"enrollment":2841,"conditions":2842,"interventions":2844},"NCT01199965","Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers",[42,43],47,[2843],"Healthy Subjects",[2804,2824],{"trials":2846,"activeCount":13},[2847],{"nctId":2848,"briefTitle":2849,"status":61,"phases":2850,"primaryCompletion":523,"completion":2851,"start":923,"enrollment":2852,"conditions":2853,"interventions":2854},"NCT00623636","Phase 3 Study of MAP0004 in Adult Migraineurs",[44],"2011-01",902,[37],[2804],{"trials":2856,"activeCount":13},[],{"trials":2858,"activeCount":13},[],{"intervention":2860,"totalTrials":380,"cells":2861},"Relamorelin",{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2866,"PHASE3":2880,"PHASE4":2918,"NA":2920},{"trials":2863,"activeCount":13},[],{"trials":2865,"activeCount":13},[],{"trials":2867,"activeCount":13},[2868],{"nctId":2869,"briefTitle":2870,"status":61,"phases":2871,"primaryCompletion":2872,"completion":2872,"start":2873,"enrollment":2874,"conditions":2875,"interventions":2879},"NCT02357420","Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis",[43],"2016-06-09","2015-01-29",393,[2876,2877,2878],"Diabetes Mellitus","Diabetes Mellitus Complications","Gastroparesis",[2860],{"trials":2881,"activeCount":13},[2882,2891,2900,2909],{"nctId":2883,"briefTitle":2884,"status":75,"phases":2885,"primaryCompletion":2886,"completion":2886,"start":2887,"enrollment":2888,"conditions":2889,"interventions":2890},"NCT03285308","A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01",[44],"2020-07-08","2017-09-29",336,[2878,2876],[2860],{"nctId":2892,"briefTitle":2893,"status":75,"phases":2894,"primaryCompletion":2895,"completion":2895,"start":2896,"enrollment":2897,"conditions":2898,"interventions":2899},"NCT03383146","A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04",[44],"2020-11-05","2018-02-01",450,[2878,2876],[2860],{"nctId":2901,"briefTitle":2902,"status":75,"phases":2903,"primaryCompletion":2904,"completion":2904,"start":2905,"enrollment":2906,"conditions":2907,"interventions":2908},"NCT03420781","A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03",[44],"2020-10-30","2018-01-24",467,[2878,2876],[2860],{"nctId":2910,"briefTitle":2911,"status":75,"phases":2912,"primaryCompletion":2913,"completion":2913,"start":2914,"enrollment":2915,"conditions":2916,"interventions":2917},"NCT03426345","Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02",[44],"2020-07-16","2018-02-16",311,[2878,2876],[2860],{"trials":2919,"activeCount":13},[],{"trials":2921,"activeCount":13},[],{"intervention":2923,"totalTrials":380,"cells":2924},"Atogepant",{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2931,"PHASE4":2980,"NA":2982},{"trials":2926,"activeCount":13},[],{"trials":2928,"activeCount":13},[],{"trials":2930,"activeCount":13},[],{"trials":2932,"activeCount":13},[2933,2943,2952,2961,2971],{"nctId":2934,"briefTitle":2935,"status":61,"phases":2936,"primaryCompletion":2937,"completion":2937,"start":2938,"enrollment":2939,"conditions":2940,"interventions":2942},"NCT03777059","12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine",[44],"2020-06-19","2018-12-14",910,[2941],"Episodic Migraine",[2923],{"nctId":2944,"briefTitle":2945,"status":61,"phases":2946,"primaryCompletion":2947,"completion":2947,"start":2762,"enrollment":2948,"conditions":2949,"interventions":2950},"NCT03700320","Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine",[44],"2020-05-21",744,[2941],[2951,2923],"Standard of Care (SOC) Migraine Preventive Medication",{"nctId":2953,"briefTitle":2954,"status":61,"phases":2955,"primaryCompletion":2956,"completion":2956,"start":2957,"enrollment":616,"conditions":2958,"interventions":2960},"NCT04829747","Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine",[44],"2022-01-20","2021-08-02",[2959],"Chronic Migraine",[2923],{"nctId":2962,"briefTitle":2963,"status":61,"phases":2964,"primaryCompletion":2965,"completion":2966,"start":2967,"enrollment":2968,"conditions":2969,"interventions":2970},"NCT02848326","Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention",[43,44],"2018-04-02","2018-04-23","2016-09-06",834,[673],[2923],{"nctId":2972,"briefTitle":2973,"status":61,"phases":2974,"primaryCompletion":2975,"completion":2975,"start":2976,"enrollment":2977,"conditions":2978,"interventions":2979},"NCT03939312","Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine",[44],"2021-03-31","2019-05-06",685,[2941],[2923],{"trials":2981,"activeCount":13},[],{"trials":2983,"activeCount":13},[],{"intervention":675,"totalTrials":79,"cells":2985},{"EARLY_PHASE1":2986,"PHASE1":2988,"PHASE2":3001,"PHASE3":3003,"PHASE4":3029,"NA":3031},{"trials":2987,"activeCount":13},[],{"trials":2989,"activeCount":13},[2990],{"nctId":2991,"briefTitle":2992,"status":61,"phases":2993,"primaryCompletion":2994,"completion":2994,"start":2995,"enrollment":1206,"conditions":2996,"interventions":2998},"NCT04179474","Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine",[42],"2019-12-23","2019-09-26",[2997],"Migraine",[675,2999,3000],"Erenumab","Galcanezumab",{"trials":3002,"activeCount":13},[],{"trials":3004,"activeCount":13},[3005,3009,3019],{"nctId":666,"briefTitle":667,"status":61,"phases":3006,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":3007,"interventions":3008},[44],[673],[675,655],{"nctId":3010,"briefTitle":3011,"status":61,"phases":3012,"primaryCompletion":3013,"completion":3014,"start":3015,"enrollment":3016,"conditions":3017,"interventions":3018},"NCT02828020","Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine",[44],"2017-12-13","2017-12-14","2016-07-22",1672,[673],[675],{"nctId":3020,"briefTitle":3021,"status":61,"phases":3022,"primaryCompletion":3023,"completion":3024,"start":3025,"enrollment":3026,"conditions":3027,"interventions":3028},"NCT02867709","Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",[44],"2018-01-25","2018-02-26","2016-08-26",1686,[673],[675],{"trials":3030,"activeCount":13},[],{"trials":3032,"activeCount":13},[],{"intervention":3034,"totalTrials":616,"cells":3035},"Bimatoprost SR",{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3040,"PHASE3":3042,"PHASE4":3076,"NA":3078},{"trials":3037,"activeCount":13},[],{"trials":3039,"activeCount":13},[],{"trials":3041,"activeCount":13},[],{"trials":3043,"activeCount":13},[3044,3055,3067],{"nctId":3045,"briefTitle":3046,"status":61,"phases":3047,"primaryCompletion":3048,"completion":3048,"start":3049,"enrollment":3050,"conditions":3051,"interventions":3053},"NCT02636946","A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension",[44],"2021-01-26","2016-02-24",144,[20,3052],"Open-Angle Ocular Hypertension",[3034,3054],"Sham Bimatoprost SR",{"nctId":3056,"briefTitle":3057,"status":61,"phases":3058,"primaryCompletion":3059,"completion":3060,"start":3061,"enrollment":3062,"conditions":3063,"interventions":3064},"NCT02250651","Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension",[44],"2018-10-25","2020-07-22","2014-12-15",528,[23,17],[3034,3065,3066],"Active Comparator: Timolol 0.5%","Timolol Vehicle",{"nctId":3068,"briefTitle":3069,"status":61,"phases":3070,"primaryCompletion":3071,"completion":3072,"start":3061,"enrollment":3073,"conditions":3074,"interventions":3075},"NCT02247804","Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension",[44],"2018-02-19","2019-07-19",594,[23,17],[3034,3065,3066],{"trials":3077,"activeCount":13},[],{"trials":3079,"activeCount":13},[],{"intervention":3081,"totalTrials":616,"cells":3082},"bimatoprost\u002Ftimolol fixed combination",{"EARLY_PHASE1":3083,"PHASE1":3085,"PHASE2":3087,"PHASE3":3089,"PHASE4":3115,"NA":3117},{"trials":3084,"activeCount":13},[],{"trials":3086,"activeCount":13},[],{"trials":3088,"activeCount":13},[],{"trials":3090,"activeCount":13},[3091,3100,3108],{"nctId":3092,"briefTitle":3093,"status":61,"phases":3094,"primaryCompletion":3095,"completion":3095,"start":3096,"enrollment":3097,"conditions":3098,"interventions":3099},"NCT00332540","Safety and Efficacy Study of Bimatoprost\u002FTimolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",[44],"2003-08","2001-08",520,[17],[3081],{"nctId":3101,"briefTitle":3093,"status":61,"phases":3102,"primaryCompletion":3103,"completion":3103,"start":3104,"enrollment":3105,"conditions":3106,"interventions":3107},"NCT00332059",[44],"2004-09","2003-05",445,[17],[3081],{"nctId":3109,"briefTitle":3110,"status":61,"phases":3111,"primaryCompletion":3095,"completion":3095,"start":3096,"enrollment":3112,"conditions":3113,"interventions":3114},"NCT00332072","Safety and Efficacy Study of Bimatoprost\u002FTimolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension",[44],541,[17],[3081],{"trials":3116,"activeCount":13},[],{"trials":3118,"activeCount":13},[],{"intervention":3120,"totalTrials":616,"cells":3121},"bimatoprost vehicle",{"EARLY_PHASE1":3122,"PHASE1":3124,"PHASE2":3126,"PHASE3":3150,"PHASE4":3162,"NA":3164},{"trials":3123,"activeCount":13},[],{"trials":3125,"activeCount":13},[],{"trials":3127,"activeCount":13},[3128,3140],{"nctId":3129,"briefTitle":3130,"status":61,"phases":3131,"primaryCompletion":89,"completion":3132,"start":3133,"enrollment":3134,"conditions":3135,"interventions":3136},"NCT01904721","A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)",[43],"2015-01","2013-08",244,[395,396,397],[3137,3138,3139],"Bimatoprost Solution 1","Bimatoprost Solution 2","Bimatoprost Vehicle",{"nctId":3141,"briefTitle":3142,"status":61,"phases":3143,"primaryCompletion":345,"completion":345,"start":3144,"enrollment":3145,"conditions":3146,"interventions":3147},"NCT01291108","Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension",[43],"2011-04",125,[23,17],[3148,3149,3120],"AGN-210669","bimatoprost",{"trials":3151,"activeCount":13},[3152],{"nctId":3153,"briefTitle":3154,"status":75,"phases":3155,"primaryCompletion":796,"completion":796,"start":3156,"enrollment":3157,"conditions":3158,"interventions":3159},"NCT01426113","A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma",[44],"2011-09",6,[20],[3160,3161,3120],"bimatoprost ophthalmic solution formulation A","timolol ophthalmic solution",{"trials":3163,"activeCount":13},[],{"trials":3165,"activeCount":13},[],{"intervention":3167,"totalTrials":616,"cells":3168},"AGN-229666",{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3173,"PHASE3":3184,"PHASE4":3204,"NA":3206},{"trials":3170,"activeCount":13},[],{"trials":3172,"activeCount":13},[],{"trials":3174,"activeCount":13},[3175],{"nctId":3176,"briefTitle":3177,"status":61,"phases":3178,"primaryCompletion":3179,"completion":1465,"start":1046,"enrollment":3180,"conditions":3181,"interventions":3183},"NCT01754766","AGN-229666 for the Treatment of Allergic Conjunctivitis",[43],"2013-01",90,[3182],"Allergic Conjunctivitis",[3167],{"trials":3185,"activeCount":13},[3186,3197],{"nctId":3187,"briefTitle":3188,"status":61,"phases":3189,"primaryCompletion":3190,"completion":3190,"start":3191,"enrollment":3192,"conditions":3193,"interventions":3194},"NCT02161146","AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis",[44],"2014-12-20","2014-06-04",240,[1234],[3167,3195,3196],"Vehicle to AGN-229666","Olopatadine",{"nctId":3198,"briefTitle":3199,"status":61,"phases":3200,"primaryCompletion":109,"completion":109,"start":3201,"enrollment":1729,"conditions":3202,"interventions":3203},"NCT02082262","AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis",[44],"2014-03",[1234],[3167],{"trials":3205,"activeCount":13},[],{"trials":3207,"activeCount":13},[],{"intervention":3209,"totalTrials":616,"cells":3210},"brimonidine\u002Ftimolol fixed combination",{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3215,"PHASE3":3226,"PHASE4":3242,"NA":3244},{"trials":3212,"activeCount":13},[],{"trials":3214,"activeCount":13},[],{"trials":3216,"activeCount":13},[3217],{"nctId":3218,"briefTitle":3219,"status":61,"phases":3220,"primaryCompletion":3221,"completion":3221,"start":3222,"enrollment":3223,"conditions":3224,"interventions":3225},"NCT00332345","Safety and Efficacy Study of Brimonidine\u002FTimolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",[43],"1999-08","1999-07",73,[17],[3209],{"trials":3227,"activeCount":13},[3228,3236],{"nctId":3229,"briefTitle":3219,"status":61,"phases":3230,"primaryCompletion":3231,"completion":3231,"start":3232,"enrollment":3233,"conditions":3234,"interventions":3235},"NCT00332384",[44],"2001-11","2000-01",573,[17],[3209],{"nctId":3237,"briefTitle":3219,"status":61,"phases":3238,"primaryCompletion":3231,"completion":3231,"start":3239,"enrollment":864,"conditions":3240,"interventions":3241},"NCT00332436",[44],"1999-12",[17],[3209],{"trials":3243,"activeCount":13},[],{"trials":3245,"activeCount":13},[],{"intervention":3247,"totalTrials":616,"cells":3248},"carboxymethylcellulose sodium based eye drops",{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3255,"PHASE4":3290,"NA":3292},{"trials":3250,"activeCount":13},[],{"trials":3252,"activeCount":13},[],{"trials":3254,"activeCount":13},[],{"trials":3256,"activeCount":13},[3257,3267,3278],{"nctId":3258,"briefTitle":3259,"status":61,"phases":3260,"primaryCompletion":3261,"completion":3261,"start":3262,"enrollment":889,"conditions":3263,"interventions":3265},"NCT01886690","A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery",[44],"2014-08-18","2013-08-20",[3264],"Bilateral LASIK Surgery",[3266,3247],"carboxymethylcellulose sodium based new eye drop formulation",{"nctId":3268,"briefTitle":3269,"status":61,"phases":3270,"primaryCompletion":3271,"completion":3271,"start":807,"enrollment":3272,"conditions":3273,"interventions":3274},"NCT02455050","A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief",[44],"2015-08",79,[26],[3275,3276,3277],"Carboxymethylcellulose Sodium Based Eye Drops","Systane® Gel Drops","Genteal® Lubricant Gel Drops",{"nctId":3279,"briefTitle":3280,"status":61,"phases":3281,"primaryCompletion":3282,"completion":3282,"start":3283,"enrollment":3284,"conditions":3285,"interventions":3286},"NCT01294384","Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease",[44],"2012-09-25","2011-05-01",305,[26],[3287,3288,3289],"carboxymethylcellulose sodium based New Eye Drop Formulation 1","carboxymethylcellulose sodium based New Eye Drop Formulation 2","carboxymethylcellulose sodium based Eye Drops",{"trials":3291,"activeCount":13},[],{"trials":3293,"activeCount":13},[],{"intervention":2680,"totalTrials":616,"cells":3295},{"EARLY_PHASE1":3296,"PHASE1":3298,"PHASE2":3300,"PHASE3":3316,"PHASE4":3322,"NA":3324},{"trials":3297,"activeCount":13},[],{"trials":3299,"activeCount":13},[],{"trials":3301,"activeCount":13},[3302,3312],{"nctId":3303,"briefTitle":3304,"status":61,"phases":3305,"primaryCompletion":2851,"completion":3306,"start":986,"enrollment":3307,"conditions":3308,"interventions":3309},"NCT00693485","Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy",[43],"2011-08",70,[23],[3310,3311,2680],"400 ug Brimonidine Implant","200 ug Brimonidine Implant",{"nctId":2671,"briefTitle":2672,"status":61,"phases":3313,"primaryCompletion":2674,"completion":2674,"start":2675,"enrollment":2676,"conditions":3314,"interventions":3315},[43],[2678],[2658,2680],{"trials":3317,"activeCount":13},[3318],{"nctId":2730,"briefTitle":2731,"status":61,"phases":3319,"primaryCompletion":888,"completion":477,"start":2701,"enrollment":2733,"conditions":3320,"interventions":3321},[43,44],[2735,2736],[2658,71,2680],{"trials":3323,"activeCount":13},[],{"trials":3325,"activeCount":13},[],{"intervention":3327,"totalTrials":616,"cells":3328},"Ulipristal acetate",{"EARLY_PHASE1":3329,"PHASE1":3331,"PHASE2":3343,"PHASE3":3345,"PHASE4":3365,"NA":3367},{"trials":3330,"activeCount":13},[],{"trials":3332,"activeCount":13},[3333],{"nctId":3334,"briefTitle":3335,"status":61,"phases":3336,"primaryCompletion":3337,"completion":3337,"start":3338,"enrollment":3339,"conditions":3340,"interventions":3342},"NCT02634437","Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects",[42],"2016-12-09","2015-12-01",19,[3341],"Renal Function",[3327],{"trials":3344,"activeCount":13},[],{"trials":3346,"activeCount":13},[3347,3356],{"nctId":3348,"briefTitle":3349,"status":61,"phases":3350,"primaryCompletion":3351,"completion":3351,"start":127,"enrollment":1232,"conditions":3352,"interventions":3355},"NCT02147197","A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas",[44],"2016-03-29",[3353,3354],"Leiomyoma","Uterine Hemorrhage",[3327],{"nctId":3357,"briefTitle":3358,"status":61,"phases":3359,"primaryCompletion":3360,"completion":3360,"start":3361,"enrollment":3362,"conditions":3363,"interventions":3364},"NCT02147158","A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas",[44],"2016-11-24","2014-01-29",432,[3353,3354],[3327],{"trials":3366,"activeCount":13},[],{"trials":3368,"activeCount":13},[],{"intervention":3370,"totalTrials":616,"cells":3371},"memantine",{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3388,"PHASE3":3390,"PHASE4":3409,"NA":3411},{"trials":3373,"activeCount":13},[],{"trials":3375,"activeCount":13},[3376],{"nctId":3377,"briefTitle":3378,"status":214,"phases":3379,"primaryCompletion":3380,"completion":3380,"start":3381,"enrollment":13,"conditions":3382,"interventions":3384},"NCT03316898","A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease",[42],"2018-11-04","2018-09-30",[3383],"Alzheimer's Disease",[3385,3386,3387],"AGN-242071","Donepezil","Memantine",{"trials":3389,"activeCount":13},[],{"trials":3391,"activeCount":13},[3392,3401],{"nctId":3393,"briefTitle":3394,"status":61,"phases":3395,"primaryCompletion":3396,"completion":3396,"start":3397,"enrollment":3398,"conditions":3399,"interventions":3400},"NCT00168350","Memantine in Patients With Chronic Glaucoma",[44],"2006-09","2000-03",1179,[1731],[3370],{"nctId":3402,"briefTitle":3394,"status":61,"phases":3403,"primaryCompletion":3404,"completion":854,"start":3405,"enrollment":3406,"conditions":3407,"interventions":3408},"NCT00141882",[44],"2006-01","1999-03",1119,[1731],[3370],{"trials":3410,"activeCount":13},[],{"trials":3412,"activeCount":13},[],{"intervention":244,"totalTrials":780,"cells":3414},{"EARLY_PHASE1":3415,"PHASE1":3417,"PHASE2":3419,"PHASE3":3421,"PHASE4":3431,"NA":3433},{"trials":3416,"activeCount":13},[],{"trials":3418,"activeCount":13},[],{"trials":3420,"activeCount":13},[],{"trials":3422,"activeCount":13},[3423,3427],{"nctId":236,"briefTitle":237,"status":75,"phases":3424,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":3425,"interventions":3426},[44],[26],[244,181],{"nctId":246,"briefTitle":237,"status":75,"phases":3428,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":3429,"interventions":3430},[44],[26],[244,181],{"trials":3432,"activeCount":13},[],{"trials":3434,"activeCount":13},[],{"intervention":3436,"totalTrials":780,"cells":3437},"700 µg Dexamethasone",{"EARLY_PHASE1":3438,"PHASE1":3440,"PHASE2":3442,"PHASE3":3444,"PHASE4":3465,"NA":3467},{"trials":3439,"activeCount":13},[],{"trials":3441,"activeCount":13},[],{"trials":3443,"activeCount":13},[],{"trials":3445,"activeCount":13},[3446,3457],{"nctId":3447,"briefTitle":3448,"status":61,"phases":3449,"primaryCompletion":3450,"completion":3451,"start":3452,"enrollment":3453,"conditions":3454,"interventions":3455},"NCT00168324","A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion",[44],"2008-03-01","2008-10-01","2004-10-01",599,[29,175],[3436,3456],"350 µg Dexamethasone",{"nctId":3458,"briefTitle":3448,"status":61,"phases":3459,"primaryCompletion":3450,"completion":3460,"start":3461,"enrollment":3462,"conditions":3463,"interventions":3464},"NCT00168298",[44],"2008-09-05","2004-11-01",668,[29,175],[3436,3456],{"trials":3466,"activeCount":13},[],{"trials":3468,"activeCount":13},[],{"intervention":3456,"totalTrials":780,"cells":3470},{"EARLY_PHASE1":3471,"PHASE1":3473,"PHASE2":3475,"PHASE3":3477,"PHASE4":3487,"NA":3489},{"trials":3472,"activeCount":13},[],{"trials":3474,"activeCount":13},[],{"trials":3476,"activeCount":13},[],{"trials":3478,"activeCount":13},[3479,3483],{"nctId":3447,"briefTitle":3448,"status":61,"phases":3480,"primaryCompletion":3450,"completion":3451,"start":3452,"enrollment":3453,"conditions":3481,"interventions":3482},[44],[29,175],[3436,3456],{"nctId":3458,"briefTitle":3448,"status":61,"phases":3484,"primaryCompletion":3450,"completion":3460,"start":3461,"enrollment":3462,"conditions":3485,"interventions":3486},[44],[29,175],[3436,3456],{"trials":3488,"activeCount":13},[],{"trials":3490,"activeCount":13},[],{"intervention":3492,"totalTrials":780,"cells":3493},"Pilocarpine HCl Ophthalmic Solution",{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3498,"PHASE3":3500,"PHASE4":3520,"NA":3522},{"trials":3495,"activeCount":13},[],{"trials":3497,"activeCount":13},[],{"trials":3499,"activeCount":13},[],{"trials":3501,"activeCount":13},[3502,3511],{"nctId":3503,"briefTitle":3504,"status":61,"phases":3505,"primaryCompletion":3506,"completion":3506,"start":3507,"enrollment":3508,"conditions":3509,"interventions":3510},"NCT03857542","A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia",[44],"2020-09-10","2019-03-01",427,[219],[3492],{"nctId":3512,"briefTitle":3513,"status":61,"phases":3514,"primaryCompletion":3515,"completion":3515,"start":3516,"enrollment":3517,"conditions":3518,"interventions":3519},"NCT03804268","Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia",[44],"2019-10-31","2018-12-21",323,[219],[3492],{"trials":3521,"activeCount":13},[],{"trials":3523,"activeCount":13},[],{"intervention":3525,"totalTrials":780,"cells":3526},"Gatifloxacin 0.5% eye drops",{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3533,"PHASE4":3550,"NA":3552},{"trials":3528,"activeCount":13},[],{"trials":3530,"activeCount":13},[],{"trials":3532,"activeCount":13},[],{"trials":3534,"activeCount":13},[3535,3542],{"nctId":3536,"briefTitle":3537,"status":61,"phases":3538,"primaryCompletion":1553,"completion":1553,"start":1554,"enrollment":3539,"conditions":3540,"interventions":3541},"NCT00509873","A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis",[44],578,[2505],[3525],{"nctId":3543,"briefTitle":3537,"status":61,"phases":3544,"primaryCompletion":3545,"completion":3545,"start":3546,"enrollment":3547,"conditions":3548,"interventions":3549},"NCT00518089",[44],"2009-01","2008-02",859,[2505],[3525],{"trials":3551,"activeCount":13},[],{"trials":3553,"activeCount":13},[],{"intervention":3555,"totalTrials":780,"cells":3556},"BOTOX®",{"EARLY_PHASE1":3557,"PHASE1":3559,"PHASE2":3561,"PHASE3":3563,"PHASE4":3589,"NA":3591},{"trials":3558,"activeCount":13},[],{"trials":3560,"activeCount":13},[],{"trials":3562,"activeCount":13},[],{"trials":3564,"activeCount":13},[3565,3579],{"nctId":3566,"briefTitle":3567,"status":61,"phases":3568,"primaryCompletion":3569,"completion":3570,"start":3571,"enrollment":3572,"conditions":3573,"interventions":3575},"NCT01767519","A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence",[44],"2014-09-30","2015-03-18","2013-03-01",356,[35,3574],"Urinary Incontinence",[3555,3576,3577,3578],"solifenacin","Botox placebo","solifenacin placebo",{"nctId":3580,"briefTitle":3581,"status":75,"phases":3582,"primaryCompletion":3583,"completion":3583,"start":3584,"enrollment":2687,"conditions":3585,"interventions":3588},"NCT02097121","OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)",[44],"2022-02-10","2014-05-23",[3574,3586,3587],"Urinary Bladder","Overactive",[3555],{"trials":3590,"activeCount":13},[],{"trials":3592,"activeCount":13},[],{"intervention":3594,"totalTrials":780,"cells":3595},"0.135mg MAP0010",{"EARLY_PHASE1":3596,"PHASE1":3598,"PHASE2":3600,"PHASE3":3602,"PHASE4":3621,"NA":3623},{"trials":3597,"activeCount":13},[],{"trials":3599,"activeCount":13},[],{"trials":3601,"activeCount":13},[],{"trials":3603,"activeCount":13},[3604,3614],{"nctId":3605,"briefTitle":3606,"status":75,"phases":3607,"primaryCompletion":476,"completion":897,"start":3608,"enrollment":3609,"conditions":3610,"interventions":3612},"NCT00697697","A Study of 2 Doses of MAP0010 in Asthmatic Children",[44],"2008-04",192,[3611],"Asthma",[3594,3613],"0.25mg MAP0010",{"nctId":3615,"briefTitle":3616,"status":61,"phases":3617,"primaryCompletion":986,"completion":3545,"start":631,"enrollment":3618,"conditions":3619,"interventions":3620},"NCT00569192","A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children",[44],360,[3611],[3594,3613],{"trials":3622,"activeCount":13},[],{"trials":3624,"activeCount":13},[],{"intervention":3613,"totalTrials":780,"cells":3626},{"EARLY_PHASE1":3627,"PHASE1":3629,"PHASE2":3631,"PHASE3":3633,"PHASE4":3643,"NA":3645},{"trials":3628,"activeCount":13},[],{"trials":3630,"activeCount":13},[],{"trials":3632,"activeCount":13},[],{"trials":3634,"activeCount":13},[3635,3639],{"nctId":3605,"briefTitle":3606,"status":75,"phases":3636,"primaryCompletion":476,"completion":897,"start":3608,"enrollment":3609,"conditions":3637,"interventions":3638},[44],[3611],[3594,3613],{"nctId":3615,"briefTitle":3616,"status":61,"phases":3640,"primaryCompletion":986,"completion":3545,"start":631,"enrollment":3618,"conditions":3641,"interventions":3642},[44],[3611],[3594,3613],{"trials":3644,"activeCount":13},[],{"trials":3646,"activeCount":13},[],{"intervention":3648,"totalTrials":780,"cells":3649},"Carboxymethylcellulose Based Eye Drop Formulation A",{"EARLY_PHASE1":3650,"PHASE1":3652,"PHASE2":3654,"PHASE3":3656,"PHASE4":3678,"NA":3680},{"trials":3651,"activeCount":13},[],{"trials":3653,"activeCount":13},[],{"trials":3655,"activeCount":13},[],{"trials":3657,"activeCount":13},[3658,3667],{"nctId":3659,"briefTitle":3660,"status":61,"phases":3661,"primaryCompletion":808,"completion":808,"start":3179,"enrollment":3662,"conditions":3663,"interventions":3665},"NCT01664949","A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease",[44],460,[3664],"Dry Eye Disease",[3648,3666],"Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops",{"nctId":3668,"briefTitle":3669,"status":61,"phases":3670,"primaryCompletion":3671,"completion":3671,"start":3672,"enrollment":3673,"conditions":3674,"interventions":3675},"NCT01459588","Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease",[44],"2012-02-15","2011-10-01",315,[26],[3648,3676,3666,3677],"Carboxymethylcellulose Based Eye Drop Formulation B","Carboxymethylcellulose Based Lubricant Eye Drops",{"trials":3679,"activeCount":13},[],{"trials":3681,"activeCount":13},[],{"intervention":3666,"totalTrials":780,"cells":3683},{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3688,"PHASE3":3690,"PHASE4":3700,"NA":3702},{"trials":3685,"activeCount":13},[],{"trials":3687,"activeCount":13},[],{"trials":3689,"activeCount":13},[],{"trials":3691,"activeCount":13},[3692,3696],{"nctId":3659,"briefTitle":3660,"status":61,"phases":3693,"primaryCompletion":808,"completion":808,"start":3179,"enrollment":3662,"conditions":3694,"interventions":3695},[44],[3664],[3648,3666],{"nctId":3668,"briefTitle":3669,"status":61,"phases":3697,"primaryCompletion":3671,"completion":3671,"start":3672,"enrollment":3673,"conditions":3698,"interventions":3699},[44],[26],[3648,3676,3666,3677],{"trials":3701,"activeCount":13},[],{"trials":3703,"activeCount":13},[],{"intervention":3065,"totalTrials":780,"cells":3705},{"EARLY_PHASE1":3706,"PHASE1":3708,"PHASE2":3710,"PHASE3":3712,"PHASE4":3722,"NA":3724},{"trials":3707,"activeCount":13},[],{"trials":3709,"activeCount":13},[],{"trials":3711,"activeCount":13},[],{"trials":3713,"activeCount":13},[3714,3718],{"nctId":3056,"briefTitle":3057,"status":61,"phases":3715,"primaryCompletion":3059,"completion":3060,"start":3061,"enrollment":3062,"conditions":3716,"interventions":3717},[44],[23,17],[3034,3065,3066],{"nctId":3068,"briefTitle":3069,"status":61,"phases":3719,"primaryCompletion":3071,"completion":3072,"start":3061,"enrollment":3073,"conditions":3720,"interventions":3721},[44],[23,17],[3034,3065,3066],{"trials":3723,"activeCount":13},[],{"trials":3725,"activeCount":13},[],{"intervention":3066,"totalTrials":780,"cells":3727},{"EARLY_PHASE1":3728,"PHASE1":3730,"PHASE2":3732,"PHASE3":3734,"PHASE4":3744,"NA":3746},{"trials":3729,"activeCount":13},[],{"trials":3731,"activeCount":13},[],{"trials":3733,"activeCount":13},[],{"trials":3735,"activeCount":13},[3736,3740],{"nctId":3056,"briefTitle":3057,"status":61,"phases":3737,"primaryCompletion":3059,"completion":3060,"start":3061,"enrollment":3062,"conditions":3738,"interventions":3739},[44],[23,17],[3034,3065,3066],{"nctId":3068,"briefTitle":3069,"status":61,"phases":3741,"primaryCompletion":3071,"completion":3072,"start":3061,"enrollment":3073,"conditions":3742,"interventions":3743},[44],[23,17],[3034,3065,3066],{"trials":3745,"activeCount":13},[],{"trials":3747,"activeCount":13},[],{"intervention":3749,"totalTrials":780,"cells":3750},"AGN-199201",{"EARLY_PHASE1":3751,"PHASE1":3753,"PHASE2":3755,"PHASE3":3765,"PHASE4":3777,"NA":3779},{"trials":3752,"activeCount":13},[],{"trials":3754,"activeCount":13},[],{"trials":3756,"activeCount":13},[3757],{"nctId":3758,"briefTitle":3759,"status":61,"phases":3760,"primaryCompletion":796,"completion":3761,"start":109,"enrollment":2608,"conditions":3762,"interventions":3763},"NCT02197806","Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia",[43],"2014-11",[219],[3749,221,3764],"AGN-199201 Vehicle",{"trials":3766,"activeCount":13},[3767],{"nctId":3768,"briefTitle":3769,"status":61,"phases":3770,"primaryCompletion":3761,"completion":807,"start":808,"enrollment":3771,"conditions":3772,"interventions":3775},"NCT02131636","Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea",[44],440,[3773,3774],"Erythema","Rosacea",[3749,3776],"Vehicle to AGN-199201",{"trials":3778,"activeCount":13},[],{"trials":3780,"activeCount":13},[],{"intervention":3782,"totalTrials":780,"cells":3783},"Oxymetazoline HCL Cream 1.0%",{"EARLY_PHASE1":3784,"PHASE1":3786,"PHASE2":3788,"PHASE3":3790,"PHASE4":3809,"NA":3811},{"trials":3785,"activeCount":13},[],{"trials":3787,"activeCount":13},[],{"trials":3789,"activeCount":13},[],{"trials":3791,"activeCount":13},[3792,3800],{"nctId":3793,"briefTitle":3794,"status":61,"phases":3795,"primaryCompletion":3271,"completion":3796,"start":3797,"enrollment":3771,"conditions":3798,"interventions":3799},"NCT02095158","A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea",[44],"2015-09","2014-04",[3773,3774],[3782],{"nctId":3801,"briefTitle":3802,"status":61,"phases":3803,"primaryCompletion":3804,"completion":3805,"start":2001,"enrollment":3105,"conditions":3806,"interventions":3807},"NCT02132117","Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea",[44],"2015-04","2015-05",[3773,3774],[3782,3808],"Vehicle to Oxymetazoline HCL Cream",{"trials":3810,"activeCount":13},[],{"trials":3812,"activeCount":13},[],{"intervention":3814,"totalTrials":780,"cells":3815},"bimatoprost\u002Fbrimonidine tartrate\u002Ftimolol ophthalmic solution",{"EARLY_PHASE1":3816,"PHASE1":3818,"PHASE2":3820,"PHASE3":3822,"PHASE4":3838,"NA":3840},{"trials":3817,"activeCount":13},[],{"trials":3819,"activeCount":13},[],{"trials":3821,"activeCount":13},[],{"trials":3823,"activeCount":13},[3824,3832],{"nctId":3825,"briefTitle":3826,"status":61,"phases":3827,"primaryCompletion":89,"completion":108,"start":2851,"enrollment":3828,"conditions":3829,"interventions":3830},"NCT01217606","Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension",[44],185,[23,17],[3814,3831],"Fixed Combination 0.2% brimonidine tartrate\u002F0.5% timolol ophthalmic solution",{"nctId":3833,"briefTitle":3826,"status":61,"phases":3834,"primaryCompletion":3835,"completion":3835,"start":466,"enrollment":3609,"conditions":3836,"interventions":3837},"NCT01241240",[44],"2013-09",[23,17],[3814,3831],{"trials":3839,"activeCount":13},[],{"trials":3841,"activeCount":13},[],{"intervention":3831,"totalTrials":780,"cells":3843},{"EARLY_PHASE1":3844,"PHASE1":3846,"PHASE2":3848,"PHASE3":3850,"PHASE4":3860,"NA":3862},{"trials":3845,"activeCount":13},[],{"trials":3847,"activeCount":13},[],{"trials":3849,"activeCount":13},[],{"trials":3851,"activeCount":13},[3852,3856],{"nctId":3825,"briefTitle":3826,"status":61,"phases":3853,"primaryCompletion":89,"completion":108,"start":2851,"enrollment":3828,"conditions":3854,"interventions":3855},[44],[23,17],[3814,3831],{"nctId":3833,"briefTitle":3826,"status":61,"phases":3857,"primaryCompletion":3835,"completion":3835,"start":466,"enrollment":3609,"conditions":3858,"interventions":3859},[44],[23,17],[3814,3831],{"trials":3861,"activeCount":13},[],{"trials":3863,"activeCount":13},[],{"intervention":3865,"totalTrials":780,"cells":3866},"Atogepant 60 mg",{"EARLY_PHASE1":3867,"PHASE1":3869,"PHASE2":3871,"PHASE3":3873,"PHASE4":3892,"NA":3894},{"trials":3868,"activeCount":13},[],{"trials":3870,"activeCount":13},[],{"trials":3872,"activeCount":13},[],{"trials":3874,"activeCount":13},[3875,3883],{"nctId":3876,"briefTitle":3877,"status":61,"phases":3878,"primaryCompletion":3879,"completion":3879,"start":3880,"enrollment":3673,"conditions":3881,"interventions":3882},"NCT04740827","Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.",[44],"2022-08-04","2021-03-05",[2941],[3865],{"nctId":3884,"briefTitle":3885,"status":61,"phases":3886,"primaryCompletion":2956,"completion":2956,"start":3887,"enrollment":3888,"conditions":3889,"interventions":3890},"NCT03855137","Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine",[44],"2019-03-11",778,[2959],[3891,3865],"Atogepant 30 mg",{"trials":3893,"activeCount":13},[],{"trials":3895,"activeCount":13},[],{"intervention":3897,"totalTrials":780,"cells":3898},"onabotulinumtoxinA 24 U",{"EARLY_PHASE1":3899,"PHASE1":3901,"PHASE2":3903,"PHASE3":3905,"PHASE4":3924,"NA":3926},{"trials":3900,"activeCount":13},[],{"trials":3902,"activeCount":13},[],{"trials":3904,"activeCount":13},[],{"trials":3906,"activeCount":13},[3907,3918],{"nctId":3908,"briefTitle":3909,"status":61,"phases":3910,"primaryCompletion":3911,"completion":129,"start":3912,"enrollment":3913,"conditions":3914,"interventions":3915},"NCT01189760","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines",[44],"2011-03-01","2010-09-01",917,[371,372,373],[3897,3916,3917],"onabotulinumtoxinA 44 U","normal saline",{"nctId":3919,"briefTitle":3909,"status":61,"phases":3920,"primaryCompletion":345,"completion":1021,"start":77,"enrollment":3921,"conditions":3922,"interventions":3923},"NCT01224015",[44],684,[371,372,373],[3917,3916,3897],{"trials":3925,"activeCount":13},[],{"trials":3927,"activeCount":13},[],{"intervention":3916,"totalTrials":780,"cells":3929},{"EARLY_PHASE1":3930,"PHASE1":3932,"PHASE2":3934,"PHASE3":3936,"PHASE4":3946,"NA":3948},{"trials":3931,"activeCount":13},[],{"trials":3933,"activeCount":13},[],{"trials":3935,"activeCount":13},[],{"trials":3937,"activeCount":13},[3938,3942],{"nctId":3908,"briefTitle":3909,"status":61,"phases":3939,"primaryCompletion":3911,"completion":129,"start":3912,"enrollment":3913,"conditions":3940,"interventions":3941},[44],[371,372,373],[3897,3916,3917],{"nctId":3919,"briefTitle":3909,"status":61,"phases":3943,"primaryCompletion":345,"completion":1021,"start":77,"enrollment":3921,"conditions":3944,"interventions":3945},[44],[371,372,373],[3917,3916,3897],{"trials":3947,"activeCount":13},[],{"trials":3949,"activeCount":13},[],{"intervention":423,"totalTrials":780,"cells":3951},{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3956,"PHASE3":3958,"PHASE4":3968,"NA":3970},{"trials":3953,"activeCount":13},[],{"trials":3955,"activeCount":13},[],{"trials":3957,"activeCount":13},[],{"trials":3959,"activeCount":13},[3960,3964],{"nctId":415,"briefTitle":416,"status":61,"phases":3961,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":3962,"interventions":3963},[44],[311],[423,350],{"nctId":425,"briefTitle":426,"status":61,"phases":3965,"primaryCompletion":428,"completion":428,"start":419,"enrollment":241,"conditions":3966,"interventions":3967},[44],[311],[423,350],{"trials":3969,"activeCount":13},[],{"trials":3971,"activeCount":13},[],{"intervention":3973,"totalTrials":10,"cells":3974},"700 μg Dexamethasone",{"EARLY_PHASE1":3975,"PHASE1":3977,"PHASE2":3979,"PHASE3":3981,"PHASE4":3992,"NA":3994},{"trials":3976,"activeCount":13},[],{"trials":3978,"activeCount":13},[],{"trials":3980,"activeCount":13},[],{"trials":3982,"activeCount":13},[3983],{"nctId":3984,"briefTitle":3985,"status":61,"phases":3986,"primaryCompletion":127,"completion":3987,"start":3988,"enrollment":3989,"conditions":3990,"interventions":3991},"NCT01660802","Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)",[44],"2014-05-20","2012-09-04",262,[29],[3973],{"trials":3993,"activeCount":13},[],{"trials":3995,"activeCount":13},[],{"intervention":3054,"totalTrials":10,"cells":3997},{"EARLY_PHASE1":3998,"PHASE1":4000,"PHASE2":4002,"PHASE3":4004,"PHASE4":4010,"NA":4012},{"trials":3999,"activeCount":13},[],{"trials":4001,"activeCount":13},[],{"trials":4003,"activeCount":13},[],{"trials":4005,"activeCount":13},[4006],{"nctId":3045,"briefTitle":3046,"status":61,"phases":4007,"primaryCompletion":3048,"completion":3048,"start":3049,"enrollment":3050,"conditions":4008,"interventions":4009},[44],[20,3052],[3034,3054],{"trials":4011,"activeCount":13},[],{"trials":4013,"activeCount":13},[],{"intervention":637,"totalTrials":10,"cells":4015},{"EARLY_PHASE1":4016,"PHASE1":4018,"PHASE2":4020,"PHASE3":4022,"PHASE4":4028,"NA":4030},{"trials":4017,"activeCount":13},[],{"trials":4019,"activeCount":13},[],{"trials":4021,"activeCount":13},[],{"trials":4023,"activeCount":13},[4024],{"nctId":627,"briefTitle":628,"status":61,"phases":4025,"primaryCompletion":630,"completion":631,"start":632,"enrollment":633,"conditions":4026,"interventions":4027},[44],[635],[637,615],{"trials":4029,"activeCount":13},[],{"trials":4031,"activeCount":13},[],{"intervention":2951,"totalTrials":10,"cells":4033},{"EARLY_PHASE1":4034,"PHASE1":4036,"PHASE2":4038,"PHASE3":4040,"PHASE4":4046,"NA":4048},{"trials":4035,"activeCount":13},[],{"trials":4037,"activeCount":13},[],{"trials":4039,"activeCount":13},[],{"trials":4041,"activeCount":13},[4042],{"nctId":2944,"briefTitle":2945,"status":61,"phases":4043,"primaryCompletion":2947,"completion":2947,"start":2762,"enrollment":2948,"conditions":4044,"interventions":4045},[44],[2941],[2951,2923],{"trials":4047,"activeCount":13},[],{"trials":4049,"activeCount":13},[],{"intervention":4051,"totalTrials":10,"cells":4052},"Refresh Optive® Gel Drops",{"EARLY_PHASE1":4053,"PHASE1":4055,"PHASE2":4057,"PHASE3":4059,"PHASE4":4071,"NA":4073},{"trials":4054,"activeCount":13},[],{"trials":4056,"activeCount":13},[],{"trials":4058,"activeCount":13},[],{"trials":4060,"activeCount":13},[4061],{"nctId":4062,"briefTitle":4063,"status":61,"phases":4064,"primaryCompletion":4065,"completion":4065,"start":4066,"enrollment":4067,"conditions":4068,"interventions":4069},"NCT02280473","A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease",[44],"2015-03-16","2014-11-13",188,[26],[4051,4070],"REFRESH LIQUIGEL®",{"trials":4072,"activeCount":13},[],{"trials":4074,"activeCount":13},[],{"intervention":4070,"totalTrials":10,"cells":4076},{"EARLY_PHASE1":4077,"PHASE1":4079,"PHASE2":4081,"PHASE3":4083,"PHASE4":4089,"NA":4091},{"trials":4078,"activeCount":13},[],{"trials":4080,"activeCount":13},[],{"trials":4082,"activeCount":13},[],{"trials":4084,"activeCount":13},[4085],{"nctId":4062,"briefTitle":4063,"status":61,"phases":4086,"primaryCompletion":4065,"completion":4065,"start":4066,"enrollment":4067,"conditions":4087,"interventions":4088},[44],[26],[4051,4070],{"trials":4090,"activeCount":13},[],{"trials":4092,"activeCount":13},[],{"intervention":4094,"totalTrials":10,"cells":4095},"carboxymethylcellulose based eye drop formula",{"EARLY_PHASE1":4096,"PHASE1":4098,"PHASE2":4100,"PHASE3":4102,"PHASE4":4115,"NA":4117},{"trials":4097,"activeCount":13},[],{"trials":4099,"activeCount":13},[],{"trials":4101,"activeCount":13},[],{"trials":4103,"activeCount":13},[4104],{"nctId":4105,"briefTitle":4106,"status":61,"phases":4107,"primaryCompletion":4108,"completion":4108,"start":4109,"enrollment":4110,"conditions":4111,"interventions":4113},"NCT01844388","A Study to Compare a New Eye Drop Formulation With Refresh Contacts®",[44],"2013-12-02","2013-05-29",365,[4112],"Contact Lens Lubrication",[4094,4114],"carboxymethylcellulose sodium based eye drop solution",{"trials":4116,"activeCount":13},[],{"trials":4118,"activeCount":13},[],{"intervention":4114,"totalTrials":10,"cells":4120},{"EARLY_PHASE1":4121,"PHASE1":4123,"PHASE2":4125,"PHASE3":4127,"PHASE4":4133,"NA":4135},{"trials":4122,"activeCount":13},[],{"trials":4124,"activeCount":13},[],{"trials":4126,"activeCount":13},[],{"trials":4128,"activeCount":13},[4129],{"nctId":4105,"briefTitle":4106,"status":61,"phases":4130,"primaryCompletion":4108,"completion":4108,"start":4109,"enrollment":4110,"conditions":4131,"interventions":4132},[44],[4112],[4094,4114],{"trials":4134,"activeCount":13},[],{"trials":4136,"activeCount":13},[],{"intervention":4138,"totalTrials":10,"cells":4139},"Bimatoprost 0.03% solution",{"EARLY_PHASE1":4140,"PHASE1":4142,"PHASE2":4144,"PHASE3":4146,"PHASE4":4157,"NA":4159},{"trials":4141,"activeCount":13},[],{"trials":4143,"activeCount":13},[],{"trials":4145,"activeCount":13},[],{"trials":4147,"activeCount":13},[4148],{"nctId":4149,"briefTitle":4150,"status":61,"phases":4151,"primaryCompletion":4152,"completion":77,"start":476,"enrollment":4153,"conditions":4154,"interventions":4155},"NCT00907426","Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin",[44],"2010-11",368,[348],[4138,4156],"Vehicle solution",{"trials":4158,"activeCount":13},[],{"trials":4160,"activeCount":13},[],{"intervention":4156,"totalTrials":10,"cells":4162},{"EARLY_PHASE1":4163,"PHASE1":4165,"PHASE2":4167,"PHASE3":4169,"PHASE4":4175,"NA":4177},{"trials":4164,"activeCount":13},[],{"trials":4166,"activeCount":13},[],{"trials":4168,"activeCount":13},[],{"trials":4170,"activeCount":13},[4171],{"nctId":4149,"briefTitle":4150,"status":61,"phases":4172,"primaryCompletion":4152,"completion":77,"start":476,"enrollment":4153,"conditions":4173,"interventions":4174},[44],[348],[4138,4156],{"trials":4176,"activeCount":13},[],{"trials":4178,"activeCount":13},[],{"intervention":1014,"totalTrials":10,"cells":4180},{"EARLY_PHASE1":4181,"PHASE1":4183,"PHASE2":4185,"PHASE3":4187,"PHASE4":4193,"NA":4195},{"trials":4182,"activeCount":13},[],{"trials":4184,"activeCount":13},[],{"trials":4186,"activeCount":13},[],{"trials":4188,"activeCount":13},[4189],{"nctId":1007,"briefTitle":1008,"status":61,"phases":4190,"primaryCompletion":1010,"completion":1010,"start":270,"enrollment":1011,"conditions":4191,"interventions":4192},[44],[20,17],[996,1014],{"trials":4194,"activeCount":13},[],{"trials":4196,"activeCount":13},[],{"intervention":4198,"totalTrials":10,"cells":4199},"Carboxymethylcellulose Based Eye Drop",{"EARLY_PHASE1":4200,"PHASE1":4202,"PHASE2":4204,"PHASE3":4206,"PHASE4":4218,"NA":4220},{"trials":4201,"activeCount":13},[],{"trials":4203,"activeCount":13},[],{"trials":4205,"activeCount":13},[],{"trials":4207,"activeCount":13},[4208],{"nctId":4209,"briefTitle":4210,"status":61,"phases":4211,"primaryCompletion":4212,"completion":4212,"start":4213,"enrollment":4214,"conditions":4215,"interventions":4216},"NCT02553772","A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.",[44],"2016-09-09","2016-01-06",242,[26],[4198,4217],"Carboxymethylcellulose Sodium 0.5%",{"trials":4219,"activeCount":13},[],{"trials":4221,"activeCount":13},[],{"intervention":4217,"totalTrials":10,"cells":4223},{"EARLY_PHASE1":4224,"PHASE1":4226,"PHASE2":4228,"PHASE3":4230,"PHASE4":4236,"NA":4238},{"trials":4225,"activeCount":13},[],{"trials":4227,"activeCount":13},[],{"trials":4229,"activeCount":13},[],{"trials":4231,"activeCount":13},[4232],{"nctId":4209,"briefTitle":4210,"status":61,"phases":4233,"primaryCompletion":4212,"completion":4212,"start":4213,"enrollment":4214,"conditions":4234,"interventions":4235},[44],[26],[4198,4217],{"trials":4237,"activeCount":13},[],{"trials":4239,"activeCount":13},[],{"intervention":4241,"totalTrials":10,"cells":4242},"Carboxymethylcellulose sodium and Glycerin",{"EARLY_PHASE1":4243,"PHASE1":4245,"PHASE2":4247,"PHASE3":4249,"PHASE4":4260,"NA":4262},{"trials":4244,"activeCount":13},[],{"trials":4246,"activeCount":13},[],{"trials":4248,"activeCount":13},[],{"trials":4250,"activeCount":13},[4251],{"nctId":4252,"briefTitle":4253,"status":61,"phases":4254,"primaryCompletion":4255,"completion":4255,"start":4256,"enrollment":2426,"conditions":4257,"interventions":4259},"NCT00243711","A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop",[43,44],"2006-04","2005-09",[4258],"Dry Eye",[4241],{"trials":4261,"activeCount":13},[],{"trials":4263,"activeCount":13},[],{"intervention":3195,"totalTrials":10,"cells":4265},{"EARLY_PHASE1":4266,"PHASE1":4268,"PHASE2":4270,"PHASE3":4272,"PHASE4":4278,"NA":4280},{"trials":4267,"activeCount":13},[],{"trials":4269,"activeCount":13},[],{"trials":4271,"activeCount":13},[],{"trials":4273,"activeCount":13},[4274],{"nctId":3187,"briefTitle":3188,"status":61,"phases":4275,"primaryCompletion":3190,"completion":3190,"start":3191,"enrollment":3192,"conditions":4276,"interventions":4277},[44],[1234],[3167,3195,3196],{"trials":4279,"activeCount":13},[],{"trials":4281,"activeCount":13},[],{"intervention":3196,"totalTrials":10,"cells":4283},{"EARLY_PHASE1":4284,"PHASE1":4286,"PHASE2":4288,"PHASE3":4290,"PHASE4":4296,"NA":4298},{"trials":4285,"activeCount":13},[],{"trials":4287,"activeCount":13},[],{"trials":4289,"activeCount":13},[],{"trials":4291,"activeCount":13},[4292],{"nctId":3187,"briefTitle":3188,"status":61,"phases":4293,"primaryCompletion":3190,"completion":3190,"start":3191,"enrollment":3192,"conditions":4294,"interventions":4295},[44],[1234],[3167,3195,3196],{"trials":4297,"activeCount":13},[],{"trials":4299,"activeCount":13},[],{"intervention":4301,"totalTrials":10,"cells":4302},"brimonidine",{"EARLY_PHASE1":4303,"PHASE1":4305,"PHASE2":4307,"PHASE3":4309,"PHASE4":4318,"NA":4320},{"trials":4304,"activeCount":13},[],{"trials":4306,"activeCount":13},[],{"trials":4308,"activeCount":13},[],{"trials":4310,"activeCount":13},[4311],{"nctId":4312,"briefTitle":4313,"status":61,"phases":4314,"primaryCompletion":854,"completion":854,"start":578,"enrollment":4315,"conditions":4316,"interventions":4317},"NCT00168363","Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension",[44],207,[20,17],[4301],{"trials":4319,"activeCount":13},[],{"trials":4321,"activeCount":13},[],{"intervention":4323,"totalTrials":10,"cells":4324},"011516X",{"EARLY_PHASE1":4325,"PHASE1":4327,"PHASE2":4329,"PHASE3":4331,"PHASE4":4345,"NA":4347},{"trials":4326,"activeCount":13},[],{"trials":4328,"activeCount":13},[],{"trials":4330,"activeCount":13},[],{"trials":4332,"activeCount":13},[4333],{"nctId":4334,"briefTitle":4335,"status":61,"phases":4336,"primaryCompletion":4337,"completion":4337,"start":4338,"enrollment":4339,"conditions":4340,"interventions":4342},"NCT04393441","Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease",[44],"2021-06-15","2020-06-29",400,[4341],"Dry Eye Disease (DED)",[4323,4343,4344],"Systane Ultra Multidose","REFRESH PLUS®",{"trials":4346,"activeCount":13},[],{"trials":4348,"activeCount":13},[],{"intervention":4343,"totalTrials":10,"cells":4350},{"EARLY_PHASE1":4351,"PHASE1":4353,"PHASE2":4355,"PHASE3":4357,"PHASE4":4363,"NA":4365},{"trials":4352,"activeCount":13},[],{"trials":4354,"activeCount":13},[],{"trials":4356,"activeCount":13},[],{"trials":4358,"activeCount":13},[4359],{"nctId":4334,"briefTitle":4335,"status":61,"phases":4360,"primaryCompletion":4337,"completion":4337,"start":4338,"enrollment":4339,"conditions":4361,"interventions":4362},[44],[4341],[4323,4343,4344],{"trials":4364,"activeCount":13},[],{"trials":4366,"activeCount":13},[],{"intervention":4344,"totalTrials":10,"cells":4368},{"EARLY_PHASE1":4369,"PHASE1":4371,"PHASE2":4373,"PHASE3":4375,"PHASE4":4381,"NA":4383},{"trials":4370,"activeCount":13},[],{"trials":4372,"activeCount":13},[],{"trials":4374,"activeCount":13},[],{"trials":4376,"activeCount":13},[4377],{"nctId":4334,"briefTitle":4335,"status":61,"phases":4378,"primaryCompletion":4337,"completion":4337,"start":4338,"enrollment":4339,"conditions":4379,"interventions":4380},[44],[4341],[4323,4343,4344],{"trials":4382,"activeCount":13},[],{"trials":4384,"activeCount":13},[],{"intervention":3576,"totalTrials":10,"cells":4386},{"EARLY_PHASE1":4387,"PHASE1":4389,"PHASE2":4391,"PHASE3":4393,"PHASE4":4399,"NA":4401},{"trials":4388,"activeCount":13},[],{"trials":4390,"activeCount":13},[],{"trials":4392,"activeCount":13},[],{"trials":4394,"activeCount":13},[4395],{"nctId":3566,"briefTitle":3567,"status":61,"phases":4396,"primaryCompletion":3569,"completion":3570,"start":3571,"enrollment":3572,"conditions":4397,"interventions":4398},[44],[35,3574],[3555,3576,3577,3578],{"trials":4400,"activeCount":13},[],{"trials":4402,"activeCount":13},[],{"intervention":3577,"totalTrials":10,"cells":4404},{"EARLY_PHASE1":4405,"PHASE1":4407,"PHASE2":4409,"PHASE3":4411,"PHASE4":4417,"NA":4419},{"trials":4406,"activeCount":13},[],{"trials":4408,"activeCount":13},[],{"trials":4410,"activeCount":13},[],{"trials":4412,"activeCount":13},[4413],{"nctId":3566,"briefTitle":3567,"status":61,"phases":4414,"primaryCompletion":3569,"completion":3570,"start":3571,"enrollment":3572,"conditions":4415,"interventions":4416},[44],[35,3574],[3555,3576,3577,3578],{"trials":4418,"activeCount":13},[],{"trials":4420,"activeCount":13},[],{"intervention":3578,"totalTrials":10,"cells":4422},{"EARLY_PHASE1":4423,"PHASE1":4425,"PHASE2":4427,"PHASE3":4429,"PHASE4":4435,"NA":4437},{"trials":4424,"activeCount":13},[],{"trials":4426,"activeCount":13},[],{"trials":4428,"activeCount":13},[],{"trials":4430,"activeCount":13},[4431],{"nctId":3566,"briefTitle":3567,"status":61,"phases":4432,"primaryCompletion":3569,"completion":3570,"start":3571,"enrollment":3572,"conditions":4433,"interventions":4434},[44],[35,3574],[3555,3576,3577,3578],{"trials":4436,"activeCount":13},[],{"trials":4438,"activeCount":13},[],{"intervention":3266,"totalTrials":10,"cells":4440},{"EARLY_PHASE1":4441,"PHASE1":4443,"PHASE2":4445,"PHASE3":4447,"PHASE4":4453,"NA":4455},{"trials":4442,"activeCount":13},[],{"trials":4444,"activeCount":13},[],{"trials":4446,"activeCount":13},[],{"trials":4448,"activeCount":13},[4449],{"nctId":3258,"briefTitle":3259,"status":61,"phases":4450,"primaryCompletion":3261,"completion":3261,"start":3262,"enrollment":889,"conditions":4451,"interventions":4452},[44],[3264],[3266,3247],{"trials":4454,"activeCount":13},[],{"trials":4456,"activeCount":13},[],{"intervention":4458,"totalTrials":10,"cells":4459},"Dapsone Topical Gel + adapalene gel 0.1%",{"EARLY_PHASE1":4460,"PHASE1":4462,"PHASE2":4464,"PHASE3":4466,"PHASE4":4478,"NA":4480},{"trials":4461,"activeCount":13},[],{"trials":4463,"activeCount":13},[],{"trials":4465,"activeCount":13},[],{"trials":4467,"activeCount":13},[4468],{"nctId":4469,"briefTitle":4470,"status":61,"phases":4471,"primaryCompletion":4472,"completion":4472,"start":2725,"enrollment":4473,"conditions":4474,"interventions":4475},"NCT00151541","A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%",[44],"2005-07",301,[273],[4458,4476,4477],"Dapsone Topical Gel + benzoyl peroxide gel 4%","Dapsone Topical Gel + vehicle control",{"trials":4479,"activeCount":13},[],{"trials":4481,"activeCount":13},[],{"intervention":4476,"totalTrials":10,"cells":4483},{"EARLY_PHASE1":4484,"PHASE1":4486,"PHASE2":4488,"PHASE3":4490,"PHASE4":4496,"NA":4498},{"trials":4485,"activeCount":13},[],{"trials":4487,"activeCount":13},[],{"trials":4489,"activeCount":13},[],{"trials":4491,"activeCount":13},[4492],{"nctId":4469,"briefTitle":4470,"status":61,"phases":4493,"primaryCompletion":4472,"completion":4472,"start":2725,"enrollment":4473,"conditions":4494,"interventions":4495},[44],[273],[4458,4476,4477],{"trials":4497,"activeCount":13},[],{"trials":4499,"activeCount":13},[],{"intervention":4477,"totalTrials":10,"cells":4501},{"EARLY_PHASE1":4502,"PHASE1":4504,"PHASE2":4506,"PHASE3":4508,"PHASE4":4514,"NA":4516},{"trials":4503,"activeCount":13},[],{"trials":4505,"activeCount":13},[],{"trials":4507,"activeCount":13},[],{"trials":4509,"activeCount":13},[4510],{"nctId":4469,"briefTitle":4470,"status":61,"phases":4511,"primaryCompletion":4472,"completion":4472,"start":2725,"enrollment":4473,"conditions":4512,"interventions":4513},[44],[273],[4458,4476,4477],{"trials":4515,"activeCount":13},[],{"trials":4517,"activeCount":13},[],{"intervention":4519,"totalTrials":10,"cells":4520},"Relamorelin 10 μg",{"EARLY_PHASE1":4521,"PHASE1":4523,"PHASE2":4525,"PHASE3":4527,"PHASE4":4538,"NA":4540},{"trials":4522,"activeCount":13},[],{"trials":4524,"activeCount":13},[],{"trials":4526,"activeCount":13},[],{"trials":4528,"activeCount":13},[4529],{"nctId":4530,"briefTitle":4531,"status":75,"phases":4532,"primaryCompletion":4533,"completion":4533,"start":4534,"enrollment":4535,"conditions":4536,"interventions":4537},"NCT03786380","Diabetic Gastroparesis Study 05",[44],"2020-10-05","2018-12-20",202,[2878],[4519],{"trials":4539,"activeCount":13},[],{"trials":4541,"activeCount":13},[],{"intervention":4543,"totalTrials":10,"cells":4544},"ketorolac eye drops",{"EARLY_PHASE1":4545,"PHASE1":4547,"PHASE2":4549,"PHASE3":4551,"PHASE4":4562,"NA":4564},{"trials":4546,"activeCount":13},[],{"trials":4548,"activeCount":13},[],{"trials":4550,"activeCount":13},[],{"trials":4552,"activeCount":13},[4553],{"nctId":4554,"briefTitle":4555,"status":61,"phases":4556,"primaryCompletion":4557,"completion":4557,"start":630,"enrollment":4558,"conditions":4559,"interventions":4561},"NCT00521456","A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery",[44],"2008-03",263,[4560],"Cataract Extraction",[4543],{"trials":4563,"activeCount":13},[],{"trials":4565,"activeCount":13},[],{"intervention":4567,"totalTrials":10,"cells":4568},"Ophthalmic Emulsion",{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4575,"PHASE4":4590,"NA":4592},{"trials":4570,"activeCount":13},[],{"trials":4572,"activeCount":13},[],{"trials":4574,"activeCount":13},[],{"trials":4576,"activeCount":13},[4577],{"nctId":4578,"briefTitle":4579,"status":61,"phases":4580,"primaryCompletion":4581,"completion":4581,"start":4582,"enrollment":4583,"conditions":4584,"interventions":4589},"NCT00025818","Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome",[44],"2003-03","2001-05",290,[754,4585,4586,4587,4588],"Sjogren's Syndrome","Lupus Erythematosus, Systemic","Arthritis, Rheumatoid","Scleroderma, Systemic",[4567],{"trials":4591,"activeCount":13},[],{"trials":4593,"activeCount":13},[],{"intervention":3776,"totalTrials":10,"cells":4595},{"EARLY_PHASE1":4596,"PHASE1":4598,"PHASE2":4600,"PHASE3":4602,"PHASE4":4608,"NA":4610},{"trials":4597,"activeCount":13},[],{"trials":4599,"activeCount":13},[],{"trials":4601,"activeCount":13},[],{"trials":4603,"activeCount":13},[4604],{"nctId":3768,"briefTitle":3769,"status":61,"phases":4605,"primaryCompletion":3761,"completion":807,"start":808,"enrollment":3771,"conditions":4606,"interventions":4607},[44],[3773,3774],[3749,3776],{"trials":4609,"activeCount":13},[],{"trials":4611,"activeCount":13},[],{"intervention":4613,"totalTrials":10,"cells":4614},"bimatoprost formulation A solution",{"EARLY_PHASE1":4615,"PHASE1":4617,"PHASE2":4619,"PHASE3":4621,"PHASE4":4635,"NA":4637},{"trials":4616,"activeCount":13},[],{"trials":4618,"activeCount":13},[],{"trials":4620,"activeCount":13},[],{"trials":4622,"activeCount":13},[4623],{"nctId":4624,"briefTitle":4625,"status":61,"phases":4626,"primaryCompletion":4627,"completion":3201,"start":1231,"enrollment":4628,"conditions":4629,"interventions":4631},"NCT01698554","Bimatoprost in the Treatment of Eyelash Hypotrichosis",[44],"2014-02",464,[4630],"Idiopathic Eyelash Hypotrichosis",[4613,4632,4633,4634],"bimatoprost solution 0.03 %","vehicle of bimatoprost formulation A solution","vehicle of bimatoprost solution 0.03 %",{"trials":4636,"activeCount":13},[],{"trials":4638,"activeCount":13},[],{"intervention":4632,"totalTrials":10,"cells":4640},{"EARLY_PHASE1":4641,"PHASE1":4643,"PHASE2":4645,"PHASE3":4647,"PHASE4":4653,"NA":4655},{"trials":4642,"activeCount":13},[],{"trials":4644,"activeCount":13},[],{"trials":4646,"activeCount":13},[],{"trials":4648,"activeCount":13},[4649],{"nctId":4624,"briefTitle":4625,"status":61,"phases":4650,"primaryCompletion":4627,"completion":3201,"start":1231,"enrollment":4628,"conditions":4651,"interventions":4652},[44],[4630],[4613,4632,4633,4634],{"trials":4654,"activeCount":13},[],{"trials":4656,"activeCount":13},[],{"intervention":4633,"totalTrials":10,"cells":4658},{"EARLY_PHASE1":4659,"PHASE1":4661,"PHASE2":4663,"PHASE3":4665,"PHASE4":4671,"NA":4673},{"trials":4660,"activeCount":13},[],{"trials":4662,"activeCount":13},[],{"trials":4664,"activeCount":13},[],{"trials":4666,"activeCount":13},[4667],{"nctId":4624,"briefTitle":4625,"status":61,"phases":4668,"primaryCompletion":4627,"completion":3201,"start":1231,"enrollment":4628,"conditions":4669,"interventions":4670},[44],[4630],[4613,4632,4633,4634],{"trials":4672,"activeCount":13},[],{"trials":4674,"activeCount":13},[],{"intervention":4634,"totalTrials":10,"cells":4676},{"EARLY_PHASE1":4677,"PHASE1":4679,"PHASE2":4681,"PHASE3":4683,"PHASE4":4689,"NA":4691},{"trials":4678,"activeCount":13},[],{"trials":4680,"activeCount":13},[],{"trials":4682,"activeCount":13},[],{"trials":4684,"activeCount":13},[4685],{"nctId":4624,"briefTitle":4625,"status":61,"phases":4686,"primaryCompletion":4627,"completion":3201,"start":1231,"enrollment":4628,"conditions":4687,"interventions":4688},[44],[4630],[4613,4632,4633,4634],{"trials":4690,"activeCount":13},[],{"trials":4692,"activeCount":13},[],{"intervention":3276,"totalTrials":10,"cells":4694},{"EARLY_PHASE1":4695,"PHASE1":4697,"PHASE2":4699,"PHASE3":4701,"PHASE4":4707,"NA":4709},{"trials":4696,"activeCount":13},[],{"trials":4698,"activeCount":13},[],{"trials":4700,"activeCount":13},[],{"trials":4702,"activeCount":13},[4703],{"nctId":3268,"briefTitle":3269,"status":61,"phases":4704,"primaryCompletion":3271,"completion":3271,"start":807,"enrollment":3272,"conditions":4705,"interventions":4706},[44],[26],[3275,3276,3277],{"trials":4708,"activeCount":13},[],{"trials":4710,"activeCount":13},[],{"intervention":3277,"totalTrials":10,"cells":4712},{"EARLY_PHASE1":4713,"PHASE1":4715,"PHASE2":4717,"PHASE3":4719,"PHASE4":4725,"NA":4727},{"trials":4714,"activeCount":13},[],{"trials":4716,"activeCount":13},[],{"trials":4718,"activeCount":13},[],{"trials":4720,"activeCount":13},[4721],{"nctId":3268,"briefTitle":3269,"status":61,"phases":4722,"primaryCompletion":3271,"completion":3271,"start":807,"enrollment":3272,"conditions":4723,"interventions":4724},[44],[26],[3275,3276,3277],{"trials":4726,"activeCount":13},[],{"trials":4728,"activeCount":13},[],{"intervention":4730,"totalTrials":10,"cells":4731},"Cyclosporine Vehicle",{"EARLY_PHASE1":4732,"PHASE1":4734,"PHASE2":4736,"PHASE3":4738,"PHASE4":4750,"NA":4752},{"trials":4733,"activeCount":13},[],{"trials":4735,"activeCount":13},[],{"trials":4737,"activeCount":13},[],{"trials":4739,"activeCount":13},[4740],{"nctId":4741,"briefTitle":4742,"status":61,"phases":4743,"primaryCompletion":4744,"completion":2221,"start":319,"enrollment":4745,"conditions":4746,"interventions":4748},"NCT00884585","Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis",[44],"2010-10",176,[4747],"Atopic Conjunctivitis",[4730,4749],"Cyclosporine 0.010%",{"trials":4751,"activeCount":13},[],{"trials":4753,"activeCount":13},[],{"intervention":4749,"totalTrials":10,"cells":4755},{"EARLY_PHASE1":4756,"PHASE1":4758,"PHASE2":4760,"PHASE3":4762,"PHASE4":4768,"NA":4770},{"trials":4757,"activeCount":13},[],{"trials":4759,"activeCount":13},[],{"trials":4761,"activeCount":13},[],{"trials":4763,"activeCount":13},[4764],{"nctId":4741,"briefTitle":4742,"status":61,"phases":4765,"primaryCompletion":4744,"completion":2221,"start":319,"enrollment":4745,"conditions":4766,"interventions":4767},[44],[4747],[4730,4749],{"trials":4769,"activeCount":13},[],{"trials":4771,"activeCount":13},[],{"intervention":3287,"totalTrials":10,"cells":4773},{"EARLY_PHASE1":4774,"PHASE1":4776,"PHASE2":4778,"PHASE3":4780,"PHASE4":4786,"NA":4788},{"trials":4775,"activeCount":13},[],{"trials":4777,"activeCount":13},[],{"trials":4779,"activeCount":13},[],{"trials":4781,"activeCount":13},[4782],{"nctId":3279,"briefTitle":3280,"status":61,"phases":4783,"primaryCompletion":3282,"completion":3282,"start":3283,"enrollment":3284,"conditions":4784,"interventions":4785},[44],[26],[3287,3288,3289],{"trials":4787,"activeCount":13},[],{"trials":4789,"activeCount":13},[],{"intervention":3288,"totalTrials":10,"cells":4791},{"EARLY_PHASE1":4792,"PHASE1":4794,"PHASE2":4796,"PHASE3":4798,"PHASE4":4804,"NA":4806},{"trials":4793,"activeCount":13},[],{"trials":4795,"activeCount":13},[],{"trials":4797,"activeCount":13},[],{"trials":4799,"activeCount":13},[4800],{"nctId":3279,"briefTitle":3280,"status":61,"phases":4801,"primaryCompletion":3282,"completion":3282,"start":3283,"enrollment":3284,"conditions":4802,"interventions":4803},[44],[26],[3287,3288,3289],{"trials":4805,"activeCount":13},[],{"trials":4807,"activeCount":13},[],{"intervention":262,"totalTrials":10,"cells":4809},{"EARLY_PHASE1":4810,"PHASE1":4812,"PHASE2":4814,"PHASE3":4816,"PHASE4":4822,"NA":4824},{"trials":4811,"activeCount":13},[],{"trials":4813,"activeCount":13},[],{"trials":4815,"activeCount":13},[],{"trials":4817,"activeCount":13},[4818],{"nctId":254,"briefTitle":255,"status":61,"phases":4819,"primaryCompletion":257,"completion":257,"start":258,"enrollment":259,"conditions":4820,"interventions":4821},[44],[219],[262,181],{"trials":4823,"activeCount":13},[],{"trials":4825,"activeCount":13},[],{"intervention":4827,"totalTrials":10,"cells":4828},"dorzolamide hydrochloride 2.0%\u002Fbrimonidine tartrate 0.2%\u002Ftimolol 0.5% ophthalmic solution",{"EARLY_PHASE1":4829,"PHASE1":4831,"PHASE2":4833,"PHASE3":4835,"PHASE4":4843,"NA":4845},{"trials":4830,"activeCount":13},[],{"trials":4832,"activeCount":13},[],{"trials":4834,"activeCount":13},[],{"trials":4836,"activeCount":13},[4837],{"nctId":4838,"briefTitle":4839,"status":214,"phases":4840,"primaryCompletion":808,"completion":808,"start":544,"enrollment":13,"conditions":4841,"interventions":4842},"NCT01284166","Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride \u002F Brimonidine Tartrate \u002F Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",[44],[20,17],[4827],{"trials":4844,"activeCount":13},[],{"trials":4846,"activeCount":13},[],{"intervention":3676,"totalTrials":10,"cells":4848},{"EARLY_PHASE1":4849,"PHASE1":4851,"PHASE2":4853,"PHASE3":4855,"PHASE4":4861,"NA":4863},{"trials":4850,"activeCount":13},[],{"trials":4852,"activeCount":13},[],{"trials":4854,"activeCount":13},[],{"trials":4856,"activeCount":13},[4857],{"nctId":3668,"briefTitle":3669,"status":61,"phases":4858,"primaryCompletion":3671,"completion":3671,"start":3672,"enrollment":3673,"conditions":4859,"interventions":4860},[44],[26],[3648,3676,3666,3677],{"trials":4862,"activeCount":13},[],{"trials":4864,"activeCount":13},[],{"intervention":3677,"totalTrials":10,"cells":4866},{"EARLY_PHASE1":4867,"PHASE1":4869,"PHASE2":4871,"PHASE3":4873,"PHASE4":4879,"NA":4881},{"trials":4868,"activeCount":13},[],{"trials":4870,"activeCount":13},[],{"trials":4872,"activeCount":13},[],{"trials":4874,"activeCount":13},[4875],{"nctId":3668,"briefTitle":3669,"status":61,"phases":4876,"primaryCompletion":3671,"completion":3671,"start":3672,"enrollment":3673,"conditions":4877,"interventions":4878},[44],[26],[3648,3676,3666,3677],{"trials":4880,"activeCount":13},[],{"trials":4882,"activeCount":13},[],{"intervention":4884,"totalTrials":10,"cells":4885},"Botulinum Toxin Type A 300U",{"EARLY_PHASE1":4886,"PHASE1":4888,"PHASE2":4890,"PHASE3":4892,"PHASE4":4904,"NA":4906},{"trials":4887,"activeCount":13},[],{"trials":4889,"activeCount":13},[],{"trials":4891,"activeCount":13},[],{"trials":4893,"activeCount":13},[4894],{"nctId":4895,"briefTitle":4896,"status":61,"phases":4897,"primaryCompletion":4898,"completion":4899,"start":2686,"enrollment":4900,"conditions":4901,"interventions":4902},"NCT00876447","A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis",[44],"2013-06-12","2013-09-04",397,[35],[4884,4903],"Botulinum Toxin Type A 200U",{"trials":4905,"activeCount":13},[],{"trials":4907,"activeCount":13},[],{"intervention":4903,"totalTrials":10,"cells":4909},{"EARLY_PHASE1":4910,"PHASE1":4912,"PHASE2":4914,"PHASE3":4916,"PHASE4":4922,"NA":4924},{"trials":4911,"activeCount":13},[],{"trials":4913,"activeCount":13},[],{"trials":4915,"activeCount":13},[],{"trials":4917,"activeCount":13},[4918],{"nctId":4895,"briefTitle":4896,"status":61,"phases":4919,"primaryCompletion":4898,"completion":4899,"start":2686,"enrollment":4900,"conditions":4920,"interventions":4921},[44],[35],[4884,4903],{"trials":4923,"activeCount":13},[],{"trials":4925,"activeCount":13},[],{"intervention":4927,"totalTrials":10,"cells":4928},"bimatoprost \u002Ftimolol formulation A fixed combination ophthalmic solution",{"EARLY_PHASE1":4929,"PHASE1":4931,"PHASE2":4933,"PHASE3":4935,"PHASE4":4945,"NA":4947},{"trials":4930,"activeCount":13},[],{"trials":4932,"activeCount":13},[],{"trials":4934,"activeCount":13},[],{"trials":4936,"activeCount":13},[4937],{"nctId":4938,"briefTitle":4939,"status":61,"phases":4940,"primaryCompletion":1021,"completion":1021,"start":4744,"enrollment":4941,"conditions":4942,"interventions":4943},"NCT01177098","Safety and Efficacy of a New Formulation of Bimatoprost\u002FTimolol Ophthalmic Solution Compared With Bimatoprost\u002FTimolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",[44],561,[20,17],[4927,4944],"bimatoprost\u002Ftimolol fixed combination ophthalmic solution",{"trials":4946,"activeCount":13},[],{"trials":4948,"activeCount":13},[],{"intervention":4944,"totalTrials":10,"cells":4950},{"EARLY_PHASE1":4951,"PHASE1":4953,"PHASE2":4955,"PHASE3":4957,"PHASE4":4963,"NA":4965},{"trials":4952,"activeCount":13},[],{"trials":4954,"activeCount":13},[],{"trials":4956,"activeCount":13},[],{"trials":4958,"activeCount":13},[4959],{"nctId":4938,"briefTitle":4939,"status":61,"phases":4960,"primaryCompletion":1021,"completion":1021,"start":4744,"enrollment":4941,"conditions":4961,"interventions":4962},[44],[20,17],[4927,4944],{"trials":4964,"activeCount":13},[],{"trials":4966,"activeCount":13},[],{"intervention":4968,"totalTrials":10,"cells":4969},"olopatadine hydrochloride \u002Fketorolac tromethamine fixed dose combination ophthalmic solution",{"EARLY_PHASE1":4970,"PHASE1":4972,"PHASE2":4974,"PHASE3":4976,"PHASE4":4987,"NA":4989},{"trials":4971,"activeCount":13},[],{"trials":4973,"activeCount":13},[],{"trials":4975,"activeCount":13},[],{"trials":4977,"activeCount":13},[4978],{"nctId":4979,"briefTitle":4980,"status":61,"phases":4981,"primaryCompletion":2851,"completion":2851,"start":523,"enrollment":4982,"conditions":4983,"interventions":4985},"NCT01258309","Safety and Efficacy of Olopatadine Hydrochloride\u002FKetorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis",[44],129,[4984,1234],"Rhinitis, Allergic, Seasonal",[4968,4986],"olopatadine hydrochloride 0.1% ophthalmic solution",{"trials":4988,"activeCount":13},[],{"trials":4990,"activeCount":13},[],{"intervention":4986,"totalTrials":10,"cells":4992},{"EARLY_PHASE1":4993,"PHASE1":4995,"PHASE2":4997,"PHASE3":4999,"PHASE4":5005,"NA":5007},{"trials":4994,"activeCount":13},[],{"trials":4996,"activeCount":13},[],{"trials":4998,"activeCount":13},[],{"trials":5000,"activeCount":13},[5001],{"nctId":4979,"briefTitle":4980,"status":61,"phases":5002,"primaryCompletion":2851,"completion":2851,"start":523,"enrollment":4982,"conditions":5003,"interventions":5004},[44],[4984,1234],[4968,4986],{"trials":5006,"activeCount":13},[],{"trials":5008,"activeCount":13},[],{"intervention":5010,"totalTrials":10,"cells":5011},"bimatoprost solution",{"EARLY_PHASE1":5012,"PHASE1":5014,"PHASE2":5016,"PHASE3":5018,"PHASE4":5032,"NA":5034},{"trials":5013,"activeCount":13},[],{"trials":5015,"activeCount":13},[],{"trials":5017,"activeCount":13},[],{"trials":5019,"activeCount":13},[5020],{"nctId":5021,"briefTitle":5022,"status":61,"phases":5023,"primaryCompletion":5024,"completion":5025,"start":5026,"enrollment":5027,"conditions":5028,"interventions":5030},"NCT01765764","Bimatoprost for the Treatment of Eyebrow Hypotrichosis",[44],"2014-01-31","2014-02-11","2013-03-13",357,[5029],"Eyebrow Hypotrichosis",[5010,5031],"Vehicle to bimatoprost solution",{"trials":5033,"activeCount":13},[],{"trials":5035,"activeCount":13},[],{"intervention":5031,"totalTrials":10,"cells":5037},{"EARLY_PHASE1":5038,"PHASE1":5040,"PHASE2":5042,"PHASE3":5044,"PHASE4":5050,"NA":5052},{"trials":5039,"activeCount":13},[],{"trials":5041,"activeCount":13},[],{"trials":5043,"activeCount":13},[],{"trials":5045,"activeCount":13},[5046],{"nctId":5021,"briefTitle":5022,"status":61,"phases":5047,"primaryCompletion":5024,"completion":5025,"start":5026,"enrollment":5027,"conditions":5048,"interventions":5049},[44],[5029],[5010,5031],{"trials":5051,"activeCount":13},[],{"trials":5053,"activeCount":13},[],{"intervention":3160,"totalTrials":10,"cells":5055},{"EARLY_PHASE1":5056,"PHASE1":5058,"PHASE2":5060,"PHASE3":5062,"PHASE4":5068,"NA":5070},{"trials":5057,"activeCount":13},[],{"trials":5059,"activeCount":13},[],{"trials":5061,"activeCount":13},[],{"trials":5063,"activeCount":13},[5064],{"nctId":3153,"briefTitle":3154,"status":75,"phases":5065,"primaryCompletion":796,"completion":796,"start":3156,"enrollment":3157,"conditions":5066,"interventions":5067},[44],[20],[3160,3161,3120],{"trials":5069,"activeCount":13},[],{"trials":5071,"activeCount":13},[],{"intervention":3891,"totalTrials":10,"cells":5073},{"EARLY_PHASE1":5074,"PHASE1":5076,"PHASE2":5078,"PHASE3":5080,"PHASE4":5086,"NA":5088},{"trials":5075,"activeCount":13},[],{"trials":5077,"activeCount":13},[],{"trials":5079,"activeCount":13},[],{"trials":5081,"activeCount":13},[5082],{"nctId":3884,"briefTitle":3885,"status":61,"phases":5083,"primaryCompletion":2956,"completion":2956,"start":3887,"enrollment":3888,"conditions":5084,"interventions":5085},[44],[2959],[3891,3865],{"trials":5087,"activeCount":13},[],{"trials":5089,"activeCount":13},[],{"intervention":5091,"totalTrials":10,"cells":5092},"0.2% brimonidine\u002F0.5% timolol fixed combination ophthalmic solution",{"EARLY_PHASE1":5093,"PHASE1":5095,"PHASE2":5097,"PHASE3":5099,"PHASE4":5110,"NA":5112},{"trials":5094,"activeCount":13},[],{"trials":5096,"activeCount":13},[],{"trials":5098,"activeCount":13},[],{"trials":5100,"activeCount":13},[5101],{"nctId":5102,"briefTitle":3219,"status":61,"phases":5103,"primaryCompletion":5104,"completion":5104,"start":5105,"enrollment":3362,"conditions":5106,"interventions":5107},"NCT00652106",[44],"2004-03","2003-06",[20,17],[5091,5108,5109],"Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution","Brimonidine 0.2% ophthalmic solution",{"trials":5111,"activeCount":13},[],{"trials":5113,"activeCount":13},[],{"intervention":5108,"totalTrials":10,"cells":5115},{"EARLY_PHASE1":5116,"PHASE1":5118,"PHASE2":5120,"PHASE3":5122,"PHASE4":5128,"NA":5130},{"trials":5117,"activeCount":13},[],{"trials":5119,"activeCount":13},[],{"trials":5121,"activeCount":13},[],{"trials":5123,"activeCount":13},[5124],{"nctId":5102,"briefTitle":3219,"status":61,"phases":5125,"primaryCompletion":5104,"completion":5104,"start":5105,"enrollment":3362,"conditions":5126,"interventions":5127},[44],[20,17],[5091,5108,5109],{"trials":5129,"activeCount":13},[],{"trials":5131,"activeCount":13},[],{"intervention":5109,"totalTrials":10,"cells":5133},{"EARLY_PHASE1":5134,"PHASE1":5136,"PHASE2":5138,"PHASE3":5140,"PHASE4":5146,"NA":5148},{"trials":5135,"activeCount":13},[],{"trials":5137,"activeCount":13},[],{"trials":5139,"activeCount":13},[],{"trials":5141,"activeCount":13},[5142],{"nctId":5102,"briefTitle":3219,"status":61,"phases":5143,"primaryCompletion":5104,"completion":5104,"start":5105,"enrollment":3362,"conditions":5144,"interventions":5145},[44],[20,17],[5091,5108,5109],{"trials":5147,"activeCount":13},[],{"trials":5149,"activeCount":13},[],{"intervention":598,"totalTrials":10,"cells":5151},{"EARLY_PHASE1":5152,"PHASE1":5154,"PHASE2":5156,"PHASE3":5158,"PHASE4":5164,"NA":5166},{"trials":5153,"activeCount":13},[],{"trials":5155,"activeCount":13},[],{"trials":5157,"activeCount":13},[],{"trials":5159,"activeCount":13},[5160],{"nctId":590,"briefTitle":591,"status":61,"phases":5161,"primaryCompletion":593,"completion":593,"start":594,"enrollment":595,"conditions":5162,"interventions":5163},[44],[20,17],[598,554],{"trials":5165,"activeCount":13},[],{"trials":5167,"activeCount":13},[],{"intervention":3808,"totalTrials":10,"cells":5169},{"EARLY_PHASE1":5170,"PHASE1":5172,"PHASE2":5174,"PHASE3":5176,"PHASE4":5182,"NA":5184},{"trials":5171,"activeCount":13},[],{"trials":5173,"activeCount":13},[],{"trials":5175,"activeCount":13},[],{"trials":5177,"activeCount":13},[5178],{"nctId":3801,"briefTitle":3802,"status":61,"phases":5179,"primaryCompletion":3804,"completion":3805,"start":2001,"enrollment":3105,"conditions":5180,"interventions":5181},[44],[3773,3774],[3782,3808],{"trials":5183,"activeCount":13},[],{"trials":5185,"activeCount":13},[],{"intervention":5187,"totalTrials":10,"cells":5188},"Levomilnacipran ER",{"EARLY_PHASE1":5189,"PHASE1":5191,"PHASE2":5193,"PHASE3":5195,"PHASE4":5208,"NA":5210},{"trials":5190,"activeCount":13},[],{"trials":5192,"activeCount":13},[],{"trials":5194,"activeCount":13},[],{"trials":5196,"activeCount":13},[5197],{"nctId":5198,"briefTitle":5199,"status":61,"phases":5200,"primaryCompletion":5201,"completion":5201,"start":5202,"enrollment":5203,"conditions":5204,"interventions":5206},"NCT03569475","Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder",[44],"2021-03-01","2018-07-06",501,[5205],"Major Depressive Disorder",[5187,5207],"Fluoxetine",{"trials":5209,"activeCount":13},[],{"trials":5211,"activeCount":13},[],{"intervention":5207,"totalTrials":10,"cells":5213},{"EARLY_PHASE1":5214,"PHASE1":5216,"PHASE2":5218,"PHASE3":5220,"PHASE4":5226,"NA":5228},{"trials":5215,"activeCount":13},[],{"trials":5217,"activeCount":13},[],{"trials":5219,"activeCount":13},[],{"trials":5221,"activeCount":13},[5222],{"nctId":5198,"briefTitle":5199,"status":61,"phases":5223,"primaryCompletion":5201,"completion":5201,"start":5202,"enrollment":5203,"conditions":5224,"interventions":5225},[44],[5205],[5187,5207],{"trials":5227,"activeCount":13},[],{"trials":5229,"activeCount":13},[],{"intervention":5231,"totalTrials":10,"cells":5232},"Brimonidine ophthalmic solution 0.1%",{"EARLY_PHASE1":5233,"PHASE1":5235,"PHASE2":5237,"PHASE3":5239,"PHASE4":5250,"NA":5252},{"trials":5234,"activeCount":13},[],{"trials":5236,"activeCount":13},[],{"trials":5238,"activeCount":13},[],{"trials":5240,"activeCount":13},[5241],{"nctId":5242,"briefTitle":5243,"status":61,"phases":5244,"primaryCompletion":5245,"completion":3103,"start":3104,"enrollment":5246,"conditions":5247,"interventions":5248},"NCT00652483","Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension",[44],"2003-12",433,[20,17],[5231,5249],"Brimonidine ophthalmic solution 0.2%",{"trials":5251,"activeCount":13},[],{"trials":5253,"activeCount":13},[],{"intervention":5249,"totalTrials":10,"cells":5255},{"EARLY_PHASE1":5256,"PHASE1":5258,"PHASE2":5260,"PHASE3":5262,"PHASE4":5268,"NA":5270},{"trials":5257,"activeCount":13},[],{"trials":5259,"activeCount":13},[],{"trials":5261,"activeCount":13},[],{"trials":5263,"activeCount":13},[5264],{"nctId":5242,"briefTitle":5243,"status":61,"phases":5265,"primaryCompletion":5245,"completion":3103,"start":3104,"enrollment":5246,"conditions":5266,"interventions":5267},[44],[20,17],[5231,5249],{"trials":5269,"activeCount":13},[],{"trials":5271,"activeCount":13},[],{"intervention":5273,"totalTrials":10,"cells":5274},"Botulinum toxin type A Dose 1",{"EARLY_PHASE1":5275,"PHASE1":5277,"PHASE2":5279,"PHASE3":5281,"PHASE4":5291,"NA":5293},{"trials":5276,"activeCount":13},[],{"trials":5278,"activeCount":13},[],{"trials":5280,"activeCount":13},[],{"trials":5282,"activeCount":13},[5283],{"nctId":5284,"briefTitle":5285,"status":61,"phases":5286,"primaryCompletion":5287,"completion":5287,"start":1046,"enrollment":3145,"conditions":5288,"interventions":5289},"NCT01662492","A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine",[44],"2016-08",[37],[5273,5290],"Botulinum toxin type A Dose 2",{"trials":5292,"activeCount":13},[],{"trials":5294,"activeCount":13},[],{"intervention":5290,"totalTrials":10,"cells":5296},{"EARLY_PHASE1":5297,"PHASE1":5299,"PHASE2":5301,"PHASE3":5303,"PHASE4":5309,"NA":5311},{"trials":5298,"activeCount":13},[],{"trials":5300,"activeCount":13},[],{"trials":5302,"activeCount":13},[],{"trials":5304,"activeCount":13},[5305],{"nctId":5284,"briefTitle":5285,"status":61,"phases":5306,"primaryCompletion":5287,"completion":5287,"start":1046,"enrollment":3145,"conditions":5307,"interventions":5308},[44],[37],[5273,5290],{"trials":5310,"activeCount":13},[],{"trials":5312,"activeCount":13},[],{"intervention":5314,"totalTrials":10,"cells":5315},"bimatoprost\u002Fbrimonidine tartrate\u002Ftimolol fixed combination ophthalmic solution",{"EARLY_PHASE1":5316,"PHASE1":5318,"PHASE2":5320,"PHASE3":5322,"PHASE4":5331,"NA":5333},{"trials":5317,"activeCount":13},[],{"trials":5319,"activeCount":13},[],{"trials":5321,"activeCount":13},[],{"trials":5323,"activeCount":13},[5324],{"nctId":5325,"briefTitle":5326,"status":61,"phases":5327,"primaryCompletion":392,"completion":392,"start":4152,"enrollment":5328,"conditions":5329,"interventions":5330},"NCT01216943","Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension",[44],126,[20,17],[5314],{"trials":5332,"activeCount":13},[],{"trials":5334,"activeCount":13},[],{"intervention":5336,"totalTrials":10,"cells":5337},"ketorolac",{"EARLY_PHASE1":5338,"PHASE1":5340,"PHASE2":5342,"PHASE3":5344,"PHASE4":5353,"NA":5355},{"trials":5339,"activeCount":13},[],{"trials":5341,"activeCount":13},[],{"trials":5343,"activeCount":13},[],{"trials":5345,"activeCount":13},[5346],{"nctId":5347,"briefTitle":4555,"status":61,"phases":5348,"primaryCompletion":3608,"completion":3608,"start":630,"enrollment":5349,"conditions":5350,"interventions":5352},"NCT00524264",[44],248,[4560,5351,1829],"Pain",[5336],{"trials":5354,"activeCount":13},[],{"trials":5356,"activeCount":13},[],{"intervention":3764,"totalTrials":380,"cells":5358},{"EARLY_PHASE1":5359,"PHASE1":5361,"PHASE2":5372,"PHASE3":5409,"PHASE4":5411,"NA":5413},{"trials":5360,"activeCount":13},[],{"trials":5362,"activeCount":13},[5363],{"nctId":5364,"briefTitle":5365,"status":61,"phases":5366,"primaryCompletion":487,"completion":487,"start":344,"enrollment":271,"conditions":5367,"interventions":5368},"NCT01579084","Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea",[42],[3774,3773],[5369,5370,5371,3764],"AGN-199201 Formulation A","AGN-199201 Formulation B","AGN-199201 Formulation C",{"trials":5373,"activeCount":13},[5374,5387,5396,5405],{"nctId":5375,"briefTitle":5376,"status":61,"phases":5377,"primaryCompletion":5378,"completion":5378,"start":5379,"enrollment":292,"conditions":5380,"interventions":5381},"NCT02595528","A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia",[43],"2017-10-18","2016-04-29",[219],[5382,5383,5384,5385,5386],"AGN-199201 ophthalmic solution","AGN-190584 ophthalmic solution","AGN-190584 vehicle","AGN-199201 + AGN-190584 Combination","AGN-199201 vehicle",{"nctId":5388,"briefTitle":5389,"status":61,"phases":5390,"primaryCompletion":5391,"completion":5391,"start":5392,"enrollment":110,"conditions":5393,"interventions":5394},"NCT02780115","A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia",[43],"2017-10-31","2016-05-26",[219],[5382,5383,3764,5395],"AGN-190584 Vehicle",{"nctId":5397,"briefTitle":5398,"status":61,"phases":5399,"primaryCompletion":2545,"completion":507,"start":1230,"enrollment":5027,"conditions":5400,"interventions":5401},"NCT01735201","AGN-199201 for the Treatment of Erythema With Rosacea",[43],[3774,3773],[5402,5403,5404,3764],"AGN-199201 Dose A","AGN-199201 Dose B","AGN-199201 Dose C",{"nctId":3758,"briefTitle":3759,"status":61,"phases":5406,"primaryCompletion":796,"completion":3761,"start":109,"enrollment":2608,"conditions":5407,"interventions":5408},[43],[219],[3749,221,3764],{"trials":5410,"activeCount":13},[],{"trials":5412,"activeCount":13},[],{"trials":5414,"activeCount":13},[],{"intervention":5416,"totalTrials":79,"cells":5417},"AGN 203818",{"EARLY_PHASE1":5418,"PHASE1":5420,"PHASE2":5422,"PHASE3":5456,"PHASE4":5458,"NA":5460},{"trials":5419,"activeCount":13},[],{"trials":5421,"activeCount":13},[],{"trials":5423,"activeCount":13},[5424,5432,5441,5449],{"nctId":5425,"briefTitle":5426,"status":75,"phases":5427,"primaryCompletion":3546,"completion":3546,"start":1488,"enrollment":5428,"conditions":5429,"interventions":5431},"NCT00441766","Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain",[43],213,[5430],"Irritable Bowel Syndrome",[5416,5416,5416],{"nctId":5433,"briefTitle":5434,"status":61,"phases":5435,"primaryCompletion":5436,"completion":5436,"start":269,"enrollment":5437,"conditions":5438,"interventions":5440},"NCT00381719","Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy",[43],"2007-11",330,[5439],"Diabetic Neuropathy, Painful",[5416,5416,5416],{"nctId":5442,"briefTitle":5443,"status":75,"phases":5444,"primaryCompletion":2607,"completion":2607,"start":1488,"enrollment":5445,"conditions":5446,"interventions":5448},"NCT00445705","Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome",[43],211,[5447],"Fibromyalgia",[5416,5416,5416],{"nctId":5450,"briefTitle":5451,"status":75,"phases":5452,"primaryCompletion":1488,"completion":1488,"start":269,"enrollment":780,"conditions":5453,"interventions":5455},"NCT00380783","Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome\u002FInterstitial Cystitis",[43],[5454],"Cystitis, Interstitial",[5416],{"trials":5457,"activeCount":13},[],{"trials":5459,"activeCount":13},[],{"trials":5461,"activeCount":13},[],{"intervention":5463,"totalTrials":616,"cells":5464},"MAP0010 low dose",{"EARLY_PHASE1":5465,"PHASE1":5467,"PHASE2":5480,"PHASE3":5497,"PHASE4":5499,"NA":5501},{"trials":5466,"activeCount":13},[],{"trials":5468,"activeCount":13},[5469],{"nctId":5470,"briefTitle":5471,"status":61,"phases":5472,"primaryCompletion":5473,"completion":2701,"start":5473,"enrollment":5474,"conditions":5475,"interventions":5476},"NCT00627679","Safety and Blood Level Study of Unit Dose Budesonide",[42],"2005-12",16,[3611],[5477,5463,5478,5479],"Budesonide Inhalation Suspension","MAP0010 intermediate dose","MAP0010 high dose",{"trials":5481,"activeCount":13},[5482,5490],{"nctId":5483,"briefTitle":5484,"status":61,"phases":5485,"primaryCompletion":2607,"completion":4557,"start":5436,"enrollment":21,"conditions":5486,"interventions":5487},"NCT00554970","A Study of 2 Doses of MAP0010 in Adult Asthmatics",[43],[3611],[5463,5479,5488,5489],"Budesonide inhalation suspension 0.25mg","Budesonide inhalation suspension 0.5mg",{"nctId":5491,"briefTitle":5492,"status":61,"phases":5493,"primaryCompletion":1530,"completion":1530,"start":1489,"enrollment":5494,"conditions":5495,"interventions":5496},"NCT00697801","Study of MAP0010 in Asthmatic Children and Adolescents",[43],208,[3611],[5463,5479],{"trials":5498,"activeCount":13},[],{"trials":5500,"activeCount":13},[],{"trials":5502,"activeCount":13},[],{"intervention":5479,"totalTrials":616,"cells":5504},{"EARLY_PHASE1":5505,"PHASE1":5507,"PHASE2":5513,"PHASE3":5523,"PHASE4":5525,"NA":5527},{"trials":5506,"activeCount":13},[],{"trials":5508,"activeCount":13},[5509],{"nctId":5470,"briefTitle":5471,"status":61,"phases":5510,"primaryCompletion":5473,"completion":2701,"start":5473,"enrollment":5474,"conditions":5511,"interventions":5512},[42],[3611],[5477,5463,5478,5479],{"trials":5514,"activeCount":13},[5515,5519],{"nctId":5483,"briefTitle":5484,"status":61,"phases":5516,"primaryCompletion":2607,"completion":4557,"start":5436,"enrollment":21,"conditions":5517,"interventions":5518},[43],[3611],[5463,5479,5488,5489],{"nctId":5491,"briefTitle":5492,"status":61,"phases":5520,"primaryCompletion":1530,"completion":1530,"start":1489,"enrollment":5494,"conditions":5521,"interventions":5522},[43],[3611],[5463,5479],{"trials":5524,"activeCount":13},[],{"trials":5526,"activeCount":13},[],{"trials":5528,"activeCount":13},[],{"intervention":399,"totalTrials":616,"cells":5530},{"EARLY_PHASE1":5531,"PHASE1":5533,"PHASE2":5543,"PHASE3":5553,"PHASE4":5555,"NA":5557},{"trials":5532,"activeCount":13},[],{"trials":5534,"activeCount":13},[5535],{"nctId":5536,"briefTitle":5537,"status":61,"phases":5538,"primaryCompletion":2851,"completion":5539,"start":4744,"enrollment":5540,"conditions":5541,"interventions":5542},"NCT01189279","Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia",[42],"2011-02",42,[395,396,397],[399,400,401],{"trials":5544,"activeCount":13},[5545,5549],{"nctId":389,"briefTitle":390,"status":61,"phases":5546,"primaryCompletion":392,"completion":393,"start":204,"enrollment":173,"conditions":5547,"interventions":5548},[43],[395,396,397],[399,400,401,350,402],{"nctId":404,"briefTitle":405,"status":61,"phases":5550,"primaryCompletion":407,"completion":393,"start":204,"enrollment":408,"conditions":5551,"interventions":5552},[43],[395,397],[399,400,401,350,411],{"trials":5554,"activeCount":13},[],{"trials":5556,"activeCount":13},[],{"trials":5558,"activeCount":13},[],{"intervention":400,"totalTrials":616,"cells":5560},{"EARLY_PHASE1":5561,"PHASE1":5563,"PHASE2":5569,"PHASE3":5579,"PHASE4":5581,"NA":5583},{"trials":5562,"activeCount":13},[],{"trials":5564,"activeCount":13},[5565],{"nctId":5536,"briefTitle":5537,"status":61,"phases":5566,"primaryCompletion":2851,"completion":5539,"start":4744,"enrollment":5540,"conditions":5567,"interventions":5568},[42],[395,396,397],[399,400,401],{"trials":5570,"activeCount":13},[5571,5575],{"nctId":389,"briefTitle":390,"status":61,"phases":5572,"primaryCompletion":392,"completion":393,"start":204,"enrollment":173,"conditions":5573,"interventions":5574},[43],[395,396,397],[399,400,401,350,402],{"nctId":404,"briefTitle":405,"status":61,"phases":5576,"primaryCompletion":407,"completion":393,"start":204,"enrollment":408,"conditions":5577,"interventions":5578},[43],[395,397],[399,400,401,350,411],{"trials":5580,"activeCount":13},[],{"trials":5582,"activeCount":13},[],{"trials":5584,"activeCount":13},[],{"intervention":401,"totalTrials":616,"cells":5586},{"EARLY_PHASE1":5587,"PHASE1":5589,"PHASE2":5595,"PHASE3":5605,"PHASE4":5607,"NA":5609},{"trials":5588,"activeCount":13},[],{"trials":5590,"activeCount":13},[5591],{"nctId":5536,"briefTitle":5537,"status":61,"phases":5592,"primaryCompletion":2851,"completion":5539,"start":4744,"enrollment":5540,"conditions":5593,"interventions":5594},[42],[395,396,397],[399,400,401],{"trials":5596,"activeCount":13},[5597,5601],{"nctId":389,"briefTitle":390,"status":61,"phases":5598,"primaryCompletion":392,"completion":393,"start":204,"enrollment":173,"conditions":5599,"interventions":5600},[43],[395,396,397],[399,400,401,350,402],{"nctId":404,"briefTitle":405,"status":61,"phases":5602,"primaryCompletion":407,"completion":393,"start":204,"enrollment":408,"conditions":5603,"interventions":5604},[43],[395,397],[399,400,401,350,411],{"trials":5606,"activeCount":13},[],{"trials":5608,"activeCount":13},[],{"trials":5610,"activeCount":13},[],{"intervention":5612,"totalTrials":616,"cells":5613},"400 µg Brimonidine Tartrate Implant",{"EARLY_PHASE1":5614,"PHASE1":5616,"PHASE2":5625,"PHASE3":5645,"PHASE4":5647,"NA":5649},{"trials":5615,"activeCount":13},[],{"trials":5617,"activeCount":13},[5618],{"nctId":5619,"briefTitle":5620,"status":61,"phases":5621,"primaryCompletion":77,"completion":345,"start":523,"enrollment":1141,"conditions":5622,"interventions":5623},"NCT01229410","Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy",[42],[2689],[5612,5624],"200 µg Brimonidine Tartrate Implant",{"trials":5626,"activeCount":13},[5627,5636],{"nctId":5628,"briefTitle":5629,"status":61,"phases":5630,"primaryCompletion":897,"completion":5631,"start":923,"enrollment":30,"conditions":5632,"interventions":5634},"NCT00661479","An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa",[42,43],"2010-05",[5633],"Retinitis Pigmentosa",[5612,5624,5635],"100 µg Brimonidine Tartrate Implant",{"nctId":5637,"briefTitle":5638,"status":61,"phases":5639,"primaryCompletion":357,"completion":5640,"start":5641,"enrollment":5642,"conditions":5643,"interventions":5644},"NCT00658619","Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)",[43],"2011-04-08","2008-05-01",119,[92],[5612,5624],{"trials":5646,"activeCount":13},[],{"trials":5648,"activeCount":13},[],{"trials":5650,"activeCount":13},[],{"intervention":5624,"totalTrials":616,"cells":5652},{"EARLY_PHASE1":5653,"PHASE1":5655,"PHASE2":5661,"PHASE3":5671,"PHASE4":5673,"NA":5675},{"trials":5654,"activeCount":13},[],{"trials":5656,"activeCount":13},[5657],{"nctId":5619,"briefTitle":5620,"status":61,"phases":5658,"primaryCompletion":77,"completion":345,"start":523,"enrollment":1141,"conditions":5659,"interventions":5660},[42],[2689],[5612,5624],{"trials":5662,"activeCount":13},[5663,5667],{"nctId":5628,"briefTitle":5629,"status":61,"phases":5664,"primaryCompletion":897,"completion":5631,"start":923,"enrollment":30,"conditions":5665,"interventions":5666},[42,43],[5633],[5612,5624,5635],{"nctId":5637,"briefTitle":5638,"status":61,"phases":5668,"primaryCompletion":357,"completion":5640,"start":5641,"enrollment":5642,"conditions":5669,"interventions":5670},[43],[92],[5612,5624],{"trials":5672,"activeCount":13},[],{"trials":5674,"activeCount":13},[],{"trials":5676,"activeCount":13},[],{"intervention":5678,"totalTrials":616,"cells":5679},"AGN-214868",{"EARLY_PHASE1":5680,"PHASE1":5682,"PHASE2":5684,"PHASE3":5711,"PHASE4":5713,"NA":5715},{"trials":5681,"activeCount":13},[],{"trials":5683,"activeCount":13},[],{"trials":5685,"activeCount":13},[5686,5695,5704],{"nctId":5687,"briefTitle":5688,"status":61,"phases":5689,"primaryCompletion":1465,"completion":2545,"start":4744,"enrollment":5690,"conditions":5691,"interventions":5693},"NCT01157377","Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence",[43],160,[5692],"Urinary Bladder, Overactive",[5678,5694],"AGN-214868 placebo",{"nctId":5696,"briefTitle":5697,"status":75,"phases":5698,"primaryCompletion":3805,"completion":3796,"start":3179,"enrollment":5699,"conditions":5700,"interventions":5702},"NCT01678924","A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia",[43],280,[5701],"Neuralgia, Postherpetic",[5678,5703],"AGN-214868 Placebo",{"nctId":5705,"briefTitle":5706,"status":61,"phases":5707,"primaryCompletion":345,"completion":1047,"start":205,"enrollment":5708,"conditions":5709,"interventions":5710},"NCT01129531","A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia",[43],294,[5701],[5678],{"trials":5712,"activeCount":13},[],{"trials":5714,"activeCount":13},[],{"trials":5716,"activeCount":13},[],{"intervention":5718,"totalTrials":780,"cells":5719},"LiRIS®",{"EARLY_PHASE1":5720,"PHASE1":5722,"PHASE2":5724,"PHASE3":5748,"PHASE4":5750,"NA":5752},{"trials":5721,"activeCount":13},[],{"trials":5723,"activeCount":13},[],{"trials":5725,"activeCount":13},[5726,5737],{"nctId":5727,"briefTitle":5728,"status":61,"phases":5729,"primaryCompletion":5730,"completion":5731,"start":5732,"enrollment":1268,"conditions":5733,"interventions":5735},"NCT02395042","A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions",[43],"2017-06-29","2017-11-20","2015-04-15",[5454,5734],"Ulcer",[5718,5736],"LiRIS Placebo",{"nctId":5738,"briefTitle":5739,"status":61,"phases":5740,"primaryCompletion":5741,"completion":5742,"start":5743,"enrollment":5744,"conditions":5745,"interventions":5747},"NCT02411110","A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis\u002FBladder Pain Syndrome",[43],"2016-10-12","2017-01-09","2015-05-21",131,[5454,5746],"Painful Bladder Syndrome",[5718,5736],{"trials":5749,"activeCount":13},[],{"trials":5751,"activeCount":13},[],{"trials":5753,"activeCount":13},[],{"intervention":5736,"totalTrials":780,"cells":5755},{"EARLY_PHASE1":5756,"PHASE1":5758,"PHASE2":5760,"PHASE3":5770,"PHASE4":5772,"NA":5774},{"trials":5757,"activeCount":13},[],{"trials":5759,"activeCount":13},[],{"trials":5761,"activeCount":13},[5762,5766],{"nctId":5727,"briefTitle":5728,"status":61,"phases":5763,"primaryCompletion":5730,"completion":5731,"start":5732,"enrollment":1268,"conditions":5764,"interventions":5765},[43],[5454,5734],[5718,5736],{"nctId":5738,"briefTitle":5739,"status":61,"phases":5767,"primaryCompletion":5741,"completion":5742,"start":5743,"enrollment":5744,"conditions":5768,"interventions":5769},[43],[5454,5746],[5718,5736],{"trials":5771,"activeCount":13},[],{"trials":5773,"activeCount":13},[],{"trials":5775,"activeCount":13},[],{"intervention":5777,"totalTrials":780,"cells":5778},"OnabotulinumtoxinA X",{"EARLY_PHASE1":5779,"PHASE1":5781,"PHASE2":5783,"PHASE3":5803,"PHASE4":5805,"NA":5807},{"trials":5780,"activeCount":13},[],{"trials":5782,"activeCount":13},[],{"trials":5784,"activeCount":13},[5785,5794],{"nctId":5786,"briefTitle":5787,"status":61,"phases":5788,"primaryCompletion":5789,"completion":5789,"start":5790,"enrollment":2774,"conditions":5791,"interventions":5793},"NCT05152576","A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines",[43],"2022-09-06","2021-11-29",[5792],"Forehead Lines",[5777],{"nctId":5795,"briefTitle":5796,"status":61,"phases":5797,"primaryCompletion":5798,"completion":5798,"start":5799,"enrollment":5800,"conditions":5801,"interventions":5802},"NCT05100199","A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines",[43],"2022-12-02","2021-10-06",328,[373],[5777],{"trials":5804,"activeCount":13},[],{"trials":5806,"activeCount":13},[],{"trials":5808,"activeCount":13},[],{"intervention":3310,"totalTrials":780,"cells":5810},{"EARLY_PHASE1":5811,"PHASE1":5813,"PHASE2":5815,"PHASE3":5828,"PHASE4":5830,"NA":5832},{"trials":5812,"activeCount":13},[],{"trials":5814,"activeCount":13},[],{"trials":5816,"activeCount":13},[5817,5821],{"nctId":3303,"briefTitle":3304,"status":61,"phases":5818,"primaryCompletion":2851,"completion":3306,"start":986,"enrollment":3307,"conditions":5819,"interventions":5820},[43],[23],[3310,3311,2680],{"nctId":5822,"briefTitle":5823,"status":61,"phases":5824,"primaryCompletion":4744,"completion":2221,"start":63,"enrollment":66,"conditions":5825,"interventions":5827},"NCT00972374","Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function",[43],[5826],"Rhegmatogenous Macula-off Retinal Detachment",[3310,3311],{"trials":5829,"activeCount":13},[],{"trials":5831,"activeCount":13},[],{"trials":5833,"activeCount":13},[],{"intervention":3311,"totalTrials":780,"cells":5835},{"EARLY_PHASE1":5836,"PHASE1":5838,"PHASE2":5840,"PHASE3":5850,"PHASE4":5852,"NA":5854},{"trials":5837,"activeCount":13},[],{"trials":5839,"activeCount":13},[],{"trials":5841,"activeCount":13},[5842,5846],{"nctId":3303,"briefTitle":3304,"status":61,"phases":5843,"primaryCompletion":2851,"completion":3306,"start":986,"enrollment":3307,"conditions":5844,"interventions":5845},[43],[23],[3310,3311,2680],{"nctId":5822,"briefTitle":5823,"status":61,"phases":5847,"primaryCompletion":4744,"completion":2221,"start":63,"enrollment":66,"conditions":5848,"interventions":5849},[43],[5826],[3310,3311],{"trials":5851,"activeCount":13},[],{"trials":5853,"activeCount":13},[],{"trials":5855,"activeCount":13},[],{"intervention":2824,"totalTrials":780,"cells":5857},{"EARLY_PHASE1":5858,"PHASE1":5860,"PHASE2":5866,"PHASE3":5872,"PHASE4":5874,"NA":5876},{"trials":5859,"activeCount":13},[],{"trials":5861,"activeCount":13},[5862],{"nctId":2819,"briefTitle":2820,"status":61,"phases":5863,"primaryCompletion":78,"completion":78,"start":307,"enrollment":1141,"conditions":5864,"interventions":5865},[42],[452],[2804,2824,2825],{"trials":5867,"activeCount":13},[5868],{"nctId":2838,"briefTitle":2839,"status":61,"phases":5869,"primaryCompletion":64,"completion":64,"start":887,"enrollment":2841,"conditions":5870,"interventions":5871},[42,43],[2843],[2804,2824],{"trials":5873,"activeCount":13},[],{"trials":5875,"activeCount":13},[],{"trials":5877,"activeCount":13},[],{"intervention":324,"totalTrials":780,"cells":5879},{"EARLY_PHASE1":5880,"PHASE1":5882,"PHASE2":5884,"PHASE3":5894,"PHASE4":5896,"NA":5898},{"trials":5881,"activeCount":13},[],{"trials":5883,"activeCount":13},[],{"trials":5885,"activeCount":13},[5886,5890],{"nctId":316,"briefTitle":317,"status":61,"phases":5887,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":5888,"interventions":5889},[42,43],[17,20],[324,325,326,279,327],{"nctId":329,"briefTitle":330,"status":61,"phases":5891,"primaryCompletion":64,"completion":64,"start":63,"enrollment":332,"conditions":5892,"interventions":5893},[43],[23,17],[335,324,325,279],{"trials":5895,"activeCount":13},[],{"trials":5897,"activeCount":13},[],{"trials":5899,"activeCount":13},[],{"intervention":325,"totalTrials":780,"cells":5901},{"EARLY_PHASE1":5902,"PHASE1":5904,"PHASE2":5906,"PHASE3":5916,"PHASE4":5918,"NA":5920},{"trials":5903,"activeCount":13},[],{"trials":5905,"activeCount":13},[],{"trials":5907,"activeCount":13},[5908,5912],{"nctId":316,"briefTitle":317,"status":61,"phases":5909,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":5910,"interventions":5911},[42,43],[17,20],[324,325,326,279,327],{"nctId":329,"briefTitle":330,"status":61,"phases":5913,"primaryCompletion":64,"completion":64,"start":63,"enrollment":332,"conditions":5914,"interventions":5915},[43],[23,17],[335,324,325,279],{"trials":5917,"activeCount":13},[],{"trials":5919,"activeCount":13},[],{"trials":5921,"activeCount":13},[],{"intervention":5382,"totalTrials":780,"cells":5923},{"EARLY_PHASE1":5924,"PHASE1":5926,"PHASE2":5928,"PHASE3":5938,"PHASE4":5940,"NA":5942},{"trials":5925,"activeCount":13},[],{"trials":5927,"activeCount":13},[],{"trials":5929,"activeCount":13},[5930,5934],{"nctId":5375,"briefTitle":5376,"status":61,"phases":5931,"primaryCompletion":5378,"completion":5378,"start":5379,"enrollment":292,"conditions":5932,"interventions":5933},[43],[219],[5382,5383,5384,5385,5386],{"nctId":5388,"briefTitle":5389,"status":61,"phases":5935,"primaryCompletion":5391,"completion":5391,"start":5392,"enrollment":110,"conditions":5936,"interventions":5937},[43],[219],[5382,5383,3764,5395],{"trials":5939,"activeCount":13},[],{"trials":5941,"activeCount":13},[],{"trials":5943,"activeCount":13},[],{"intervention":5383,"totalTrials":780,"cells":5945},{"EARLY_PHASE1":5946,"PHASE1":5948,"PHASE2":5950,"PHASE3":5960,"PHASE4":5962,"NA":5964},{"trials":5947,"activeCount":13},[],{"trials":5949,"activeCount":13},[],{"trials":5951,"activeCount":13},[5952,5956],{"nctId":5375,"briefTitle":5376,"status":61,"phases":5953,"primaryCompletion":5378,"completion":5378,"start":5379,"enrollment":292,"conditions":5954,"interventions":5955},[43],[219],[5382,5383,5384,5385,5386],{"nctId":5388,"briefTitle":5389,"status":61,"phases":5957,"primaryCompletion":5391,"completion":5391,"start":5392,"enrollment":110,"conditions":5958,"interventions":5959},[43],[219],[5382,5383,3764,5395],{"trials":5961,"activeCount":13},[],{"trials":5963,"activeCount":13},[],{"trials":5965,"activeCount":13},[],{"intervention":5384,"totalTrials":780,"cells":5967},{"EARLY_PHASE1":5968,"PHASE1":5970,"PHASE2":5972,"PHASE3":5982,"PHASE4":5984,"NA":5986},{"trials":5969,"activeCount":13},[],{"trials":5971,"activeCount":13},[],{"trials":5973,"activeCount":13},[5974,5978],{"nctId":5375,"briefTitle":5376,"status":61,"phases":5975,"primaryCompletion":5378,"completion":5378,"start":5379,"enrollment":292,"conditions":5976,"interventions":5977},[43],[219],[5382,5383,5384,5385,5386],{"nctId":5388,"briefTitle":5389,"status":61,"phases":5979,"primaryCompletion":5391,"completion":5391,"start":5392,"enrollment":110,"conditions":5980,"interventions":5981},[43],[219],[5382,5383,3764,5395],{"trials":5983,"activeCount":13},[],{"trials":5985,"activeCount":13},[],{"trials":5987,"activeCount":13},[],{"intervention":5694,"totalTrials":780,"cells":5989},{"EARLY_PHASE1":5990,"PHASE1":5992,"PHASE2":5994,"PHASE3":6004,"PHASE4":6006,"NA":6008},{"trials":5991,"activeCount":13},[],{"trials":5993,"activeCount":13},[],{"trials":5995,"activeCount":13},[5996,6000],{"nctId":5687,"briefTitle":5688,"status":61,"phases":5997,"primaryCompletion":1465,"completion":2545,"start":4744,"enrollment":5690,"conditions":5998,"interventions":5999},[43],[5692],[5678,5694],{"nctId":5696,"briefTitle":5697,"status":75,"phases":6001,"primaryCompletion":3805,"completion":3796,"start":3179,"enrollment":5699,"conditions":6002,"interventions":6003},[43],[5701],[5678,5703],{"trials":6005,"activeCount":13},[],{"trials":6007,"activeCount":13},[],{"trials":6009,"activeCount":13},[],{"intervention":221,"totalTrials":780,"cells":6011},{"EARLY_PHASE1":6012,"PHASE1":6014,"PHASE2":6016,"PHASE3":6026,"PHASE4":6028,"NA":6030},{"trials":6013,"activeCount":13},[],{"trials":6015,"activeCount":13},[],{"trials":6017,"activeCount":13},[6018,6022],{"nctId":212,"briefTitle":213,"status":214,"phases":6019,"primaryCompletion":216,"completion":216,"start":217,"enrollment":13,"conditions":6020,"interventions":6021},[43],[219],[221,181],{"nctId":3758,"briefTitle":3759,"status":61,"phases":6023,"primaryCompletion":796,"completion":3761,"start":109,"enrollment":2608,"conditions":6024,"interventions":6025},[43],[219],[3749,221,3764],{"trials":6027,"activeCount":13},[],{"trials":6029,"activeCount":13},[],{"trials":6031,"activeCount":13},[],{"intervention":6033,"totalTrials":780,"cells":6034},"MK-1602",{"EARLY_PHASE1":6035,"PHASE1":6037,"PHASE2":6039,"PHASE3":6057,"PHASE4":6059,"NA":6061},{"trials":6036,"activeCount":13},[],{"trials":6038,"activeCount":13},[],{"trials":6040,"activeCount":13},[6041,6049],{"nctId":6042,"briefTitle":6043,"status":61,"phases":6044,"primaryCompletion":1231,"completion":1230,"start":392,"enrollment":6045,"conditions":6046,"interventions":6047},"NCT01657370","A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)",[43],195,[2997],[6033,6048],"Rescue medication",{"nctId":6050,"briefTitle":6051,"status":61,"phases":6052,"primaryCompletion":6053,"completion":6053,"start":6054,"enrollment":2968,"conditions":6055,"interventions":6056},"NCT01613248","A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)",[43],"2012-12-01","2012-07-01",[2997],[6033,6048],{"trials":6058,"activeCount":13},[],{"trials":6060,"activeCount":13},[],{"trials":6062,"activeCount":13},[],{"intervention":6048,"totalTrials":780,"cells":6064},{"EARLY_PHASE1":6065,"PHASE1":6067,"PHASE2":6069,"PHASE3":6079,"PHASE4":6081,"NA":6083},{"trials":6066,"activeCount":13},[],{"trials":6068,"activeCount":13},[],{"trials":6070,"activeCount":13},[6071,6075],{"nctId":6042,"briefTitle":6043,"status":61,"phases":6072,"primaryCompletion":1231,"completion":1230,"start":392,"enrollment":6045,"conditions":6073,"interventions":6074},[43],[2997],[6033,6048],{"nctId":6050,"briefTitle":6051,"status":61,"phases":6076,"primaryCompletion":6053,"completion":6053,"start":6054,"enrollment":2968,"conditions":6077,"interventions":6078},[43],[2997],[6033,6048],{"trials":6080,"activeCount":13},[],{"trials":6082,"activeCount":13},[],{"trials":6084,"activeCount":13},[],{"intervention":6086,"totalTrials":10,"cells":6087},"AGN 211745",{"EARLY_PHASE1":6088,"PHASE1":6090,"PHASE2":6092,"PHASE3":6104,"PHASE4":6106,"NA":6108},{"trials":6089,"activeCount":13},[],{"trials":6091,"activeCount":13},[],{"trials":6093,"activeCount":13},[6094],{"nctId":6095,"briefTitle":6096,"status":75,"phases":6097,"primaryCompletion":1093,"completion":320,"start":1010,"enrollment":6098,"conditions":6099,"interventions":6102},"NCT00395057","A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration",[43],138,[6100,6101],"Choroid Neovascularization","Age-Related Macular Degeneration",[6086,6086,6086,6103],"Ranibizumab 500µg",{"trials":6105,"activeCount":13},[],{"trials":6107,"activeCount":13},[],{"trials":6109,"activeCount":13},[],{"intervention":6103,"totalTrials":10,"cells":6111},{"EARLY_PHASE1":6112,"PHASE1":6114,"PHASE2":6116,"PHASE3":6122,"PHASE4":6124,"NA":6126},{"trials":6113,"activeCount":13},[],{"trials":6115,"activeCount":13},[],{"trials":6117,"activeCount":13},[6118],{"nctId":6095,"briefTitle":6096,"status":75,"phases":6119,"primaryCompletion":1093,"completion":320,"start":1010,"enrollment":6098,"conditions":6120,"interventions":6121},[43],[6100,6101],[6086,6086,6086,6103],{"trials":6123,"activeCount":13},[],{"trials":6125,"activeCount":13},[],{"trials":6127,"activeCount":13},[],{"intervention":6129,"totalTrials":10,"cells":6130},"botulinum toxin type A Formulation 2",{"EARLY_PHASE1":6131,"PHASE1":6133,"PHASE2":6135,"PHASE3":6146,"PHASE4":6148,"NA":6150},{"trials":6132,"activeCount":13},[],{"trials":6134,"activeCount":13},[],{"trials":6136,"activeCount":13},[6137],{"nctId":6138,"briefTitle":6139,"status":61,"phases":6140,"primaryCompletion":888,"completion":897,"start":631,"enrollment":4214,"conditions":6141,"interventions":6143},"NCT00564681","Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia",[43],[6142],"Cervical Dystonia",[6144,6129,6145],"botulinum toxin type A","Normal Saline",{"trials":6147,"activeCount":13},[],{"trials":6149,"activeCount":13},[],{"trials":6151,"activeCount":13},[],{"intervention":199,"totalTrials":10,"cells":6153},{"EARLY_PHASE1":6154,"PHASE1":6156,"PHASE2":6158,"PHASE3":6164,"PHASE4":6166,"NA":6168},{"trials":6155,"activeCount":13},[],{"trials":6157,"activeCount":13},[],{"trials":6159,"activeCount":13},[6160],{"nctId":191,"briefTitle":192,"status":75,"phases":6161,"primaryCompletion":194,"completion":194,"start":195,"enrollment":196,"conditions":6162,"interventions":6163},[43],[26],[181,199],{"trials":6165,"activeCount":13},[],{"trials":6167,"activeCount":13},[],{"trials":6169,"activeCount":13},[],{"intervention":5488,"totalTrials":10,"cells":6171},{"EARLY_PHASE1":6172,"PHASE1":6174,"PHASE2":6176,"PHASE3":6182,"PHASE4":6184,"NA":6186},{"trials":6173,"activeCount":13},[],{"trials":6175,"activeCount":13},[],{"trials":6177,"activeCount":13},[6178],{"nctId":5483,"briefTitle":5484,"status":61,"phases":6179,"primaryCompletion":2607,"completion":4557,"start":5436,"enrollment":21,"conditions":6180,"interventions":6181},[43],[3611],[5463,5479,5488,5489],{"trials":6183,"activeCount":13},[],{"trials":6185,"activeCount":13},[],{"trials":6187,"activeCount":13},[],{"intervention":5489,"totalTrials":10,"cells":6189},{"EARLY_PHASE1":6190,"PHASE1":6192,"PHASE2":6194,"PHASE3":6200,"PHASE4":6202,"NA":6204},{"trials":6191,"activeCount":13},[],{"trials":6193,"activeCount":13},[],{"trials":6195,"activeCount":13},[6196],{"nctId":5483,"briefTitle":5484,"status":61,"phases":6197,"primaryCompletion":2607,"completion":4557,"start":5436,"enrollment":21,"conditions":6198,"interventions":6199},[43],[3611],[5463,5479,5488,5489],{"trials":6201,"activeCount":13},[],{"trials":6203,"activeCount":13},[],{"trials":6205,"activeCount":13},[],{"intervention":83,"totalTrials":10,"cells":6207},{"EARLY_PHASE1":6208,"PHASE1":6210,"PHASE2":6212,"PHASE3":6218,"PHASE4":6220,"NA":6222},{"trials":6209,"activeCount":13},[],{"trials":6211,"activeCount":13},[],{"trials":6213,"activeCount":13},[6214],{"nctId":73,"briefTitle":74,"status":75,"phases":6215,"primaryCompletion":77,"completion":77,"start":78,"enrollment":79,"conditions":6216,"interventions":6217},[43],[81,69],[83,49],{"trials":6219,"activeCount":13},[],{"trials":6221,"activeCount":13},[],{"trials":6223,"activeCount":13},[],{"intervention":402,"totalTrials":10,"cells":6225},{"EARLY_PHASE1":6226,"PHASE1":6228,"PHASE2":6230,"PHASE3":6236,"PHASE4":6238,"NA":6240},{"trials":6227,"activeCount":13},[],{"trials":6229,"activeCount":13},[],{"trials":6231,"activeCount":13},[6232],{"nctId":389,"briefTitle":390,"status":61,"phases":6233,"primaryCompletion":392,"completion":393,"start":204,"enrollment":173,"conditions":6234,"interventions":6235},[43],[395,396,397],[399,400,401,350,402],{"trials":6237,"activeCount":13},[],{"trials":6239,"activeCount":13},[],{"trials":6241,"activeCount":13},[],{"intervention":6243,"totalTrials":10,"cells":6244},"Botulinum Neurotoxin Serotype E",{"EARLY_PHASE1":6245,"PHASE1":6247,"PHASE2":6249,"PHASE3":6261,"PHASE4":6263,"NA":6265},{"trials":6246,"activeCount":13},[],{"trials":6248,"activeCount":13},[],{"trials":6250,"activeCount":13},[6251],{"nctId":6252,"briefTitle":6253,"status":75,"phases":6254,"primaryCompletion":6255,"completion":6255,"start":6256,"enrollment":6257,"conditions":6258,"interventions":6260},"NCT03429556","Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty",[43],"2018-07-10","2018-05-08",23,[6259],"Abdominoplasty",[6243],{"trials":6262,"activeCount":13},[],{"trials":6264,"activeCount":13},[],{"trials":6266,"activeCount":13},[],{"intervention":296,"totalTrials":10,"cells":6268},{"EARLY_PHASE1":6269,"PHASE1":6271,"PHASE2":6273,"PHASE3":6279,"PHASE4":6281,"NA":6283},{"trials":6270,"activeCount":13},[],{"trials":6272,"activeCount":13},[],{"trials":6274,"activeCount":13},[6275],{"nctId":289,"briefTitle":290,"status":61,"phases":6276,"primaryCompletion":77,"completion":204,"start":205,"enrollment":292,"conditions":6277,"interventions":6278},[43],[17,294],[296,297,298,299,300,301,302,279],{"trials":6280,"activeCount":13},[],{"trials":6282,"activeCount":13},[],{"trials":6284,"activeCount":13},[],{"intervention":297,"totalTrials":10,"cells":6286},{"EARLY_PHASE1":6287,"PHASE1":6289,"PHASE2":6291,"PHASE3":6297,"PHASE4":6299,"NA":6301},{"trials":6288,"activeCount":13},[],{"trials":6290,"activeCount":13},[],{"trials":6292,"activeCount":13},[6293],{"nctId":289,"briefTitle":290,"status":61,"phases":6294,"primaryCompletion":77,"completion":204,"start":205,"enrollment":292,"conditions":6295,"interventions":6296},[43],[17,294],[296,297,298,299,300,301,302,279],{"trials":6298,"activeCount":13},[],{"trials":6300,"activeCount":13},[],{"trials":6302,"activeCount":13},[],{"intervention":298,"totalTrials":10,"cells":6304},{"EARLY_PHASE1":6305,"PHASE1":6307,"PHASE2":6309,"PHASE3":6315,"PHASE4":6317,"NA":6319},{"trials":6306,"activeCount":13},[],{"trials":6308,"activeCount":13},[],{"trials":6310,"activeCount":13},[6311],{"nctId":289,"briefTitle":290,"status":61,"phases":6312,"primaryCompletion":77,"completion":204,"start":205,"enrollment":292,"conditions":6313,"interventions":6314},[43],[17,294],[296,297,298,299,300,301,302,279],{"trials":6316,"activeCount":13},[],{"trials":6318,"activeCount":13},[],{"trials":6320,"activeCount":13},[],{"intervention":299,"totalTrials":10,"cells":6322},{"EARLY_PHASE1":6323,"PHASE1":6325,"PHASE2":6327,"PHASE3":6333,"PHASE4":6335,"NA":6337},{"trials":6324,"activeCount":13},[],{"trials":6326,"activeCount":13},[],{"trials":6328,"activeCount":13},[6329],{"nctId":289,"briefTitle":290,"status":61,"phases":6330,"primaryCompletion":77,"completion":204,"start":205,"enrollment":292,"conditions":6331,"interventions":6332},[43],[17,294],[296,297,298,299,300,301,302,279],{"trials":6334,"activeCount":13},[],{"trials":6336,"activeCount":13},[],{"trials":6338,"activeCount":13},[],{"intervention":300,"totalTrials":10,"cells":6340},{"EARLY_PHASE1":6341,"PHASE1":6343,"PHASE2":6345,"PHASE3":6351,"PHASE4":6353,"NA":6355},{"trials":6342,"activeCount":13},[],{"trials":6344,"activeCount":13},[],{"trials":6346,"activeCount":13},[6347],{"nctId":289,"briefTitle":290,"status":61,"phases":6348,"primaryCompletion":77,"completion":204,"start":205,"enrollment":292,"conditions":6349,"interventions":6350},[43],[17,294],[296,297,298,299,300,301,302,279],{"trials":6352,"activeCount":13},[],{"trials":6354,"activeCount":13},[],{"trials":6356,"activeCount":13},[],{"intervention":301,"totalTrials":10,"cells":6358},{"EARLY_PHASE1":6359,"PHASE1":6361,"PHASE2":6363,"PHASE3":6369,"PHASE4":6371,"NA":6373},{"trials":6360,"activeCount":13},[],{"trials":6362,"activeCount":13},[],{"trials":6364,"activeCount":13},[6365],{"nctId":289,"briefTitle":290,"status":61,"phases":6366,"primaryCompletion":77,"completion":204,"start":205,"enrollment":292,"conditions":6367,"interventions":6368},[43],[17,294],[296,297,298,299,300,301,302,279],{"trials":6370,"activeCount":13},[],{"trials":6372,"activeCount":13},[],{"trials":6374,"activeCount":13},[],{"intervention":302,"totalTrials":10,"cells":6376},{"EARLY_PHASE1":6377,"PHASE1":6379,"PHASE2":6381,"PHASE3":6387,"PHASE4":6389,"NA":6391},{"trials":6378,"activeCount":13},[],{"trials":6380,"activeCount":13},[],{"trials":6382,"activeCount":13},[6383],{"nctId":289,"briefTitle":290,"status":61,"phases":6384,"primaryCompletion":77,"completion":204,"start":205,"enrollment":292,"conditions":6385,"interventions":6386},[43],[17,294],[296,297,298,299,300,301,302,279],{"trials":6388,"activeCount":13},[],{"trials":6390,"activeCount":13},[],{"trials":6392,"activeCount":13},[],{"intervention":6394,"totalTrials":10,"cells":6395},"400 µg Brimonidine Implant",{"EARLY_PHASE1":6396,"PHASE1":6398,"PHASE2":6400,"PHASE3":6412,"PHASE4":6414,"NA":6416},{"trials":6397,"activeCount":13},[],{"trials":6399,"activeCount":13},[],{"trials":6401,"activeCount":13},[6402],{"nctId":6403,"briefTitle":6404,"status":75,"phases":6405,"primaryCompletion":6406,"completion":6406,"start":6407,"enrollment":6408,"conditions":6409,"interventions":6411},"NCT02087085","A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration",[43],"2018-03-30","2014-05-09",310,[6410,92],"Geographic Atrophy",[6394],{"trials":6413,"activeCount":13},[],{"trials":6415,"activeCount":13},[],{"trials":6417,"activeCount":13},[],{"intervention":3137,"totalTrials":10,"cells":6419},{"EARLY_PHASE1":6420,"PHASE1":6422,"PHASE2":6424,"PHASE3":6430,"PHASE4":6432,"NA":6434},{"trials":6421,"activeCount":13},[],{"trials":6423,"activeCount":13},[],{"trials":6425,"activeCount":13},[6426],{"nctId":3129,"briefTitle":3130,"status":61,"phases":6427,"primaryCompletion":89,"completion":3132,"start":3133,"enrollment":3134,"conditions":6428,"interventions":6429},[43],[395,396,397],[3137,3138,3139],{"trials":6431,"activeCount":13},[],{"trials":6433,"activeCount":13},[],{"trials":6435,"activeCount":13},[],{"intervention":3138,"totalTrials":10,"cells":6437},{"EARLY_PHASE1":6438,"PHASE1":6440,"PHASE2":6442,"PHASE3":6448,"PHASE4":6450,"NA":6452},{"trials":6439,"activeCount":13},[],{"trials":6441,"activeCount":13},[],{"trials":6443,"activeCount":13},[6444],{"nctId":3129,"briefTitle":3130,"status":61,"phases":6445,"primaryCompletion":89,"completion":3132,"start":3133,"enrollment":3134,"conditions":6446,"interventions":6447},[43],[395,396,397],[3137,3138,3139],{"trials":6449,"activeCount":13},[],{"trials":6451,"activeCount":13},[],{"trials":6453,"activeCount":13},[],{"intervention":6455,"totalTrials":10,"cells":6456},"bimatoprost 20 µg generation 2",{"EARLY_PHASE1":6457,"PHASE1":6459,"PHASE2":6461,"PHASE3":6479,"PHASE4":6481,"NA":6483},{"trials":6458,"activeCount":13},[],{"trials":6460,"activeCount":13},[],{"trials":6462,"activeCount":13},[6463],{"nctId":6464,"briefTitle":6465,"status":61,"phases":6466,"primaryCompletion":6467,"completion":6468,"start":6469,"enrollment":6470,"conditions":6471,"interventions":6472},"NCT01157364","Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension",[42,43],"2016-07-27","2016-08-09","2010-09-23",109,[1731,17],[6455,6473,6474,6475,6476,6477,6478],"bimatoprost 15 µg generation 2","bimatoprost 10 µg generation 2","bimatoprost 6 µg generation 2","bimatoprost 15 µg generation 1","bimatoprost 10 µg generation 1","bimatoprost 0.03%",{"trials":6480,"activeCount":13},[],{"trials":6482,"activeCount":13},[],{"trials":6484,"activeCount":13},[],{"intervention":6473,"totalTrials":10,"cells":6486},{"EARLY_PHASE1":6487,"PHASE1":6489,"PHASE2":6491,"PHASE3":6497,"PHASE4":6499,"NA":6501},{"trials":6488,"activeCount":13},[],{"trials":6490,"activeCount":13},[],{"trials":6492,"activeCount":13},[6493],{"nctId":6464,"briefTitle":6465,"status":61,"phases":6494,"primaryCompletion":6467,"completion":6468,"start":6469,"enrollment":6470,"conditions":6495,"interventions":6496},[42,43],[1731,17],[6455,6473,6474,6475,6476,6477,6478],{"trials":6498,"activeCount":13},[],{"trials":6500,"activeCount":13},[],{"trials":6502,"activeCount":13},[],{"intervention":6474,"totalTrials":10,"cells":6504},{"EARLY_PHASE1":6505,"PHASE1":6507,"PHASE2":6509,"PHASE3":6515,"PHASE4":6517,"NA":6519},{"trials":6506,"activeCount":13},[],{"trials":6508,"activeCount":13},[],{"trials":6510,"activeCount":13},[6511],{"nctId":6464,"briefTitle":6465,"status":61,"phases":6512,"primaryCompletion":6467,"completion":6468,"start":6469,"enrollment":6470,"conditions":6513,"interventions":6514},[42,43],[1731,17],[6455,6473,6474,6475,6476,6477,6478],{"trials":6516,"activeCount":13},[],{"trials":6518,"activeCount":13},[],{"trials":6520,"activeCount":13},[],{"intervention":6475,"totalTrials":10,"cells":6522},{"EARLY_PHASE1":6523,"PHASE1":6525,"PHASE2":6527,"PHASE3":6533,"PHASE4":6535,"NA":6537},{"trials":6524,"activeCount":13},[],{"trials":6526,"activeCount":13},[],{"trials":6528,"activeCount":13},[6529],{"nctId":6464,"briefTitle":6465,"status":61,"phases":6530,"primaryCompletion":6467,"completion":6468,"start":6469,"enrollment":6470,"conditions":6531,"interventions":6532},[42,43],[1731,17],[6455,6473,6474,6475,6476,6477,6478],{"trials":6534,"activeCount":13},[],{"trials":6536,"activeCount":13},[],{"trials":6538,"activeCount":13},[],{"intervention":6476,"totalTrials":10,"cells":6540},{"EARLY_PHASE1":6541,"PHASE1":6543,"PHASE2":6545,"PHASE3":6551,"PHASE4":6553,"NA":6555},{"trials":6542,"activeCount":13},[],{"trials":6544,"activeCount":13},[],{"trials":6546,"activeCount":13},[6547],{"nctId":6464,"briefTitle":6465,"status":61,"phases":6548,"primaryCompletion":6467,"completion":6468,"start":6469,"enrollment":6470,"conditions":6549,"interventions":6550},[42,43],[1731,17],[6455,6473,6474,6475,6476,6477,6478],{"trials":6552,"activeCount":13},[],{"trials":6554,"activeCount":13},[],{"trials":6556,"activeCount":13},[],{"intervention":6477,"totalTrials":10,"cells":6558},{"EARLY_PHASE1":6559,"PHASE1":6561,"PHASE2":6563,"PHASE3":6569,"PHASE4":6571,"NA":6573},{"trials":6560,"activeCount":13},[],{"trials":6562,"activeCount":13},[],{"trials":6564,"activeCount":13},[6565],{"nctId":6464,"briefTitle":6465,"status":61,"phases":6566,"primaryCompletion":6467,"completion":6468,"start":6469,"enrollment":6470,"conditions":6567,"interventions":6568},[42,43],[1731,17],[6455,6473,6474,6475,6476,6477,6478],{"trials":6570,"activeCount":13},[],{"trials":6572,"activeCount":13},[],{"trials":6574,"activeCount":13},[],{"intervention":511,"totalTrials":10,"cells":6576},{"EARLY_PHASE1":6577,"PHASE1":6579,"PHASE2":6581,"PHASE3":6587,"PHASE4":6589,"NA":6591},{"trials":6578,"activeCount":13},[],{"trials":6580,"activeCount":13},[],{"trials":6582,"activeCount":13},[6583],{"nctId":503,"briefTitle":504,"status":61,"phases":6584,"primaryCompletion":506,"completion":506,"start":507,"enrollment":508,"conditions":6585,"interventions":6586},[43],[20,17],[511,512,513,514],{"trials":6588,"activeCount":13},[],{"trials":6590,"activeCount":13},[],{"trials":6592,"activeCount":13},[],{"intervention":513,"totalTrials":10,"cells":6594},{"EARLY_PHASE1":6595,"PHASE1":6597,"PHASE2":6599,"PHASE3":6605,"PHASE4":6607,"NA":6609},{"trials":6596,"activeCount":13},[],{"trials":6598,"activeCount":13},[],{"trials":6600,"activeCount":13},[6601],{"nctId":503,"briefTitle":504,"status":61,"phases":6602,"primaryCompletion":506,"completion":506,"start":507,"enrollment":508,"conditions":6603,"interventions":6604},[43],[20,17],[511,512,513,514],{"trials":6606,"activeCount":13},[],{"trials":6608,"activeCount":13},[],{"trials":6610,"activeCount":13},[],{"intervention":514,"totalTrials":10,"cells":6612},{"EARLY_PHASE1":6613,"PHASE1":6615,"PHASE2":6617,"PHASE3":6623,"PHASE4":6625,"NA":6627},{"trials":6614,"activeCount":13},[],{"trials":6616,"activeCount":13},[],{"trials":6618,"activeCount":13},[6619],{"nctId":503,"briefTitle":504,"status":61,"phases":6620,"primaryCompletion":506,"completion":506,"start":507,"enrollment":508,"conditions":6621,"interventions":6622},[43],[20,17],[511,512,513,514],{"trials":6624,"activeCount":13},[],{"trials":6626,"activeCount":13},[],{"trials":6628,"activeCount":13},[],{"intervention":6630,"totalTrials":10,"cells":6631},"Setipiprant",{"EARLY_PHASE1":6632,"PHASE1":6634,"PHASE2":6636,"PHASE3":6649,"PHASE4":6651,"NA":6653},{"trials":6633,"activeCount":13},[],{"trials":6635,"activeCount":13},[],{"trials":6637,"activeCount":13},[6638],{"nctId":6639,"briefTitle":6640,"status":61,"phases":6641,"primaryCompletion":6642,"completion":6643,"start":6644,"enrollment":6645,"conditions":6646,"interventions":6647},"NCT02781311","A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males",[43],"2018-03-15","2018-05-22","2016-07-14",169,[395],[6630,6648],"Finasteride",{"trials":6650,"activeCount":13},[],{"trials":6652,"activeCount":13},[],{"trials":6654,"activeCount":13},[],{"intervention":6648,"totalTrials":10,"cells":6656},{"EARLY_PHASE1":6657,"PHASE1":6659,"PHASE2":6661,"PHASE3":6667,"PHASE4":6669,"NA":6671},{"trials":6658,"activeCount":13},[],{"trials":6660,"activeCount":13},[],{"trials":6662,"activeCount":13},[6663],{"nctId":6639,"briefTitle":6640,"status":61,"phases":6664,"primaryCompletion":6642,"completion":6643,"start":6644,"enrollment":6645,"conditions":6665,"interventions":6666},[43],[395],[6630,6648],{"trials":6668,"activeCount":13},[],{"trials":6670,"activeCount":13},[],{"trials":6672,"activeCount":13},[],{"intervention":6674,"totalTrials":10,"cells":6675},"AGN211745",{"EARLY_PHASE1":6676,"PHASE1":6678,"PHASE2":6680,"PHASE3":6690,"PHASE4":6692,"NA":6694},{"trials":6677,"activeCount":13},[],{"trials":6679,"activeCount":13},[],{"trials":6681,"activeCount":13},[6682],{"nctId":6683,"briefTitle":6684,"status":61,"phases":6685,"primaryCompletion":632,"completion":632,"start":6686,"enrollment":6687,"conditions":6688,"interventions":6689},"NCT00363714","A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)",[42,43],"2004-11",26,[6101,68],[6674,6674,6674,6674,6674,6674],{"trials":6691,"activeCount":13},[],{"trials":6693,"activeCount":13},[],{"trials":6695,"activeCount":13},[],{"intervention":6697,"totalTrials":10,"cells":6698},"Brimo PS DDS®",{"EARLY_PHASE1":6699,"PHASE1":6701,"PHASE2":6703,"PHASE3":6714,"PHASE4":6716,"NA":6718},{"trials":6700,"activeCount":13},[],{"trials":6702,"activeCount":13},[],{"trials":6704,"activeCount":13},[6705],{"nctId":6706,"briefTitle":6707,"status":61,"phases":6708,"primaryCompletion":4627,"completion":4627,"start":6709,"enrollment":6710,"conditions":6711,"interventions":6713},"NCT01080209","Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System",[43],"2010-02",215,[6712],"Patients Who Participated in an Intravitreal Brimo PS DDS® Study",[6697],{"trials":6715,"activeCount":13},[],{"trials":6717,"activeCount":13},[],{"trials":6719,"activeCount":13},[],{"intervention":572,"totalTrials":10,"cells":6721},{"EARLY_PHASE1":6722,"PHASE1":6724,"PHASE2":6726,"PHASE3":6732,"PHASE4":6734,"NA":6736},{"trials":6723,"activeCount":13},[],{"trials":6725,"activeCount":13},[],{"trials":6727,"activeCount":13},[6728],{"nctId":563,"briefTitle":564,"status":61,"phases":6729,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":6730,"interventions":6731},[43],[20,17],[571,554,572],{"trials":6733,"activeCount":13},[],{"trials":6735,"activeCount":13},[],{"trials":6737,"activeCount":13},[],{"intervention":6739,"totalTrials":10,"cells":6740},"Cyclosporine 0.010% eye drops",{"EARLY_PHASE1":6741,"PHASE1":6743,"PHASE2":6745,"PHASE3":6756,"PHASE4":6758,"NA":6760},{"trials":6742,"activeCount":13},[],{"trials":6744,"activeCount":13},[],{"trials":6746,"activeCount":13},[6747],{"nctId":6748,"briefTitle":6749,"status":61,"phases":6750,"primaryCompletion":3144,"completion":3144,"start":450,"enrollment":6751,"conditions":6752,"interventions":6754},"NCT00991458","Study of Cyclosporine in Post-LASIK Patients",[43],621,[6753],"Laser In Situ Keratomileusis",[6739,6755],"Cyclosporine 0.005% eye drops",{"trials":6757,"activeCount":13},[],{"trials":6759,"activeCount":13},[],{"trials":6761,"activeCount":13},[],{"intervention":6755,"totalTrials":10,"cells":6763},{"EARLY_PHASE1":6764,"PHASE1":6766,"PHASE2":6768,"PHASE3":6774,"PHASE4":6776,"NA":6778},{"trials":6765,"activeCount":13},[],{"trials":6767,"activeCount":13},[],{"trials":6769,"activeCount":13},[6770],{"nctId":6748,"briefTitle":6749,"status":61,"phases":6771,"primaryCompletion":3144,"completion":3144,"start":450,"enrollment":6751,"conditions":6772,"interventions":6773},[43],[6753],[6739,6755],{"trials":6775,"activeCount":13},[],{"trials":6777,"activeCount":13},[],{"trials":6779,"activeCount":13},[],{"intervention":313,"totalTrials":10,"cells":6781},{"EARLY_PHASE1":6782,"PHASE1":6784,"PHASE2":6786,"PHASE3":6792,"PHASE4":6794,"NA":6796},{"trials":6783,"activeCount":13},[],{"trials":6785,"activeCount":13},[],{"trials":6787,"activeCount":13},[6788],{"nctId":304,"briefTitle":305,"status":61,"phases":6789,"primaryCompletion":307,"completion":307,"start":308,"enrollment":309,"conditions":6790,"interventions":6791},[43],[311],[313,314,279],{"trials":6793,"activeCount":13},[],{"trials":6795,"activeCount":13},[],{"trials":6797,"activeCount":13},[],{"intervention":314,"totalTrials":10,"cells":6799},{"EARLY_PHASE1":6800,"PHASE1":6802,"PHASE2":6804,"PHASE3":6810,"PHASE4":6812,"NA":6814},{"trials":6801,"activeCount":13},[],{"trials":6803,"activeCount":13},[],{"trials":6805,"activeCount":13},[6806],{"nctId":304,"briefTitle":305,"status":61,"phases":6807,"primaryCompletion":307,"completion":307,"start":308,"enrollment":309,"conditions":6808,"interventions":6809},[43],[311],[313,314,279],{"trials":6811,"activeCount":13},[],{"trials":6813,"activeCount":13},[],{"trials":6815,"activeCount":13},[],{"intervention":5635,"totalTrials":10,"cells":6817},{"EARLY_PHASE1":6818,"PHASE1":6820,"PHASE2":6822,"PHASE3":6828,"PHASE4":6830,"NA":6832},{"trials":6819,"activeCount":13},[],{"trials":6821,"activeCount":13},[],{"trials":6823,"activeCount":13},[6824],{"nctId":5628,"briefTitle":5629,"status":61,"phases":6825,"primaryCompletion":897,"completion":5631,"start":923,"enrollment":30,"conditions":6826,"interventions":6827},[42,43],[5633],[5612,5624,5635],{"trials":6829,"activeCount":13},[],{"trials":6831,"activeCount":13},[],{"trials":6833,"activeCount":13},[],{"intervention":583,"totalTrials":10,"cells":6835},{"EARLY_PHASE1":6836,"PHASE1":6838,"PHASE2":6840,"PHASE3":6846,"PHASE4":6848,"NA":6850},{"trials":6837,"activeCount":13},[],{"trials":6839,"activeCount":13},[],{"trials":6841,"activeCount":13},[6842],{"nctId":574,"briefTitle":575,"status":61,"phases":6843,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":6844,"interventions":6845},[43],[20,17],[582,583,584,585,586],{"trials":6847,"activeCount":13},[],{"trials":6849,"activeCount":13},[],{"trials":6851,"activeCount":13},[],{"intervention":584,"totalTrials":10,"cells":6853},{"EARLY_PHASE1":6854,"PHASE1":6856,"PHASE2":6858,"PHASE3":6864,"PHASE4":6866,"NA":6868},{"trials":6855,"activeCount":13},[],{"trials":6857,"activeCount":13},[],{"trials":6859,"activeCount":13},[6860],{"nctId":574,"briefTitle":575,"status":61,"phases":6861,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":6862,"interventions":6863},[43],[20,17],[582,583,584,585,586],{"trials":6865,"activeCount":13},[],{"trials":6867,"activeCount":13},[],{"trials":6869,"activeCount":13},[],{"intervention":585,"totalTrials":10,"cells":6871},{"EARLY_PHASE1":6872,"PHASE1":6874,"PHASE2":6876,"PHASE3":6882,"PHASE4":6884,"NA":6886},{"trials":6873,"activeCount":13},[],{"trials":6875,"activeCount":13},[],{"trials":6877,"activeCount":13},[6878],{"nctId":574,"briefTitle":575,"status":61,"phases":6879,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":6880,"interventions":6881},[43],[20,17],[582,583,584,585,586],{"trials":6883,"activeCount":13},[],{"trials":6885,"activeCount":13},[],{"trials":6887,"activeCount":13},[],{"intervention":6889,"totalTrials":10,"cells":6890},"LiRIS 400 mg",{"EARLY_PHASE1":6891,"PHASE1":6893,"PHASE2":6895,"PHASE3":6905,"PHASE4":6907,"NA":6909},{"trials":6892,"activeCount":13},[],{"trials":6894,"activeCount":13},[],{"trials":6896,"activeCount":13},[6897],{"nctId":6898,"briefTitle":6899,"status":75,"phases":6900,"primaryCompletion":3761,"completion":807,"start":6901,"enrollment":24,"conditions":6902,"interventions":6904},"NCT01824303","Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis",[43],"2013-03",[6903],"Interstitial Cystitis",[6889],{"trials":6906,"activeCount":13},[],{"trials":6908,"activeCount":13},[],{"trials":6910,"activeCount":13},[],{"intervention":326,"totalTrials":10,"cells":6912},{"EARLY_PHASE1":6913,"PHASE1":6915,"PHASE2":6917,"PHASE3":6923,"PHASE4":6925,"NA":6927},{"trials":6914,"activeCount":13},[],{"trials":6916,"activeCount":13},[],{"trials":6918,"activeCount":13},[6919],{"nctId":316,"briefTitle":317,"status":61,"phases":6920,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":6921,"interventions":6922},[42,43],[17,20],[324,325,326,279,327],{"trials":6924,"activeCount":13},[],{"trials":6926,"activeCount":13},[],{"trials":6928,"activeCount":13},[],{"intervention":327,"totalTrials":10,"cells":6930},{"EARLY_PHASE1":6931,"PHASE1":6933,"PHASE2":6935,"PHASE3":6941,"PHASE4":6943,"NA":6945},{"trials":6932,"activeCount":13},[],{"trials":6934,"activeCount":13},[],{"trials":6936,"activeCount":13},[6937],{"nctId":316,"briefTitle":317,"status":61,"phases":6938,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":6939,"interventions":6940},[42,43],[17,20],[324,325,326,279,327],{"trials":6942,"activeCount":13},[],{"trials":6944,"activeCount":13},[],{"trials":6946,"activeCount":13},[],{"intervention":6948,"totalTrials":10,"cells":6949},"Vehicle control, 2x\u002Fday",{"EARLY_PHASE1":6950,"PHASE1":6952,"PHASE2":6954,"PHASE3":6966,"PHASE4":6968,"NA":6970},{"trials":6951,"activeCount":13},[],{"trials":6953,"activeCount":13},[],{"trials":6955,"activeCount":13},[6956],{"nctId":6957,"briefTitle":6958,"status":61,"phases":6959,"primaryCompletion":2701,"completion":2701,"start":270,"enrollment":4339,"conditions":6960,"interventions":6961},"NCT00249782","A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.",[43],[3774],[6948,6962,6963,6964,6965],"ACZONE (dapsone) Gel, 5%, 2x\u002Fday","ACZONE (dapsone) Gel, 5%, 1x\u002Fday","MetroGel® (metronidazole gel), 1.0% 1x\u002Fday","ACZONE",{"trials":6967,"activeCount":13},[],{"trials":6969,"activeCount":13},[],{"trials":6971,"activeCount":13},[],{"intervention":6962,"totalTrials":10,"cells":6973},{"EARLY_PHASE1":6974,"PHASE1":6976,"PHASE2":6978,"PHASE3":6984,"PHASE4":6986,"NA":6988},{"trials":6975,"activeCount":13},[],{"trials":6977,"activeCount":13},[],{"trials":6979,"activeCount":13},[6980],{"nctId":6957,"briefTitle":6958,"status":61,"phases":6981,"primaryCompletion":2701,"completion":2701,"start":270,"enrollment":4339,"conditions":6982,"interventions":6983},[43],[3774],[6948,6962,6963,6964,6965],{"trials":6985,"activeCount":13},[],{"trials":6987,"activeCount":13},[],{"trials":6989,"activeCount":13},[],{"intervention":6963,"totalTrials":10,"cells":6991},{"EARLY_PHASE1":6992,"PHASE1":6994,"PHASE2":6996,"PHASE3":7002,"PHASE4":7004,"NA":7006},{"trials":6993,"activeCount":13},[],{"trials":6995,"activeCount":13},[],{"trials":6997,"activeCount":13},[6998],{"nctId":6957,"briefTitle":6958,"status":61,"phases":6999,"primaryCompletion":2701,"completion":2701,"start":270,"enrollment":4339,"conditions":7000,"interventions":7001},[43],[3774],[6948,6962,6963,6964,6965],{"trials":7003,"activeCount":13},[],{"trials":7005,"activeCount":13},[],{"trials":7007,"activeCount":13},[],{"intervention":6964,"totalTrials":10,"cells":7009},{"EARLY_PHASE1":7010,"PHASE1":7012,"PHASE2":7014,"PHASE3":7020,"PHASE4":7022,"NA":7024},{"trials":7011,"activeCount":13},[],{"trials":7013,"activeCount":13},[],{"trials":7015,"activeCount":13},[7016],{"nctId":6957,"briefTitle":6958,"status":61,"phases":7017,"primaryCompletion":2701,"completion":2701,"start":270,"enrollment":4339,"conditions":7018,"interventions":7019},[43],[3774],[6948,6962,6963,6964,6965],{"trials":7021,"activeCount":13},[],{"trials":7023,"activeCount":13},[],{"trials":7025,"activeCount":13},[],{"intervention":6965,"totalTrials":10,"cells":7027},{"EARLY_PHASE1":7028,"PHASE1":7030,"PHASE2":7032,"PHASE3":7038,"PHASE4":7040,"NA":7042},{"trials":7029,"activeCount":13},[],{"trials":7031,"activeCount":13},[],{"trials":7033,"activeCount":13},[7034],{"nctId":6957,"briefTitle":6958,"status":61,"phases":7035,"primaryCompletion":2701,"completion":2701,"start":270,"enrollment":4339,"conditions":7036,"interventions":7037},[43],[3774],[6948,6962,6963,6964,6965],{"trials":7039,"activeCount":13},[],{"trials":7041,"activeCount":13},[],{"trials":7043,"activeCount":13},[],{"intervention":7045,"totalTrials":10,"cells":7046},"Gatifloxacin 0.3% ophthalmic solution",{"EARLY_PHASE1":7047,"PHASE1":7049,"PHASE2":7051,"PHASE3":7064,"PHASE4":7066,"NA":7068},{"trials":7048,"activeCount":13},[],{"trials":7050,"activeCount":13},[],{"trials":7052,"activeCount":13},[7053],{"nctId":7054,"briefTitle":7055,"status":61,"phases":7056,"primaryCompletion":7057,"completion":7057,"start":7058,"enrollment":4982,"conditions":7059,"interventions":7062},"NCT00651586","Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers",[43],"2005-04","2003-10",[7060,7061],"Acute Bacterial Corneal Ulcers","Bacterial Keratitis",[7045,7063],"Ciprofloxacin 0.3% ophthalmic solution",{"trials":7065,"activeCount":13},[],{"trials":7067,"activeCount":13},[],{"trials":7069,"activeCount":13},[],{"intervention":7063,"totalTrials":10,"cells":7071},{"EARLY_PHASE1":7072,"PHASE1":7074,"PHASE2":7076,"PHASE3":7082,"PHASE4":7084,"NA":7086},{"trials":7073,"activeCount":13},[],{"trials":7075,"activeCount":13},[],{"trials":7077,"activeCount":13},[7078],{"nctId":7054,"briefTitle":7055,"status":61,"phases":7079,"primaryCompletion":7057,"completion":7057,"start":7058,"enrollment":4982,"conditions":7080,"interventions":7081},[43],[7060,7061],[7045,7063],{"trials":7083,"activeCount":13},[],{"trials":7085,"activeCount":13},[],{"trials":7087,"activeCount":13},[],{"intervention":7089,"totalTrials":10,"cells":7090},"Linaclotide",{"EARLY_PHASE1":7091,"PHASE1":7093,"PHASE2":7095,"PHASE3":7107,"PHASE4":7109,"NA":7111},{"trials":7092,"activeCount":13},[],{"trials":7094,"activeCount":13},[],{"trials":7096,"activeCount":13},[7097],{"nctId":7098,"briefTitle":7099,"status":61,"phases":7100,"primaryCompletion":7101,"completion":7101,"start":7102,"enrollment":7103,"conditions":7104,"interventions":7106},"NCT04110145","Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation",[43],"2021-04-20","2019-10-14",35,[7105],"Functional Constipation",[7089],{"trials":7108,"activeCount":13},[],{"trials":7110,"activeCount":13},[],{"trials":7112,"activeCount":13},[],{"intervention":5385,"totalTrials":10,"cells":7114},{"EARLY_PHASE1":7115,"PHASE1":7117,"PHASE2":7119,"PHASE3":7125,"PHASE4":7127,"NA":7129},{"trials":7116,"activeCount":13},[],{"trials":7118,"activeCount":13},[],{"trials":7120,"activeCount":13},[7121],{"nctId":5375,"briefTitle":5376,"status":61,"phases":7122,"primaryCompletion":5378,"completion":5378,"start":5379,"enrollment":292,"conditions":7123,"interventions":7124},[43],[219],[5382,5383,5384,5385,5386],{"trials":7126,"activeCount":13},[],{"trials":7128,"activeCount":13},[],{"trials":7130,"activeCount":13},[],{"intervention":7132,"totalTrials":10,"cells":7133},"OnabotulinumtoxinA and Hydrogel admixture",{"EARLY_PHASE1":7134,"PHASE1":7136,"PHASE2":7138,"PHASE3":7150,"PHASE4":7152,"NA":7154},{"trials":7135,"activeCount":13},[],{"trials":7137,"activeCount":13},[],{"trials":7139,"activeCount":13},[7140],{"nctId":7141,"briefTitle":7142,"status":61,"phases":7143,"primaryCompletion":7144,"completion":7144,"start":7145,"enrollment":7146,"conditions":7147,"interventions":7149},"NCT03320850","BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence",[43],"2020-07-21","2017-10-04",383,[3574,7148],"Overactive Bladder With Urinary Incontinence",[7132],{"trials":7151,"activeCount":13},[],{"trials":7153,"activeCount":13},[],{"trials":7155,"activeCount":13},[],{"intervention":7157,"totalTrials":10,"cells":7158},"AGN208397 intravitreal",{"EARLY_PHASE1":7159,"PHASE1":7161,"PHASE2":7163,"PHASE3":7171,"PHASE4":7173,"NA":7175},{"trials":7160,"activeCount":13},[],{"trials":7162,"activeCount":13},[],{"trials":7164,"activeCount":13},[7165],{"nctId":7166,"briefTitle":7167,"status":61,"phases":7168,"primaryCompletion":344,"completion":1465,"start":308,"enrollment":2385,"conditions":7169,"interventions":7170},"NCT01027650","Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)",[42,43],[29,175],[7157,177],{"trials":7172,"activeCount":13},[],{"trials":7174,"activeCount":13},[],{"trials":7176,"activeCount":13},[],{"intervention":7178,"totalTrials":10,"cells":7179},"bimatoprost eye drops",{"EARLY_PHASE1":7180,"PHASE1":7182,"PHASE2":7184,"PHASE3":7194,"PHASE4":7196,"NA":7198},{"trials":7181,"activeCount":13},[],{"trials":7183,"activeCount":13},[],{"trials":7185,"activeCount":13},[7186],{"nctId":7187,"briefTitle":7188,"status":61,"phases":7189,"primaryCompletion":7190,"completion":7190,"start":5436,"enrollment":7191,"conditions":7192,"interventions":7193},"NCT00538304","A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension",[43],"2008-05",222,[20,17],[7178],{"trials":7195,"activeCount":13},[],{"trials":7197,"activeCount":13},[],{"trials":7199,"activeCount":13},[],{"intervention":411,"totalTrials":10,"cells":7201},{"EARLY_PHASE1":7202,"PHASE1":7204,"PHASE2":7206,"PHASE3":7212,"PHASE4":7214,"NA":7216},{"trials":7203,"activeCount":13},[],{"trials":7205,"activeCount":13},[],{"trials":7207,"activeCount":13},[7208],{"nctId":404,"briefTitle":405,"status":61,"phases":7209,"primaryCompletion":407,"completion":393,"start":204,"enrollment":408,"conditions":7210,"interventions":7211},[43],[395,397],[399,400,401,350,411],{"trials":7213,"activeCount":13},[],{"trials":7215,"activeCount":13},[],{"trials":7217,"activeCount":13},[],{"intervention":719,"totalTrials":10,"cells":7219},{"EARLY_PHASE1":7220,"PHASE1":7222,"PHASE2":7224,"PHASE3":7230,"PHASE4":7232,"NA":7234},{"trials":7221,"activeCount":13},[],{"trials":7223,"activeCount":13},[],{"trials":7225,"activeCount":13},[7226],{"nctId":711,"briefTitle":712,"status":75,"phases":7227,"primaryCompletion":714,"completion":714,"start":715,"enrollment":10,"conditions":7228,"interventions":7229},[43],[717],[688,719],{"trials":7231,"activeCount":13},[],{"trials":7233,"activeCount":13},[],{"trials":7235,"activeCount":13},[],{"intervention":7237,"totalTrials":10,"cells":7238},"Artificial Tears REFRESH ENDURA®",{"EARLY_PHASE1":7239,"PHASE1":7241,"PHASE2":7243,"PHASE3":7252,"PHASE4":7254,"NA":7256},{"trials":7240,"activeCount":13},[],{"trials":7242,"activeCount":13},[],{"trials":7244,"activeCount":13},[7245],{"nctId":7246,"briefTitle":7247,"status":61,"phases":7248,"primaryCompletion":888,"completion":761,"start":631,"enrollment":1048,"conditions":7249,"interventions":7250},"NCT00611403","Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients",[43],[26],[7251,7237],"Cyclosporine Ophthalmic Emulsion 0.05%",{"trials":7253,"activeCount":13},[],{"trials":7255,"activeCount":13},[],{"trials":7257,"activeCount":13},[],{"intervention":7259,"totalTrials":10,"cells":7260},"AGN-195263 0.1%",{"EARLY_PHASE1":7261,"PHASE1":7263,"PHASE2":7265,"PHASE3":7280,"PHASE4":7282,"NA":7284},{"trials":7262,"activeCount":13},[],{"trials":7264,"activeCount":13},[],{"trials":7266,"activeCount":13},[7267],{"nctId":7268,"briefTitle":7269,"status":61,"phases":7270,"primaryCompletion":7271,"completion":7271,"start":7272,"enrollment":7273,"conditions":7274,"interventions":7276},"NCT01633788","A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction",[43],"2015-02-05","2012-08-22",232,[7275],"Meibomian Gland Dysfunction",[7259,7277,7278,7279],"AGN-195263 0.03%","AGN-195263 0.01%","AGN-195263 Vehicle",{"trials":7281,"activeCount":13},[],{"trials":7283,"activeCount":13},[],{"trials":7285,"activeCount":13},[],{"intervention":7277,"totalTrials":10,"cells":7287},{"EARLY_PHASE1":7288,"PHASE1":7290,"PHASE2":7292,"PHASE3":7298,"PHASE4":7300,"NA":7302},{"trials":7289,"activeCount":13},[],{"trials":7291,"activeCount":13},[],{"trials":7293,"activeCount":13},[7294],{"nctId":7268,"briefTitle":7269,"status":61,"phases":7295,"primaryCompletion":7271,"completion":7271,"start":7272,"enrollment":7273,"conditions":7296,"interventions":7297},[43],[7275],[7259,7277,7278,7279],{"trials":7299,"activeCount":13},[],{"trials":7301,"activeCount":13},[],{"trials":7303,"activeCount":13},[],{"intervention":7278,"totalTrials":10,"cells":7305},{"EARLY_PHASE1":7306,"PHASE1":7308,"PHASE2":7310,"PHASE3":7316,"PHASE4":7318,"NA":7320},{"trials":7307,"activeCount":13},[],{"trials":7309,"activeCount":13},[],{"trials":7311,"activeCount":13},[7312],{"nctId":7268,"briefTitle":7269,"status":61,"phases":7313,"primaryCompletion":7271,"completion":7271,"start":7272,"enrollment":7273,"conditions":7314,"interventions":7315},[43],[7275],[7259,7277,7278,7279],{"trials":7317,"activeCount":13},[],{"trials":7319,"activeCount":13},[],{"trials":7321,"activeCount":13},[],{"intervention":7279,"totalTrials":10,"cells":7323},{"EARLY_PHASE1":7324,"PHASE1":7326,"PHASE2":7328,"PHASE3":7334,"PHASE4":7336,"NA":7338},{"trials":7325,"activeCount":13},[],{"trials":7327,"activeCount":13},[],{"trials":7329,"activeCount":13},[7330],{"nctId":7268,"briefTitle":7269,"status":61,"phases":7331,"primaryCompletion":7271,"completion":7271,"start":7272,"enrollment":7273,"conditions":7332,"interventions":7333},[43],[7275],[7259,7277,7278,7279],{"trials":7335,"activeCount":13},[],{"trials":7337,"activeCount":13},[],{"trials":7339,"activeCount":13},[],{"intervention":3148,"totalTrials":10,"cells":7341},{"EARLY_PHASE1":7342,"PHASE1":7344,"PHASE2":7346,"PHASE3":7352,"PHASE4":7354,"NA":7356},{"trials":7343,"activeCount":13},[],{"trials":7345,"activeCount":13},[],{"trials":7347,"activeCount":13},[7348],{"nctId":3141,"briefTitle":3142,"status":61,"phases":7349,"primaryCompletion":345,"completion":345,"start":3144,"enrollment":3145,"conditions":7350,"interventions":7351},[43],[23,17],[3148,3149,3120],{"trials":7353,"activeCount":13},[],{"trials":7355,"activeCount":13},[],{"trials":7357,"activeCount":13},[],{"intervention":7359,"totalTrials":10,"cells":7360},"Formulation A: OnabotulinumtoxinA",{"EARLY_PHASE1":7361,"PHASE1":7363,"PHASE2":7365,"PHASE3":7378,"PHASE4":7380,"NA":7382},{"trials":7362,"activeCount":13},[],{"trials":7364,"activeCount":13},[],{"trials":7366,"activeCount":13},[7367],{"nctId":7368,"briefTitle":7369,"status":61,"phases":7370,"primaryCompletion":7371,"completion":7371,"start":7372,"enrollment":7373,"conditions":7374,"interventions":7375},"NCT05013424","A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines",[43],"2022-07-07","2021-09-01",92,[373],[7359,7376,7377],"Formulation B: OnabotulinumtoxinA","Formulation C: OnabotulinumtoxinA",{"trials":7379,"activeCount":13},[],{"trials":7381,"activeCount":13},[],{"trials":7383,"activeCount":13},[],{"intervention":7376,"totalTrials":10,"cells":7385},{"EARLY_PHASE1":7386,"PHASE1":7388,"PHASE2":7390,"PHASE3":7396,"PHASE4":7398,"NA":7400},{"trials":7387,"activeCount":13},[],{"trials":7389,"activeCount":13},[],{"trials":7391,"activeCount":13},[7392],{"nctId":7368,"briefTitle":7369,"status":61,"phases":7393,"primaryCompletion":7371,"completion":7371,"start":7372,"enrollment":7373,"conditions":7394,"interventions":7395},[43],[373],[7359,7376,7377],{"trials":7397,"activeCount":13},[],{"trials":7399,"activeCount":13},[],{"trials":7401,"activeCount":13},[],{"intervention":7377,"totalTrials":10,"cells":7403},{"EARLY_PHASE1":7404,"PHASE1":7406,"PHASE2":7408,"PHASE3":7414,"PHASE4":7416,"NA":7418},{"trials":7405,"activeCount":13},[],{"trials":7407,"activeCount":13},[],{"trials":7409,"activeCount":13},[7410],{"nctId":7368,"briefTitle":7369,"status":61,"phases":7411,"primaryCompletion":7371,"completion":7371,"start":7372,"enrollment":7373,"conditions":7412,"interventions":7413},[43],[373],[7359,7376,7377],{"trials":7415,"activeCount":13},[],{"trials":7417,"activeCount":13},[],{"trials":7419,"activeCount":13},[],{"intervention":5402,"totalTrials":10,"cells":7421},{"EARLY_PHASE1":7422,"PHASE1":7424,"PHASE2":7426,"PHASE3":7432,"PHASE4":7434,"NA":7436},{"trials":7423,"activeCount":13},[],{"trials":7425,"activeCount":13},[],{"trials":7427,"activeCount":13},[7428],{"nctId":5397,"briefTitle":5398,"status":61,"phases":7429,"primaryCompletion":2545,"completion":507,"start":1230,"enrollment":5027,"conditions":7430,"interventions":7431},[43],[3774,3773],[5402,5403,5404,3764],{"trials":7433,"activeCount":13},[],{"trials":7435,"activeCount":13},[],{"trials":7437,"activeCount":13},[],{"intervention":5403,"totalTrials":10,"cells":7439},{"EARLY_PHASE1":7440,"PHASE1":7442,"PHASE2":7444,"PHASE3":7450,"PHASE4":7452,"NA":7454},{"trials":7441,"activeCount":13},[],{"trials":7443,"activeCount":13},[],{"trials":7445,"activeCount":13},[7446],{"nctId":5397,"briefTitle":5398,"status":61,"phases":7447,"primaryCompletion":2545,"completion":507,"start":1230,"enrollment":5027,"conditions":7448,"interventions":7449},[43],[3774,3773],[5402,5403,5404,3764],{"trials":7451,"activeCount":13},[],{"trials":7453,"activeCount":13},[],{"trials":7455,"activeCount":13},[],{"intervention":5404,"totalTrials":10,"cells":7457},{"EARLY_PHASE1":7458,"PHASE1":7460,"PHASE2":7462,"PHASE3":7468,"PHASE4":7470,"NA":7472},{"trials":7459,"activeCount":13},[],{"trials":7461,"activeCount":13},[],{"trials":7463,"activeCount":13},[7464],{"nctId":5397,"briefTitle":5398,"status":61,"phases":7465,"primaryCompletion":2545,"completion":507,"start":1230,"enrollment":5027,"conditions":7466,"interventions":7467},[43],[3774,3773],[5402,5403,5404,3764],{"trials":7469,"activeCount":13},[],{"trials":7471,"activeCount":13},[],{"trials":7473,"activeCount":13},[],{"intervention":7475,"totalTrials":10,"cells":7476},"AGN-223575 ophthalmic solution",{"EARLY_PHASE1":7477,"PHASE1":7479,"PHASE2":7481,"PHASE3":7492,"PHASE4":7494,"NA":7496},{"trials":7478,"activeCount":13},[],{"trials":7480,"activeCount":13},[],{"trials":7482,"activeCount":13},[7483],{"nctId":7484,"briefTitle":7485,"status":61,"phases":7486,"primaryCompletion":7487,"completion":7487,"start":108,"enrollment":7488,"conditions":7489,"interventions":7490},"NCT02435914","Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease",[43],"2016-01",236,[26],[7475,7491],"AGN-223575 vehicle ophthalmic solution",{"trials":7493,"activeCount":13},[],{"trials":7495,"activeCount":13},[],{"trials":7497,"activeCount":13},[],{"intervention":7491,"totalTrials":10,"cells":7499},{"EARLY_PHASE1":7500,"PHASE1":7502,"PHASE2":7504,"PHASE3":7510,"PHASE4":7512,"NA":7514},{"trials":7501,"activeCount":13},[],{"trials":7503,"activeCount":13},[],{"trials":7505,"activeCount":13},[7506],{"nctId":7484,"briefTitle":7485,"status":61,"phases":7507,"primaryCompletion":7487,"completion":7487,"start":108,"enrollment":7488,"conditions":7508,"interventions":7509},[43],[26],[7475,7491],{"trials":7511,"activeCount":13},[],{"trials":7513,"activeCount":13},[],{"trials":7515,"activeCount":13},[],{"intervention":7517,"totalTrials":10,"cells":7518},"Lidocaine Releasing Intravesical System - LiRIS®",{"EARLY_PHASE1":7519,"PHASE1":7521,"PHASE2":7523,"PHASE3":7532,"PHASE4":7534,"NA":7536},{"trials":7520,"activeCount":13},[],{"trials":7522,"activeCount":13},[],{"trials":7524,"activeCount":13},[7525],{"nctId":7526,"briefTitle":7527,"status":75,"phases":7528,"primaryCompletion":1230,"completion":1230,"start":7529,"enrollment":309,"conditions":7530,"interventions":7531},"NCT01475253","Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis",[43],"2011-11",[6903],[7517],{"trials":7533,"activeCount":13},[],{"trials":7535,"activeCount":13},[],{"trials":7537,"activeCount":13},[],{"intervention":7539,"totalTrials":10,"cells":7540},"DEX PS DDS®",{"EARLY_PHASE1":7541,"PHASE1":7543,"PHASE2":7545,"PHASE3":7559,"PHASE4":7561,"NA":7563},{"trials":7542,"activeCount":13},[],{"trials":7544,"activeCount":13},[],{"trials":7546,"activeCount":13},[7547],{"nctId":7548,"briefTitle":7549,"status":61,"phases":7550,"primaryCompletion":7551,"completion":7551,"start":7552,"enrollment":3673,"conditions":7553,"interventions":7558},"NCT00035906","Research Study in Patients With Persistent Macular Edema",[43],"2004-08","2001-10",[7554,29,7555,7556,7557],"Diabetes","Diabetic Retinopathy","Retinal Disease","Uveitis, Posterior",[7539],{"trials":7560,"activeCount":13},[],{"trials":7562,"activeCount":13},[],{"trials":7564,"activeCount":13},[],{"intervention":335,"totalTrials":10,"cells":7566},{"EARLY_PHASE1":7567,"PHASE1":7569,"PHASE2":7571,"PHASE3":7577,"PHASE4":7579,"NA":7581},{"trials":7568,"activeCount":13},[],{"trials":7570,"activeCount":13},[],{"trials":7572,"activeCount":13},[7573],{"nctId":329,"briefTitle":330,"status":61,"phases":7574,"primaryCompletion":64,"completion":64,"start":63,"enrollment":332,"conditions":7575,"interventions":7576},[43],[23,17],[335,324,325,279],{"trials":7578,"activeCount":13},[],{"trials":7580,"activeCount":13},[],{"trials":7582,"activeCount":13},[],{"intervention":134,"totalTrials":10,"cells":7584},{"EARLY_PHASE1":7585,"PHASE1":7587,"PHASE2":7589,"PHASE3":7595,"PHASE4":7597,"NA":7599},{"trials":7586,"activeCount":13},[],{"trials":7588,"activeCount":13},[],{"trials":7590,"activeCount":13},[7591],{"nctId":124,"briefTitle":125,"status":61,"phases":7592,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":7593,"interventions":7594},[43],[132],[134,49],{"trials":7596,"activeCount":13},[],{"trials":7598,"activeCount":13},[],{"trials":7600,"activeCount":13},[],{"intervention":7602,"totalTrials":10,"cells":7603},"AGN-151586",{"EARLY_PHASE1":7604,"PHASE1":7606,"PHASE2":7608,"PHASE3":7618,"PHASE4":7620,"NA":7622},{"trials":7605,"activeCount":13},[],{"trials":7607,"activeCount":13},[],{"trials":7609,"activeCount":13},[7610],{"nctId":7611,"briefTitle":7612,"status":61,"phases":7613,"primaryCompletion":7614,"completion":7614,"start":2995,"enrollment":7615,"conditions":7616,"interventions":7617},"NCT04096326","AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines",[43],"2020-09-09",198,[373],[7602],{"trials":7619,"activeCount":13},[],{"trials":7621,"activeCount":13},[],{"trials":7623,"activeCount":13},[],{"intervention":7625,"totalTrials":10,"cells":7626},"Armour® Thyroid",{"EARLY_PHASE1":7627,"PHASE1":7629,"PHASE2":7631,"PHASE3":7647,"PHASE4":7649,"NA":7651},{"trials":7628,"activeCount":13},[],{"trials":7630,"activeCount":13},[],{"trials":7632,"activeCount":13},[7633],{"nctId":7634,"briefTitle":7635,"status":61,"phases":7636,"primaryCompletion":7637,"completion":7637,"start":7638,"enrollment":2711,"conditions":7639,"interventions":7645},"NCT04124705","A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants",[43],"2021-06-22","2019-10-11",[7640,7641,7642,7643,7644],"Hypothyroidism","Thyroid Disease","Euthyroid","Thyroid Gland","Thyroid Hormones",[7625,7646],"Levothyroxine",{"trials":7648,"activeCount":13},[],{"trials":7650,"activeCount":13},[],{"trials":7652,"activeCount":13},[],{"intervention":7646,"totalTrials":10,"cells":7654},{"EARLY_PHASE1":7655,"PHASE1":7657,"PHASE2":7659,"PHASE3":7665,"PHASE4":7667,"NA":7669},{"trials":7656,"activeCount":13},[],{"trials":7658,"activeCount":13},[],{"trials":7660,"activeCount":13},[7661],{"nctId":7634,"briefTitle":7635,"status":61,"phases":7662,"primaryCompletion":7637,"completion":7637,"start":7638,"enrollment":2711,"conditions":7663,"interventions":7664},[43],[7640,7641,7642,7643,7644],[7625,7646],{"trials":7666,"activeCount":13},[],{"trials":7668,"activeCount":13},[],{"trials":7670,"activeCount":13},[],{"intervention":7672,"totalTrials":10,"cells":7673},"AGN201781",{"EARLY_PHASE1":7674,"PHASE1":7676,"PHASE2":7678,"PHASE3":7687,"PHASE4":7689,"NA":7691},{"trials":7675,"activeCount":13},[],{"trials":7677,"activeCount":13},[],{"trials":7679,"activeCount":13},[7680],{"nctId":7681,"briefTitle":7682,"status":75,"phases":7683,"primaryCompletion":1553,"completion":1553,"start":4557,"enrollment":1827,"conditions":7684,"interventions":7686},"NCT00533351","Safety and Efficacy of AGN201781 in Neuropathic Pain",[43],[7685],"Neuralgia",[7672],{"trials":7688,"activeCount":13},[],{"trials":7690,"activeCount":13},[],{"trials":7692,"activeCount":13},[],{"intervention":7694,"totalTrials":10,"cells":7695},"saline",{"EARLY_PHASE1":7696,"PHASE1":7698,"PHASE2":7700,"PHASE3":7712,"PHASE4":7714,"NA":7716},{"trials":7697,"activeCount":13},[],{"trials":7699,"activeCount":13},[],{"trials":7701,"activeCount":13},[7702],{"nctId":7703,"briefTitle":7704,"status":61,"phases":7705,"primaryCompletion":476,"completion":476,"start":7058,"enrollment":7706,"conditions":7707,"interventions":7710},"NCT00076687","Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function",[43],155,[7708,32,7709],"Stroke","Motor Neuron Disease",[7711,7711,7694],"botulinum toxin Type A",{"trials":7713,"activeCount":13},[],{"trials":7715,"activeCount":13},[],{"trials":7717,"activeCount":13},[],{"intervention":7719,"totalTrials":10,"cells":7720},"BOTOX® purified neurotoxin complex",{"EARLY_PHASE1":7721,"PHASE1":7723,"PHASE2":7725,"PHASE3":7736,"PHASE4":7738,"NA":7740},{"trials":7722,"activeCount":13},[],{"trials":7724,"activeCount":13},[],{"trials":7726,"activeCount":13},[7727],{"nctId":7728,"briefTitle":7729,"status":61,"phases":7730,"primaryCompletion":7731,"completion":7731,"start":7732,"enrollment":1924,"conditions":7733,"interventions":7735},"NCT03915067","BOTOX® for the Treatment of Platysma Prominence",[43],"2020-04-16","2019-04-23",[7734],"Platysma Prominence",[7719],{"trials":7737,"activeCount":13},[],{"trials":7739,"activeCount":13},[],{"trials":7741,"activeCount":13},[],{"intervention":7743,"totalTrials":10,"cells":7744},"84ug MAP0020",{"EARLY_PHASE1":7745,"PHASE1":7747,"PHASE2":7749,"PHASE3":7759,"PHASE4":7761,"NA":7763},{"trials":7746,"activeCount":13},[],{"trials":7748,"activeCount":13},[],{"trials":7750,"activeCount":13},[7751],{"nctId":7752,"briefTitle":7753,"status":61,"phases":7754,"primaryCompletion":63,"completion":63,"start":1923,"enrollment":90,"conditions":7755,"interventions":7756},"NCT00995904","Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma",[43],[3611],[7743,7757,7758],"42ug MAP0020","21ug MAP0020",{"trials":7760,"activeCount":13},[],{"trials":7762,"activeCount":13},[],{"trials":7764,"activeCount":13},[],{"intervention":7757,"totalTrials":10,"cells":7766},{"EARLY_PHASE1":7767,"PHASE1":7769,"PHASE2":7771,"PHASE3":7777,"PHASE4":7779,"NA":7781},{"trials":7768,"activeCount":13},[],{"trials":7770,"activeCount":13},[],{"trials":7772,"activeCount":13},[7773],{"nctId":7752,"briefTitle":7753,"status":61,"phases":7774,"primaryCompletion":63,"completion":63,"start":1923,"enrollment":90,"conditions":7775,"interventions":7776},[43],[3611],[7743,7757,7758],{"trials":7778,"activeCount":13},[],{"trials":7780,"activeCount":13},[],{"trials":7782,"activeCount":13},[],{"intervention":7758,"totalTrials":10,"cells":7784},{"EARLY_PHASE1":7785,"PHASE1":7787,"PHASE2":7789,"PHASE3":7795,"PHASE4":7797,"NA":7799},{"trials":7786,"activeCount":13},[],{"trials":7788,"activeCount":13},[],{"trials":7790,"activeCount":13},[7791],{"nctId":7752,"briefTitle":7753,"status":61,"phases":7792,"primaryCompletion":63,"completion":63,"start":1923,"enrollment":90,"conditions":7793,"interventions":7794},[43],[3611],[7743,7757,7758],{"trials":7796,"activeCount":13},[],{"trials":7798,"activeCount":13},[],{"trials":7800,"activeCount":13},[],{"intervention":7802,"totalTrials":10,"cells":7803},"ACZONE (dapsone) Gel, 5%",{"EARLY_PHASE1":7804,"PHASE1":7806,"PHASE2":7808,"PHASE3":7821,"PHASE4":7823,"NA":7825},{"trials":7805,"activeCount":13},[],{"trials":7807,"activeCount":13},[],{"trials":7809,"activeCount":13},[7810],{"nctId":7811,"briefTitle":7812,"status":75,"phases":7813,"primaryCompletion":7814,"completion":7814,"start":7815,"enrollment":780,"conditions":7816,"interventions":7819},"NCT00343187","A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash",[43],"2007-07","2006-06",[7817,7818],"Rash","Non-small-Cell Lung Cancer",[7802,7820],"Vehicle Control",{"trials":7822,"activeCount":13},[],{"trials":7824,"activeCount":13},[],{"trials":7826,"activeCount":13},[],{"intervention":7820,"totalTrials":10,"cells":7828},{"EARLY_PHASE1":7829,"PHASE1":7831,"PHASE2":7833,"PHASE3":7839,"PHASE4":7841,"NA":7843},{"trials":7830,"activeCount":13},[],{"trials":7832,"activeCount":13},[],{"trials":7834,"activeCount":13},[7835],{"nctId":7811,"briefTitle":7812,"status":75,"phases":7836,"primaryCompletion":7814,"completion":7814,"start":7815,"enrollment":780,"conditions":7837,"interventions":7838},[43],[7817,7818],[7802,7820],{"trials":7840,"activeCount":13},[],{"trials":7842,"activeCount":13},[],{"trials":7844,"activeCount":13},[],{"intervention":232,"totalTrials":10,"cells":7846},{"EARLY_PHASE1":7847,"PHASE1":7849,"PHASE2":7851,"PHASE3":7857,"PHASE4":7859,"NA":7861},{"trials":7848,"activeCount":13},[],{"trials":7850,"activeCount":13},[],{"trials":7852,"activeCount":13},[7853],{"nctId":223,"briefTitle":224,"status":61,"phases":7854,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":7855,"interventions":7856},[43],[230],[181,232],{"trials":7858,"activeCount":13},[],{"trials":7860,"activeCount":13},[],{"trials":7862,"activeCount":13},[],{"intervention":7864,"totalTrials":616,"cells":7865},"Dapsone 5% Gel",{"EARLY_PHASE1":7866,"PHASE1":7868,"PHASE2":7899,"PHASE3":7901,"PHASE4":7903,"NA":7905},{"trials":7867,"activeCount":13},[],{"trials":7869,"activeCount":13},[7870,7880,7890],{"nctId":7871,"briefTitle":7872,"status":214,"phases":7873,"primaryCompletion":7874,"completion":7874,"start":6901,"enrollment":13,"conditions":7875,"interventions":7876},"NCT01785836","An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris",[42],"2013-10",[273],[7877,7878,7879,7864],"Dapsone Formulation A","Dapsone Formulation B","Dapsone Formulation C",{"nctId":7881,"briefTitle":7882,"status":214,"phases":7883,"primaryCompletion":507,"completion":507,"start":3179,"enrollment":13,"conditions":7884,"interventions":7885},"NCT01425320","Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne",[42],[273],[7886,7887,7888,7889],"Fixed Combination dapsone\u002Fadapalene Formulation A Gel","Fixed Combination dapsone\u002Fadapalene Formulation B Gel","dapsone 5% gel","adapalene 0.3% gel",{"nctId":7891,"briefTitle":7892,"status":61,"phases":7893,"primaryCompletion":7894,"completion":7894,"start":7895,"enrollment":7896,"conditions":7897,"interventions":7898},"NCT01773122","Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris",[42],"2013-05-05","2013-01-21",77,[273],[7877,7878,7879,7864],{"trials":7900,"activeCount":13},[],{"trials":7902,"activeCount":13},[],{"trials":7904,"activeCount":13},[],{"trials":7906,"activeCount":13},[],{"intervention":7877,"totalTrials":780,"cells":7908},{"EARLY_PHASE1":7909,"PHASE1":7911,"PHASE2":7921,"PHASE3":7923,"PHASE4":7925,"NA":7927},{"trials":7910,"activeCount":13},[],{"trials":7912,"activeCount":13},[7913,7917],{"nctId":7871,"briefTitle":7872,"status":214,"phases":7914,"primaryCompletion":7874,"completion":7874,"start":6901,"enrollment":13,"conditions":7915,"interventions":7916},[42],[273],[7877,7878,7879,7864],{"nctId":7891,"briefTitle":7892,"status":61,"phases":7918,"primaryCompletion":7894,"completion":7894,"start":7895,"enrollment":7896,"conditions":7919,"interventions":7920},[42],[273],[7877,7878,7879,7864],{"trials":7922,"activeCount":13},[],{"trials":7924,"activeCount":13},[],{"trials":7926,"activeCount":13},[],{"trials":7928,"activeCount":13},[],{"intervention":7878,"totalTrials":780,"cells":7930},{"EARLY_PHASE1":7931,"PHASE1":7933,"PHASE2":7943,"PHASE3":7945,"PHASE4":7947,"NA":7949},{"trials":7932,"activeCount":13},[],{"trials":7934,"activeCount":13},[7935,7939],{"nctId":7871,"briefTitle":7872,"status":214,"phases":7936,"primaryCompletion":7874,"completion":7874,"start":6901,"enrollment":13,"conditions":7937,"interventions":7938},[42],[273],[7877,7878,7879,7864],{"nctId":7891,"briefTitle":7892,"status":61,"phases":7940,"primaryCompletion":7894,"completion":7894,"start":7895,"enrollment":7896,"conditions":7941,"interventions":7942},[42],[273],[7877,7878,7879,7864],{"trials":7944,"activeCount":13},[],{"trials":7946,"activeCount":13},[],{"trials":7948,"activeCount":13},[],{"trials":7950,"activeCount":13},[],{"intervention":7879,"totalTrials":780,"cells":7952},{"EARLY_PHASE1":7953,"PHASE1":7955,"PHASE2":7965,"PHASE3":7967,"PHASE4":7969,"NA":7971},{"trials":7954,"activeCount":13},[],{"trials":7956,"activeCount":13},[7957,7961],{"nctId":7871,"briefTitle":7872,"status":214,"phases":7958,"primaryCompletion":7874,"completion":7874,"start":6901,"enrollment":13,"conditions":7959,"interventions":7960},[42],[273],[7877,7878,7879,7864],{"nctId":7891,"briefTitle":7892,"status":61,"phases":7962,"primaryCompletion":7894,"completion":7894,"start":7895,"enrollment":7896,"conditions":7963,"interventions":7964},[42],[273],[7877,7878,7879,7864],{"trials":7966,"activeCount":13},[],{"trials":7968,"activeCount":13},[],{"trials":7970,"activeCount":13},[],{"trials":7972,"activeCount":13},[],{"intervention":7974,"totalTrials":780,"cells":7975},"MP0112",{"EARLY_PHASE1":7976,"PHASE1":7978,"PHASE2":7994,"PHASE3":7996,"PHASE4":7998,"NA":8000},{"trials":7977,"activeCount":13},[],{"trials":7979,"activeCount":13},[7980,7987],{"nctId":7981,"briefTitle":7982,"status":75,"phases":7983,"primaryCompletion":523,"completion":523,"start":6709,"enrollment":7984,"conditions":7985,"interventions":7986},"NCT01042678","Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema",[42],18,[2678],[7974],{"nctId":7988,"briefTitle":7989,"status":75,"phases":7990,"primaryCompletion":4152,"completion":4152,"start":308,"enrollment":21,"conditions":7991,"interventions":7993},"NCT01086761","Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration",[42],[7992],"Wet Age-Related Macular Degeneration",[7974],{"trials":7995,"activeCount":13},[],{"trials":7997,"activeCount":13},[],{"trials":7999,"activeCount":13},[],{"trials":8001,"activeCount":13},[],{"intervention":7886,"totalTrials":10,"cells":8003},{"EARLY_PHASE1":8004,"PHASE1":8006,"PHASE2":8012,"PHASE3":8014,"PHASE4":8016,"NA":8018},{"trials":8005,"activeCount":13},[],{"trials":8007,"activeCount":13},[8008],{"nctId":7881,"briefTitle":7882,"status":214,"phases":8009,"primaryCompletion":507,"completion":507,"start":3179,"enrollment":13,"conditions":8010,"interventions":8011},[42],[273],[7886,7887,7888,7889],{"trials":8013,"activeCount":13},[],{"trials":8015,"activeCount":13},[],{"trials":8017,"activeCount":13},[],{"trials":8019,"activeCount":13},[],{"intervention":7887,"totalTrials":10,"cells":8021},{"EARLY_PHASE1":8022,"PHASE1":8024,"PHASE2":8030,"PHASE3":8032,"PHASE4":8034,"NA":8036},{"trials":8023,"activeCount":13},[],{"trials":8025,"activeCount":13},[8026],{"nctId":7881,"briefTitle":7882,"status":214,"phases":8027,"primaryCompletion":507,"completion":507,"start":3179,"enrollment":13,"conditions":8028,"interventions":8029},[42],[273],[7886,7887,7888,7889],{"trials":8031,"activeCount":13},[],{"trials":8033,"activeCount":13},[],{"trials":8035,"activeCount":13},[],{"trials":8037,"activeCount":13},[],{"intervention":7889,"totalTrials":10,"cells":8039},{"EARLY_PHASE1":8040,"PHASE1":8042,"PHASE2":8048,"PHASE3":8050,"PHASE4":8052,"NA":8054},{"trials":8041,"activeCount":13},[],{"trials":8043,"activeCount":13},[8044],{"nctId":7881,"briefTitle":7882,"status":214,"phases":8045,"primaryCompletion":507,"completion":507,"start":3179,"enrollment":13,"conditions":8046,"interventions":8047},[42],[273],[7886,7887,7888,7889],{"trials":8049,"activeCount":13},[],{"trials":8051,"activeCount":13},[],{"trials":8053,"activeCount":13},[],{"trials":8055,"activeCount":13},[],{"intervention":2816,"totalTrials":10,"cells":8057},{"EARLY_PHASE1":8058,"PHASE1":8060,"PHASE2":8066,"PHASE3":8068,"PHASE4":8070,"NA":8072},{"trials":8059,"activeCount":13},[],{"trials":8061,"activeCount":13},[8062],{"nctId":2811,"briefTitle":2812,"status":61,"phases":8063,"primaryCompletion":751,"completion":523,"start":308,"enrollment":1141,"conditions":8064,"interventions":8065},[42],[452],[2804,2816,2817],{"trials":8067,"activeCount":13},[],{"trials":8069,"activeCount":13},[],{"trials":8071,"activeCount":13},[],{"trials":8073,"activeCount":13},[],{"intervention":2817,"totalTrials":10,"cells":8075},{"EARLY_PHASE1":8076,"PHASE1":8078,"PHASE2":8084,"PHASE3":8086,"PHASE4":8088,"NA":8090},{"trials":8077,"activeCount":13},[],{"trials":8079,"activeCount":13},[8080],{"nctId":2811,"briefTitle":2812,"status":61,"phases":8081,"primaryCompletion":751,"completion":523,"start":308,"enrollment":1141,"conditions":8082,"interventions":8083},[42],[452],[2804,2816,2817],{"trials":8085,"activeCount":13},[],{"trials":8087,"activeCount":13},[],{"trials":8089,"activeCount":13},[],{"trials":8091,"activeCount":13},[],{"intervention":8093,"totalTrials":10,"cells":8094},"LiRIS low dose and LiRIS high dose",{"EARLY_PHASE1":8095,"PHASE1":8097,"PHASE2":8105,"PHASE3":8107,"PHASE4":8109,"NA":8111},{"trials":8096,"activeCount":13},[],{"trials":8098,"activeCount":13},[8099],{"nctId":8100,"briefTitle":8101,"status":61,"phases":8102,"primaryCompletion":3156,"completion":3156,"start":307,"enrollment":7984,"conditions":8103,"interventions":8104},"NCT01150565","Safety Study of LiRIS in Interstitial Cystitis (IC) Patients",[42],[6903],[8093],{"trials":8106,"activeCount":13},[],{"trials":8108,"activeCount":13},[],{"trials":8110,"activeCount":13},[],{"trials":8112,"activeCount":13},[],{"intervention":8114,"totalTrials":10,"cells":8115},"LiRIS® 400 mg",{"EARLY_PHASE1":8116,"PHASE1":8118,"PHASE2":8128,"PHASE3":8130,"PHASE4":8132,"NA":8134},{"trials":8117,"activeCount":13},[],{"trials":8119,"activeCount":13},[8120],{"nctId":8121,"briefTitle":8122,"status":61,"phases":8123,"primaryCompletion":808,"completion":2001,"start":544,"enrollment":8124,"conditions":8125,"interventions":8127},"NCT01879683","A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions",[42],10,[8126],"Chronic Interstitial Cystitis",[8114],{"trials":8129,"activeCount":13},[],{"trials":8131,"activeCount":13},[],{"trials":8133,"activeCount":13},[],{"trials":8135,"activeCount":13},[],{"intervention":8137,"totalTrials":10,"cells":8138},"Dexamethasone Drug Delivery System",{"EARLY_PHASE1":8139,"PHASE1":8141,"PHASE2":8149,"PHASE3":8151,"PHASE4":8153,"NA":8155},{"trials":8140,"activeCount":13},[],{"trials":8142,"activeCount":13},[8143],{"nctId":8144,"briefTitle":8145,"status":75,"phases":8146,"primaryCompletion":393,"completion":393,"start":487,"enrollment":182,"conditions":8147,"interventions":8148},"NCT01605942","A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery",[42],[2548],[8137],{"trials":8150,"activeCount":13},[],{"trials":8152,"activeCount":13},[],{"trials":8154,"activeCount":13},[],{"trials":8156,"activeCount":13},[],{"intervention":8158,"totalTrials":10,"cells":8159},"cyclosporine ophthalmic emulsion Formulation A",{"EARLY_PHASE1":8160,"PHASE1":8162,"PHASE2":8174,"PHASE3":8176,"PHASE4":8178,"NA":8180},{"trials":8161,"activeCount":13},[],{"trials":8163,"activeCount":13},[8164],{"nctId":8165,"briefTitle":8166,"status":61,"phases":8167,"primaryCompletion":2851,"completion":2851,"start":4152,"enrollment":66,"conditions":8168,"interventions":8169},"NCT01319773","Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye",[42],[26],[8158,8170,8171,8172,8173],"cyclosporine ophthalmic emulsion Formulation B","cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%","cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%","cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B",{"trials":8175,"activeCount":13},[],{"trials":8177,"activeCount":13},[],{"trials":8179,"activeCount":13},[],{"trials":8181,"activeCount":13},[],{"intervention":8170,"totalTrials":10,"cells":8183},{"EARLY_PHASE1":8184,"PHASE1":8186,"PHASE2":8192,"PHASE3":8194,"PHASE4":8196,"NA":8198},{"trials":8185,"activeCount":13},[],{"trials":8187,"activeCount":13},[8188],{"nctId":8165,"briefTitle":8166,"status":61,"phases":8189,"primaryCompletion":2851,"completion":2851,"start":4152,"enrollment":66,"conditions":8190,"interventions":8191},[42],[26],[8158,8170,8171,8172,8173],{"trials":8193,"activeCount":13},[],{"trials":8195,"activeCount":13},[],{"trials":8197,"activeCount":13},[],{"trials":8199,"activeCount":13},[],{"intervention":8171,"totalTrials":10,"cells":8201},{"EARLY_PHASE1":8202,"PHASE1":8204,"PHASE2":8210,"PHASE3":8212,"PHASE4":8214,"NA":8216},{"trials":8203,"activeCount":13},[],{"trials":8205,"activeCount":13},[8206],{"nctId":8165,"briefTitle":8166,"status":61,"phases":8207,"primaryCompletion":2851,"completion":2851,"start":4152,"enrollment":66,"conditions":8208,"interventions":8209},[42],[26],[8158,8170,8171,8172,8173],{"trials":8211,"activeCount":13},[],{"trials":8213,"activeCount":13},[],{"trials":8215,"activeCount":13},[],{"trials":8217,"activeCount":13},[],{"intervention":8172,"totalTrials":10,"cells":8219},{"EARLY_PHASE1":8220,"PHASE1":8222,"PHASE2":8228,"PHASE3":8230,"PHASE4":8232,"NA":8234},{"trials":8221,"activeCount":13},[],{"trials":8223,"activeCount":13},[8224],{"nctId":8165,"briefTitle":8166,"status":61,"phases":8225,"primaryCompletion":2851,"completion":2851,"start":4152,"enrollment":66,"conditions":8226,"interventions":8227},[42],[26],[8158,8170,8171,8172,8173],{"trials":8229,"activeCount":13},[],{"trials":8231,"activeCount":13},[],{"trials":8233,"activeCount":13},[],{"trials":8235,"activeCount":13},[],{"intervention":8173,"totalTrials":10,"cells":8237},{"EARLY_PHASE1":8238,"PHASE1":8240,"PHASE2":8246,"PHASE3":8248,"PHASE4":8250,"NA":8252},{"trials":8239,"activeCount":13},[],{"trials":8241,"activeCount":13},[8242],{"nctId":8165,"briefTitle":8166,"status":61,"phases":8243,"primaryCompletion":2851,"completion":2851,"start":4152,"enrollment":66,"conditions":8244,"interventions":8245},[42],[26],[8158,8170,8171,8172,8173],{"trials":8247,"activeCount":13},[],{"trials":8249,"activeCount":13},[],{"trials":8251,"activeCount":13},[],{"trials":8253,"activeCount":13},[],{"intervention":8255,"totalTrials":10,"cells":8256},"AGN-207281 ophthalmic solutions",{"EARLY_PHASE1":8257,"PHASE1":8259,"PHASE2":8269,"PHASE3":8271,"PHASE4":8273,"NA":8275},{"trials":8258,"activeCount":13},[],{"trials":8260,"activeCount":13},[8261],{"nctId":8262,"briefTitle":8263,"status":61,"phases":8264,"primaryCompletion":523,"completion":523,"start":4744,"enrollment":1555,"conditions":8265,"interventions":8266},"NCT01215786","Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma",[42],[23,17],[8255,8267,8268],"timolol ophthalmic solution 0.5%","AGN-207281 vehicle ophthalmic solution",{"trials":8270,"activeCount":13},[],{"trials":8272,"activeCount":13},[],{"trials":8274,"activeCount":13},[],{"trials":8276,"activeCount":13},[],{"intervention":8267,"totalTrials":10,"cells":8278},{"EARLY_PHASE1":8279,"PHASE1":8281,"PHASE2":8287,"PHASE3":8289,"PHASE4":8291,"NA":8293},{"trials":8280,"activeCount":13},[],{"trials":8282,"activeCount":13},[8283],{"nctId":8262,"briefTitle":8263,"status":61,"phases":8284,"primaryCompletion":523,"completion":523,"start":4744,"enrollment":1555,"conditions":8285,"interventions":8286},[42],[23,17],[8255,8267,8268],{"trials":8288,"activeCount":13},[],{"trials":8290,"activeCount":13},[],{"trials":8292,"activeCount":13},[],{"trials":8294,"activeCount":13},[],{"intervention":8268,"totalTrials":10,"cells":8296},{"EARLY_PHASE1":8297,"PHASE1":8299,"PHASE2":8305,"PHASE3":8307,"PHASE4":8309,"NA":8311},{"trials":8298,"activeCount":13},[],{"trials":8300,"activeCount":13},[8301],{"nctId":8262,"briefTitle":8263,"status":61,"phases":8302,"primaryCompletion":523,"completion":523,"start":4744,"enrollment":1555,"conditions":8303,"interventions":8304},[42],[23,17],[8255,8267,8268],{"trials":8306,"activeCount":13},[],{"trials":8308,"activeCount":13},[],{"trials":8310,"activeCount":13},[],{"trials":8312,"activeCount":13},[],{"intervention":8314,"totalTrials":10,"cells":8315},"AGN-232411",{"EARLY_PHASE1":8316,"PHASE1":8318,"PHASE2":8329,"PHASE3":8331,"PHASE4":8333,"NA":8335},{"trials":8317,"activeCount":13},[],{"trials":8319,"activeCount":13},[8320],{"nctId":8321,"briefTitle":8322,"status":61,"phases":8323,"primaryCompletion":8324,"completion":8324,"start":108,"enrollment":7896,"conditions":8325,"interventions":8327},"NCT02420730","Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye",[42],"2016-03",[8326,26],"Healthy Volunteers",[8314,8328],"AGN-232411 Vehicle",{"trials":8330,"activeCount":13},[],{"trials":8332,"activeCount":13},[],{"trials":8334,"activeCount":13},[],{"trials":8336,"activeCount":13},[],{"intervention":8328,"totalTrials":10,"cells":8338},{"EARLY_PHASE1":8339,"PHASE1":8341,"PHASE2":8347,"PHASE3":8349,"PHASE4":8351,"NA":8353},{"trials":8340,"activeCount":13},[],{"trials":8342,"activeCount":13},[8343],{"nctId":8321,"briefTitle":8322,"status":61,"phases":8344,"primaryCompletion":8324,"completion":8324,"start":108,"enrollment":7896,"conditions":8345,"interventions":8346},[42],[8326,26],[8314,8328],{"trials":8348,"activeCount":13},[],{"trials":8350,"activeCount":13},[],{"trials":8352,"activeCount":13},[],{"trials":8354,"activeCount":13},[],{"intervention":5477,"totalTrials":10,"cells":8356},{"EARLY_PHASE1":8357,"PHASE1":8359,"PHASE2":8365,"PHASE3":8367,"PHASE4":8369,"NA":8371},{"trials":8358,"activeCount":13},[],{"trials":8360,"activeCount":13},[8361],{"nctId":5470,"briefTitle":5471,"status":61,"phases":8362,"primaryCompletion":5473,"completion":2701,"start":5473,"enrollment":5474,"conditions":8363,"interventions":8364},[42],[3611],[5477,5463,5478,5479],{"trials":8366,"activeCount":13},[],{"trials":8368,"activeCount":13},[],{"trials":8370,"activeCount":13},[],{"trials":8372,"activeCount":13},[],{"intervention":5478,"totalTrials":10,"cells":8374},{"EARLY_PHASE1":8375,"PHASE1":8377,"PHASE2":8383,"PHASE3":8385,"PHASE4":8387,"NA":8389},{"trials":8376,"activeCount":13},[],{"trials":8378,"activeCount":13},[8379],{"nctId":5470,"briefTitle":5471,"status":61,"phases":8380,"primaryCompletion":5473,"completion":2701,"start":5473,"enrollment":5474,"conditions":8381,"interventions":8382},[42],[3611],[5477,5463,5478,5479],{"trials":8384,"activeCount":13},[],{"trials":8386,"activeCount":13},[],{"trials":8388,"activeCount":13},[],{"trials":8390,"activeCount":13},[],{"intervention":1080,"totalTrials":10,"cells":8392},{"EARLY_PHASE1":8393,"PHASE1":8395,"PHASE2":8401,"PHASE3":8403,"PHASE4":8405,"NA":8407},{"trials":8394,"activeCount":13},[],{"trials":8396,"activeCount":13},[8397],{"nctId":1073,"briefTitle":1074,"status":61,"phases":8398,"primaryCompletion":139,"completion":139,"start":1076,"enrollment":1077,"conditions":8399,"interventions":8400},[42],[273],[1080,1081,1082,1066],{"trials":8402,"activeCount":13},[],{"trials":8404,"activeCount":13},[],{"trials":8406,"activeCount":13},[],{"trials":8408,"activeCount":13},[],{"intervention":1081,"totalTrials":10,"cells":8410},{"EARLY_PHASE1":8411,"PHASE1":8413,"PHASE2":8419,"PHASE3":8421,"PHASE4":8423,"NA":8425},{"trials":8412,"activeCount":13},[],{"trials":8414,"activeCount":13},[8415],{"nctId":1073,"briefTitle":1074,"status":61,"phases":8416,"primaryCompletion":139,"completion":139,"start":1076,"enrollment":1077,"conditions":8417,"interventions":8418},[42],[273],[1080,1081,1082,1066],{"trials":8420,"activeCount":13},[],{"trials":8422,"activeCount":13},[],{"trials":8424,"activeCount":13},[],{"trials":8426,"activeCount":13},[],{"intervention":1082,"totalTrials":10,"cells":8428},{"EARLY_PHASE1":8429,"PHASE1":8431,"PHASE2":8437,"PHASE3":8439,"PHASE4":8441,"NA":8443},{"trials":8430,"activeCount":13},[],{"trials":8432,"activeCount":13},[8433],{"nctId":1073,"briefTitle":1074,"status":61,"phases":8434,"primaryCompletion":139,"completion":139,"start":1076,"enrollment":1077,"conditions":8435,"interventions":8436},[42],[273],[1080,1081,1082,1066],{"trials":8438,"activeCount":13},[],{"trials":8440,"activeCount":13},[],{"trials":8442,"activeCount":13},[],{"trials":8444,"activeCount":13},[],{"intervention":2825,"totalTrials":10,"cells":8446},{"EARLY_PHASE1":8447,"PHASE1":8449,"PHASE2":8455,"PHASE3":8457,"PHASE4":8459,"NA":8461},{"trials":8448,"activeCount":13},[],{"trials":8450,"activeCount":13},[8451],{"nctId":2819,"briefTitle":2820,"status":61,"phases":8452,"primaryCompletion":78,"completion":78,"start":307,"enrollment":1141,"conditions":8453,"interventions":8454},[42],[452],[2804,2824,2825],{"trials":8456,"activeCount":13},[],{"trials":8458,"activeCount":13},[],{"trials":8460,"activeCount":13},[],{"trials":8462,"activeCount":13},[],{"intervention":8464,"totalTrials":10,"cells":8465},"Bimatoprost 1% Formulation A",{"EARLY_PHASE1":8466,"PHASE1":8468,"PHASE2":8480,"PHASE3":8482,"PHASE4":8484,"NA":8486},{"trials":8467,"activeCount":13},[],{"trials":8469,"activeCount":13},[8470],{"nctId":8471,"briefTitle":8472,"status":61,"phases":8473,"primaryCompletion":8474,"completion":8474,"start":8475,"enrollment":50,"conditions":8476,"interventions":8478},"NCT02848300","Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia",[42],"2016-10","2016-07",[8477],"Androgenetic Alopecia",[8464,8479],"Bimatoprost 1% Formulation B",{"trials":8481,"activeCount":13},[],{"trials":8483,"activeCount":13},[],{"trials":8485,"activeCount":13},[],{"trials":8487,"activeCount":13},[],{"intervention":8479,"totalTrials":10,"cells":8489},{"EARLY_PHASE1":8490,"PHASE1":8492,"PHASE2":8498,"PHASE3":8500,"PHASE4":8502,"NA":8504},{"trials":8491,"activeCount":13},[],{"trials":8493,"activeCount":13},[8494],{"nctId":8471,"briefTitle":8472,"status":61,"phases":8495,"primaryCompletion":8474,"completion":8474,"start":8475,"enrollment":50,"conditions":8496,"interventions":8497},[42],[8477],[8464,8479],{"trials":8499,"activeCount":13},[],{"trials":8501,"activeCount":13},[],{"trials":8503,"activeCount":13},[],{"trials":8505,"activeCount":13},[],{"intervention":8507,"totalTrials":10,"cells":8508},"AGN 201904",{"EARLY_PHASE1":8509,"PHASE1":8511,"PHASE2":8521,"PHASE3":8523,"PHASE4":8525,"NA":8527},{"trials":8510,"activeCount":13},[],{"trials":8512,"activeCount":13},[8513],{"nctId":8514,"briefTitle":8515,"status":61,"phases":8516,"primaryCompletion":854,"completion":854,"start":4255,"enrollment":2102,"conditions":8517,"interventions":8519},"NCT00325715","AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers",[42],[8518],"Peptic Ulcer",[8507,8520],"esomeprazole",{"trials":8522,"activeCount":13},[],{"trials":8524,"activeCount":13},[],{"trials":8526,"activeCount":13},[],{"trials":8528,"activeCount":13},[],{"intervention":8520,"totalTrials":10,"cells":8530},{"EARLY_PHASE1":8531,"PHASE1":8533,"PHASE2":8539,"PHASE3":8541,"PHASE4":8543,"NA":8545},{"trials":8532,"activeCount":13},[],{"trials":8534,"activeCount":13},[8535],{"nctId":8514,"briefTitle":8515,"status":61,"phases":8536,"primaryCompletion":854,"completion":854,"start":4255,"enrollment":2102,"conditions":8537,"interventions":8538},[42],[8518],[8507,8520],{"trials":8540,"activeCount":13},[],{"trials":8542,"activeCount":13},[],{"trials":8544,"activeCount":13},[],{"trials":8546,"activeCount":13},[],{"intervention":3385,"totalTrials":10,"cells":8548},{"EARLY_PHASE1":8549,"PHASE1":8551,"PHASE2":8557,"PHASE3":8559,"PHASE4":8561,"NA":8563},{"trials":8550,"activeCount":13},[],{"trials":8552,"activeCount":13},[8553],{"nctId":3377,"briefTitle":3378,"status":214,"phases":8554,"primaryCompletion":3380,"completion":3380,"start":3381,"enrollment":13,"conditions":8555,"interventions":8556},[42],[3383],[3385,3386,3387],{"trials":8558,"activeCount":13},[],{"trials":8560,"activeCount":13},[],{"trials":8562,"activeCount":13},[],{"trials":8564,"activeCount":13},[],{"intervention":3386,"totalTrials":10,"cells":8566},{"EARLY_PHASE1":8567,"PHASE1":8569,"PHASE2":8575,"PHASE3":8577,"PHASE4":8579,"NA":8581},{"trials":8568,"activeCount":13},[],{"trials":8570,"activeCount":13},[8571],{"nctId":3377,"briefTitle":3378,"status":214,"phases":8572,"primaryCompletion":3380,"completion":3380,"start":3381,"enrollment":13,"conditions":8573,"interventions":8574},[42],[3383],[3385,3386,3387],{"trials":8576,"activeCount":13},[],{"trials":8578,"activeCount":13},[],{"trials":8580,"activeCount":13},[],{"trials":8582,"activeCount":13},[],{"intervention":5369,"totalTrials":10,"cells":8584},{"EARLY_PHASE1":8585,"PHASE1":8587,"PHASE2":8593,"PHASE3":8595,"PHASE4":8597,"NA":8599},{"trials":8586,"activeCount":13},[],{"trials":8588,"activeCount":13},[8589],{"nctId":5364,"briefTitle":5365,"status":61,"phases":8590,"primaryCompletion":487,"completion":487,"start":344,"enrollment":271,"conditions":8591,"interventions":8592},[42],[3774,3773],[5369,5370,5371,3764],{"trials":8594,"activeCount":13},[],{"trials":8596,"activeCount":13},[],{"trials":8598,"activeCount":13},[],{"trials":8600,"activeCount":13},[],{"intervention":5370,"totalTrials":10,"cells":8602},{"EARLY_PHASE1":8603,"PHASE1":8605,"PHASE2":8611,"PHASE3":8613,"PHASE4":8615,"NA":8617},{"trials":8604,"activeCount":13},[],{"trials":8606,"activeCount":13},[8607],{"nctId":5364,"briefTitle":5365,"status":61,"phases":8608,"primaryCompletion":487,"completion":487,"start":344,"enrollment":271,"conditions":8609,"interventions":8610},[42],[3774,3773],[5369,5370,5371,3764],{"trials":8612,"activeCount":13},[],{"trials":8614,"activeCount":13},[],{"trials":8616,"activeCount":13},[],{"trials":8618,"activeCount":13},[],{"intervention":5371,"totalTrials":10,"cells":8620},{"EARLY_PHASE1":8621,"PHASE1":8623,"PHASE2":8629,"PHASE3":8631,"PHASE4":8633,"NA":8635},{"trials":8622,"activeCount":13},[],{"trials":8624,"activeCount":13},[8625],{"nctId":5364,"briefTitle":5365,"status":61,"phases":8626,"primaryCompletion":487,"completion":487,"start":344,"enrollment":271,"conditions":8627,"interventions":8628},[42],[3774,3773],[5369,5370,5371,3764],{"trials":8630,"activeCount":13},[],{"trials":8632,"activeCount":13},[],{"trials":8634,"activeCount":13},[],{"trials":8636,"activeCount":13},[],{"intervention":8638,"totalTrials":10,"cells":8639},"AGN-223575 Formulation A",{"EARLY_PHASE1":8640,"PHASE1":8642,"PHASE2":8653,"PHASE3":8655,"PHASE4":8657,"NA":8659},{"trials":8641,"activeCount":13},[],{"trials":8643,"activeCount":13},[8644],{"nctId":8645,"briefTitle":8646,"status":61,"phases":8647,"primaryCompletion":807,"completion":3132,"start":808,"enrollment":1197,"conditions":8648,"interventions":8649},"NCT02155543","A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects",[42],[8326],[8638,8650,8651,8652],"AGN-223575 Formulation B","AGN-223575 Formulation C","AGN-223575 Vehicle",{"trials":8654,"activeCount":13},[],{"trials":8656,"activeCount":13},[],{"trials":8658,"activeCount":13},[],{"trials":8660,"activeCount":13},[],{"intervention":8650,"totalTrials":10,"cells":8662},{"EARLY_PHASE1":8663,"PHASE1":8665,"PHASE2":8671,"PHASE3":8673,"PHASE4":8675,"NA":8677},{"trials":8664,"activeCount":13},[],{"trials":8666,"activeCount":13},[8667],{"nctId":8645,"briefTitle":8646,"status":61,"phases":8668,"primaryCompletion":807,"completion":3132,"start":808,"enrollment":1197,"conditions":8669,"interventions":8670},[42],[8326],[8638,8650,8651,8652],{"trials":8672,"activeCount":13},[],{"trials":8674,"activeCount":13},[],{"trials":8676,"activeCount":13},[],{"trials":8678,"activeCount":13},[],{"intervention":8651,"totalTrials":10,"cells":8680},{"EARLY_PHASE1":8681,"PHASE1":8683,"PHASE2":8689,"PHASE3":8691,"PHASE4":8693,"NA":8695},{"trials":8682,"activeCount":13},[],{"trials":8684,"activeCount":13},[8685],{"nctId":8645,"briefTitle":8646,"status":61,"phases":8686,"primaryCompletion":807,"completion":3132,"start":808,"enrollment":1197,"conditions":8687,"interventions":8688},[42],[8326],[8638,8650,8651,8652],{"trials":8690,"activeCount":13},[],{"trials":8692,"activeCount":13},[],{"trials":8694,"activeCount":13},[],{"trials":8696,"activeCount":13},[],{"intervention":8652,"totalTrials":10,"cells":8698},{"EARLY_PHASE1":8699,"PHASE1":8701,"PHASE2":8707,"PHASE3":8709,"PHASE4":8711,"NA":8713},{"trials":8700,"activeCount":13},[],{"trials":8702,"activeCount":13},[8703],{"nctId":8645,"briefTitle":8646,"status":61,"phases":8704,"primaryCompletion":807,"completion":3132,"start":808,"enrollment":1197,"conditions":8705,"interventions":8706},[42],[8326],[8638,8650,8651,8652],{"trials":8708,"activeCount":13},[],{"trials":8710,"activeCount":13},[],{"trials":8712,"activeCount":13},[],{"trials":8714,"activeCount":13},[],{"intervention":2999,"totalTrials":10,"cells":8716},{"EARLY_PHASE1":8717,"PHASE1":8719,"PHASE2":8725,"PHASE3":8727,"PHASE4":8729,"NA":8731},{"trials":8718,"activeCount":13},[],{"trials":8720,"activeCount":13},[8721],{"nctId":2991,"briefTitle":2992,"status":61,"phases":8722,"primaryCompletion":2994,"completion":2994,"start":2995,"enrollment":1206,"conditions":8723,"interventions":8724},[42],[2997],[675,2999,3000],{"trials":8726,"activeCount":13},[],{"trials":8728,"activeCount":13},[],{"trials":8730,"activeCount":13},[],{"trials":8732,"activeCount":13},[],{"intervention":3000,"totalTrials":10,"cells":8734},{"EARLY_PHASE1":8735,"PHASE1":8737,"PHASE2":8743,"PHASE3":8745,"PHASE4":8747,"NA":8749},{"trials":8736,"activeCount":13},[],{"trials":8738,"activeCount":13},[8739],{"nctId":2991,"briefTitle":2992,"status":61,"phases":8740,"primaryCompletion":2994,"completion":2994,"start":2995,"enrollment":1206,"conditions":8741,"interventions":8742},[42],[2997],[675,2999,3000],{"trials":8744,"activeCount":13},[],{"trials":8746,"activeCount":13},[],{"trials":8748,"activeCount":13},[],{"trials":8750,"activeCount":13},[],{"intervention":455,"totalTrials":10,"cells":8752},{"EARLY_PHASE1":8753,"PHASE1":8755,"PHASE2":8761,"PHASE3":8763,"PHASE4":8765,"NA":8767},{"trials":8754,"activeCount":13},[],{"trials":8756,"activeCount":13},[8757],{"nctId":447,"briefTitle":448,"status":61,"phases":8758,"primaryCompletion":63,"completion":63,"start":450,"enrollment":66,"conditions":8759,"interventions":8760},[42],[452],[454,455],{"trials":8762,"activeCount":13},[],{"trials":8764,"activeCount":13},[],{"trials":8766,"activeCount":13},[],{"trials":8768,"activeCount":13},[],{"intervention":2833,"totalTrials":10,"cells":8770},{"EARLY_PHASE1":8771,"PHASE1":8773,"PHASE2":8779,"PHASE3":8781,"PHASE4":8783,"NA":8785},{"trials":8772,"activeCount":13},[],{"trials":8774,"activeCount":13},[8775],{"nctId":2827,"briefTitle":2828,"status":61,"phases":8776,"primaryCompletion":751,"completion":751,"start":78,"enrollment":2830,"conditions":8777,"interventions":8778},[42],[452],[2804,2833,2834],{"trials":8780,"activeCount":13},[],{"trials":8782,"activeCount":13},[],{"trials":8784,"activeCount":13},[],{"trials":8786,"activeCount":13},[],{"intervention":2834,"totalTrials":10,"cells":8788},{"EARLY_PHASE1":8789,"PHASE1":8791,"PHASE2":8797,"PHASE3":8799,"PHASE4":8801,"NA":8803},{"trials":8790,"activeCount":13},[],{"trials":8792,"activeCount":13},[8793],{"nctId":2827,"briefTitle":2828,"status":61,"phases":8794,"primaryCompletion":751,"completion":751,"start":78,"enrollment":2830,"conditions":8795,"interventions":8796},[42],[452],[2804,2833,2834],{"trials":8798,"activeCount":13},[],{"trials":8800,"activeCount":13},[],{"trials":8802,"activeCount":13},[],{"trials":8804,"activeCount":13},[],{"intervention":8806,"totalTrials":10,"cells":8807},"Cenicriviroc",{"EARLY_PHASE1":8808,"PHASE1":8810,"PHASE2":8822,"PHASE3":8824,"PHASE4":8826,"NA":8828},{"trials":8809,"activeCount":13},[],{"trials":8811,"activeCount":13},[8812],{"nctId":8813,"briefTitle":8814,"status":61,"phases":8815,"primaryCompletion":8816,"completion":8817,"start":8818,"enrollment":5474,"conditions":8819,"interventions":8821},"NCT03376841","Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites",[42],"2017-11-24","2017-12-17","2017-06-06",[8820],"Hepatic Impairment",[8806],{"trials":8823,"activeCount":13},[],{"trials":8825,"activeCount":13},[],{"trials":8827,"activeCount":13},[],{"trials":8829,"activeCount":13},[],{"intervention":7711,"totalTrials":2830,"cells":8831},{"EARLY_PHASE1":8832,"PHASE1":8834,"PHASE2":8836,"PHASE3":8928,"PHASE4":9072,"NA":9154},{"trials":8833,"activeCount":13},[],{"trials":8835,"activeCount":13},[],{"trials":8837,"activeCount":13},[8838,8842,8853,8859,8869,8876,8886,8893,8900,8906,8913,8924],{"nctId":6138,"briefTitle":6139,"status":61,"phases":8839,"primaryCompletion":888,"completion":897,"start":631,"enrollment":4214,"conditions":8840,"interventions":8841},[43],[6142],[6144,6129,6145],{"nctId":8843,"briefTitle":8844,"status":61,"phases":8845,"primaryCompletion":8846,"completion":8847,"start":8848,"enrollment":3673,"conditions":8849,"interventions":8851},"NCT01107392","Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia",[43],"2012-03-16","2012-06-08","2010-08-01",[8850],"Benign Prostatic Hyperplasia",[7711,8852],"Normal saline",{"nctId":8854,"briefTitle":8855,"status":75,"phases":8856,"primaryCompletion":6709,"completion":307,"start":631,"enrollment":18,"conditions":8857,"interventions":8858},"NCT00575016","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder",[43],[35],[8852,7711,7711,7711],{"nctId":8860,"briefTitle":8861,"status":61,"phases":8862,"primaryCompletion":8863,"completion":8863,"start":8864,"enrollment":8865,"conditions":8866,"interventions":8867},"NCT00651729","Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity",[43],"2004-12","2003-04",279,[7708,32],[8868],"Botulinum Toxin Type A",{"nctId":8870,"briefTitle":8871,"status":61,"phases":8872,"primaryCompletion":319,"completion":5631,"start":5473,"enrollment":8873,"conditions":8874,"interventions":8875},"NCT00284518","Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia",[43],380,[8850],[7711,3917],{"nctId":8877,"briefTitle":8878,"status":61,"phases":8879,"primaryCompletion":8880,"completion":8880,"start":8881,"enrollment":8882,"conditions":8883,"interventions":8885},"NCT00168441","A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia",[43],"2005-06","2004-06",117,[8884],"Postherpetic Neuralgia",[8868],{"nctId":8887,"briefTitle":8888,"status":61,"phases":8889,"primaryCompletion":487,"completion":392,"start":476,"enrollment":8890,"conditions":8891,"interventions":8892},"NCT00894517","A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia",[42,43],61,[8850],[8868],{"nctId":8894,"briefTitle":8895,"status":61,"phases":8896,"primaryCompletion":577,"completion":577,"start":5104,"enrollment":8897,"conditions":8898,"interventions":8899},"NCT00651690","Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment",[43],62,[7708,32],[8868],{"nctId":8901,"briefTitle":8902,"status":61,"phases":8903,"primaryCompletion":2607,"completion":1553,"start":4472,"enrollment":684,"conditions":8904,"interventions":8905},"NCT00168454","A Research Study for Patients With Overactive Bladder",[43],[35,3574],[7711],{"nctId":8907,"briefTitle":8908,"status":61,"phases":8909,"primaryCompletion":3179,"completion":3179,"start":1047,"enrollment":2385,"conditions":8910,"interventions":8912},"NCT01518257","Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthritis Knee Pain",[42,43],[8911],"Osteoarthritis",[7711,6145],{"nctId":8914,"briefTitle":8915,"status":61,"phases":8916,"primaryCompletion":8917,"completion":8918,"start":8919,"enrollment":8920,"conditions":8921,"interventions":8923},"NCT02010775","Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy",[43],"2017-03-07","2017-11-29","2014-01-20",187,[8922],"Masseter Muscle Hypertrophy",[7711,8852],{"nctId":7703,"briefTitle":7704,"status":61,"phases":8925,"primaryCompletion":476,"completion":476,"start":7058,"enrollment":7706,"conditions":8926,"interventions":8927},[43],[7708,32,7709],[7711,7711,7694],{"trials":8929,"activeCount":13},[8930,8938,8946,8957,8965,8972,8981,8987,8996,9003,9011,9020,9029,9040,9049,9055,9063],{"nctId":8931,"briefTitle":8932,"status":214,"phases":8933,"primaryCompletion":8934,"completion":8934,"start":8935,"enrollment":13,"conditions":8936,"interventions":8937},"NCT03193359","Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine",[44],"2021-09-09","2018-01-15",[37],[7711],{"nctId":8939,"briefTitle":8940,"status":61,"phases":8941,"primaryCompletion":5436,"completion":923,"start":8942,"enrollment":8943,"conditions":8944,"interventions":8945},"NCT00156910","A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches",[44],"2006-02",679,[37],[8868],{"nctId":8947,"briefTitle":8948,"status":61,"phases":8949,"primaryCompletion":5730,"completion":8950,"start":8951,"enrollment":8952,"conditions":8953,"interventions":8956},"NCT01603602","BOTOX® Treatment in Pediatric Upper Limb Spasticity",[44],"2017-07-06","2012-07-12",235,[8954,32,8955,7708],"Pediatrics","Cerebral Palsy",[7711,6145],{"nctId":8958,"briefTitle":8959,"status":61,"phases":8960,"primaryCompletion":1400,"completion":1400,"start":8961,"enrollment":8962,"conditions":8963,"interventions":8964},"NCT00915525","Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence",[44],"2010-02-01",829,[35,3574],[7711],{"nctId":8966,"briefTitle":8855,"status":61,"phases":8967,"primaryCompletion":308,"completion":64,"start":8968,"enrollment":8969,"conditions":8970,"interventions":8971},"NCT00461292",[44],"2007-05",275,[35],[7711,7711],{"nctId":8973,"briefTitle":8974,"status":61,"phases":8975,"primaryCompletion":8976,"completion":8976,"start":8977,"enrollment":8978,"conditions":8979,"interventions":8980},"NCT00168402","A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis",[44],"2005-10","2002-02",193,[230],[8868],{"nctId":8982,"briefTitle":8855,"status":75,"phases":8983,"primaryCompletion":1230,"completion":1230,"start":2503,"enrollment":8984,"conditions":8985,"interventions":8986},"NCT00439140",[44],41,[35],[7711,6145],{"nctId":8988,"briefTitle":8989,"status":61,"phases":8990,"primaryCompletion":8991,"completion":108,"start":89,"enrollment":8992,"conditions":8993,"interventions":8995},"NCT02195687","BOTOX® in the Treatment of Crow's Feet Lines in China",[44],"2015-02",417,[8994,372],"Lateral Canthal Lines",[7711,6145],{"nctId":8997,"briefTitle":8940,"status":61,"phases":8998,"primaryCompletion":631,"completion":863,"start":8999,"enrollment":9000,"conditions":9001,"interventions":9002},"NCT00168428",[44],"2006-03",705,[37],[8868],{"nctId":9004,"briefTitle":9005,"status":214,"phases":9006,"primaryCompletion":9007,"completion":9007,"start":9008,"enrollment":13,"conditions":9009,"interventions":9010},"NCT03193346","BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine",[44],"2021-03-25","2017-07-03",[37],[7711],{"nctId":9012,"briefTitle":9013,"status":61,"phases":9014,"primaryCompletion":9015,"completion":9015,"start":9016,"enrollment":9017,"conditions":9018,"interventions":9019},"NCT01603641","BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity",[44],"2018-08-25","2012-11-05",370,[8954,32,8955],[8868],{"nctId":9021,"briefTitle":9022,"status":61,"phases":9023,"primaryCompletion":9024,"completion":9024,"start":9025,"enrollment":9026,"conditions":9027,"interventions":9028},"NCT01603628","BOTOX® Treatment in Pediatric Lower Limb Spasticity",[44],"2017-06-28","2012-09-11",384,[8954,32,8955],[7711,6145],{"nctId":9030,"briefTitle":9031,"status":61,"phases":9032,"primaryCompletion":9033,"completion":9034,"start":9035,"enrollment":9036,"conditions":9037,"interventions":9039},"NCT01797081","BOTOX® in the Treatment of Crow's Feet Lines in Japan",[44],"2013-07-18","2014-07-07","2013-01-31",300,[9038,372],"Lateral Canthus Rhytides",[7711,7711],{"nctId":9041,"briefTitle":9042,"status":61,"phases":9043,"primaryCompletion":9044,"completion":9044,"start":9045,"enrollment":9046,"conditions":9047,"interventions":9048},"NCT01603615","BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity",[44],"2018-09-03","2012-10-30",220,[8954,32,8955,7708],[8868],{"nctId":9050,"briefTitle":8855,"status":61,"phases":9051,"primaryCompletion":5631,"completion":5631,"start":854,"enrollment":9052,"conditions":9053,"interventions":9054},"NCT00311376",[44],416,[35],[7711,7711],{"nctId":9056,"briefTitle":9057,"status":61,"phases":9058,"primaryCompletion":89,"completion":9059,"start":2718,"enrollment":9060,"conditions":9061,"interventions":9062},"NCT01575054","BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity",[44],"2015-07",468,[32],[7711,6145],{"nctId":9064,"briefTitle":9065,"status":61,"phases":9066,"primaryCompletion":544,"completion":109,"start":1465,"enrollment":9067,"conditions":9068,"interventions":9071},"NCT01797094","BOTOX® in the Treatment of Upper Facial Lines in Japan",[44],101,[9069,372,373,9070],"Upper Facial Rhytides","Frown Lines",[7711,7711],{"trials":9073,"activeCount":13},[9074,9080,9087,9094,9104,9111,9117,9124,9131,9138,9146],{"nctId":9075,"briefTitle":9076,"status":61,"phases":9077,"primaryCompletion":8991,"completion":8991,"start":109,"enrollment":5699,"conditions":9078,"interventions":9079},"NCT02147561","A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine",[45],[37],[7711],{"nctId":9081,"briefTitle":9082,"status":61,"phases":9083,"primaryCompletion":2851,"completion":3144,"start":751,"enrollment":9084,"conditions":9085,"interventions":9086},"NCT01271452","Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines",[45],224,[373],[6144,6144],{"nctId":9088,"briefTitle":9089,"status":61,"phases":9090,"primaryCompletion":1923,"completion":1923,"start":987,"enrollment":228,"conditions":9091,"interventions":9093},"NCT00528541","Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia",[45],[9092],"Spasmodic Torticollis",[6144,6144],{"nctId":9095,"briefTitle":9096,"status":61,"phases":9097,"primaryCompletion":9098,"completion":9099,"start":9100,"enrollment":3828,"conditions":9101,"interventions":9103},"NCT01814670","Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines",[45],"2014-07-31","2014-10-29","2013-03-06",[9102],"Glabellar Rhytides",[7711],{"nctId":9105,"briefTitle":8974,"status":61,"phases":9106,"primaryCompletion":632,"completion":632,"start":9107,"enrollment":9108,"conditions":9109,"interventions":9110},"NCT00168480",[45],"2003-11",424,[230],[8868],{"nctId":9112,"briefTitle":9113,"status":75,"phases":9114,"primaryCompletion":2124,"completion":761,"start":2503,"enrollment":2830,"conditions":9115,"interventions":9116},"NCT00432341","Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia",[45],[9092],[6144,6144],{"nctId":9118,"briefTitle":9119,"status":61,"phases":9120,"primaryCompletion":8475,"completion":8475,"start":9121,"enrollment":2246,"conditions":9122,"interventions":9123},"NCT02601287","A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients",[45],"2015-11",[3574,35],[8868],{"nctId":9125,"briefTitle":9126,"status":61,"phases":9127,"primaryCompletion":345,"completion":345,"start":204,"enrollment":1206,"conditions":9128,"interventions":9130},"NCT01391312","Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines",[45],[9129],"Glabellar Frown Lines",[7711,3917],{"nctId":9132,"briefTitle":9133,"status":61,"phases":9134,"primaryCompletion":2503,"completion":2503,"start":9135,"enrollment":3050,"conditions":9136,"interventions":9137},"NCT00168415","A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis",[45],"2005-08",[230],[8868],{"nctId":9139,"briefTitle":9140,"status":61,"phases":9141,"primaryCompletion":477,"completion":477,"start":2124,"enrollment":9142,"conditions":9143,"interventions":9145},"NCT00856414","Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines",[45],45,[9144],"Skin Aging",[7711],{"nctId":9147,"briefTitle":9148,"status":61,"phases":9149,"primaryCompletion":761,"completion":761,"start":1093,"enrollment":9150,"conditions":9151,"interventions":9153},"NCT01384214","Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia",[45],28,[9152],"Torticollis",[7711],{"trials":9155,"activeCount":13},[9156,9163,9170,9179,9189,9198,9206,9213,9222,9231,9239,9247,9255,9262],{"nctId":9157,"briefTitle":9158,"status":61,"phases":9159,"primaryCompletion":8475,"completion":8475,"start":4627,"enrollment":9160,"conditions":9161,"interventions":9162},"NCT02010788","Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea",[],523,[3574,5692],[7711],{"nctId":9164,"briefTitle":9165,"status":61,"phases":9166,"primaryCompletion":344,"completion":344,"start":923,"enrollment":9167,"conditions":9168,"interventions":9169},"NCT02043145","Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea",[],727,[230,32,373],[7711],{"nctId":9171,"briefTitle":9172,"status":61,"phases":9173,"primaryCompletion":9174,"completion":9174,"start":9175,"enrollment":9176,"conditions":9177,"interventions":9178},"NCT01608659","An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A",[],"2011-06-17","2011-04-01",110,[371],[7711],{"nctId":9180,"briefTitle":9181,"status":61,"phases":9182,"primaryCompletion":9183,"completion":9184,"start":9185,"enrollment":9186,"conditions":9187,"interventions":9188},"NCT01391299","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines",[46],"2011-10-18","2012-02-28","2011-06-01",175,[371,9129],[7711,6145],{"nctId":9190,"briefTitle":9191,"status":61,"phases":9192,"primaryCompletion":9193,"completion":9193,"start":9194,"enrollment":9195,"conditions":9196,"interventions":9197},"NCT01432379","BOTOX® Prophylaxis in Patients With Chronic Migraine",[],"2015-05-12","2011-09-09",1168,[37],[7711],{"nctId":9199,"briefTitle":9200,"status":61,"phases":9201,"primaryCompletion":9202,"completion":9202,"start":9203,"enrollment":196,"conditions":9204,"interventions":9205},"NCT02072928","Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium",[],"2015-09-30","2014-01-28",[3574],[7711],{"nctId":9207,"briefTitle":9208,"status":61,"phases":9209,"primaryCompletion":7487,"completion":7487,"start":2001,"enrollment":9210,"conditions":9211,"interventions":9212},"NCT02161159","An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder",[],515,[3574,5692],[7711],{"nctId":9214,"briefTitle":9215,"status":61,"phases":9216,"primaryCompletion":9217,"completion":9217,"start":9218,"enrollment":9219,"conditions":9220,"interventions":9221},"NCT02248844","Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea",[],"2017-08-14","2014-09-26",667,[8994,372],[8868],{"nctId":9223,"briefTitle":9224,"status":61,"phases":9225,"primaryCompletion":5287,"completion":5287,"start":9226,"enrollment":9227,"conditions":9228,"interventions":9230},"NCT02673047","Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder",[],"2016-02",474,[5692,9229],"Urinary Bladder, Neurogenic",[7711],{"nctId":9232,"briefTitle":9233,"status":61,"phases":9234,"primaryCompletion":9235,"completion":9235,"start":9236,"enrollment":4315,"conditions":9237,"interventions":9238},"NCT01608672","Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®",[],"2012-12-31","2012-04-01",[373],[7711],{"nctId":9240,"briefTitle":9241,"status":61,"phases":9242,"primaryCompletion":8991,"completion":8991,"start":487,"enrollment":9243,"conditions":9244,"interventions":9246},"NCT01976611","Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea",[],402,[37,9245],"Headache",[7711],{"nctId":9248,"briefTitle":9249,"status":61,"phases":9250,"primaryCompletion":5741,"completion":5741,"start":9251,"enrollment":9252,"conditions":9253,"interventions":9254},"NCT01686581","An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine",[],"2012-07-23",641,[37],[7711],{"nctId":9256,"briefTitle":9257,"status":61,"phases":9258,"primaryCompletion":3179,"completion":3179,"start":204,"enrollment":9259,"conditions":9260,"interventions":9261},"NCT01387074","Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity",[],108,[32],[7711],{"nctId":9263,"briefTitle":9264,"status":61,"phases":9265,"primaryCompletion":9266,"completion":9266,"start":9267,"enrollment":9268,"conditions":9269,"interventions":9270},"NCT02590250","A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India",[],"2017-08-07","2015-12-16",250,[3574,35],[7711],{"intervention":6145,"totalTrials":9272,"cells":9273},27,{"EARLY_PHASE1":9274,"PHASE1":9276,"PHASE2":9278,"PHASE3":9341,"PHASE4":9413,"NA":9444},{"trials":9275,"activeCount":13},[],{"trials":9277,"activeCount":13},[],{"trials":9279,"activeCount":13},[9280,9284,9288,9292,9303,9307,9311,9317,9328,9332],{"nctId":6138,"briefTitle":6139,"status":61,"phases":9281,"primaryCompletion":888,"completion":897,"start":631,"enrollment":4214,"conditions":9282,"interventions":9283},[43],[6142],[6144,6129,6145],{"nctId":8843,"briefTitle":8844,"status":61,"phases":9285,"primaryCompletion":8846,"completion":8847,"start":8848,"enrollment":3673,"conditions":9286,"interventions":9287},[43],[8850],[7711,8852],{"nctId":8854,"briefTitle":8855,"status":75,"phases":9289,"primaryCompletion":6709,"completion":307,"start":631,"enrollment":18,"conditions":9290,"interventions":9291},[43],[35],[8852,7711,7711,7711],{"nctId":9293,"briefTitle":9294,"status":61,"phases":9295,"primaryCompletion":9296,"completion":9297,"start":9298,"enrollment":9299,"conditions":9300,"interventions":9302},"NCT02116361","OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females",[43],"2016-08-25","2016-12-22","2014-04-22",258,[9301],"Depressive Disorder, Major",[376,6145],{"nctId":8870,"briefTitle":8871,"status":61,"phases":9304,"primaryCompletion":319,"completion":5631,"start":5473,"enrollment":8873,"conditions":9305,"interventions":9306},[43],[8850],[7711,3917],{"nctId":8907,"briefTitle":8908,"status":61,"phases":9308,"primaryCompletion":3179,"completion":3179,"start":1047,"enrollment":2385,"conditions":9309,"interventions":9310},[42,43],[8911],[7711,6145],{"nctId":9312,"briefTitle":9313,"status":61,"phases":9314,"primaryCompletion":8324,"completion":8324,"start":796,"enrollment":4745,"conditions":9315,"interventions":9316},"NCT02230956","BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis",[43],[8911],[376,6145],{"nctId":9318,"briefTitle":9319,"status":61,"phases":9320,"primaryCompletion":9321,"completion":9322,"start":9323,"enrollment":2102,"conditions":9324,"interventions":9326},"NCT03861936","BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence",[43],"2020-04-03","2020-07-02","2019-05-16",[9325],"Masseter Muscle Prominence",[9327,8852],"OnabotulinumtoxinA",{"nctId":8914,"briefTitle":8915,"status":61,"phases":9329,"primaryCompletion":8917,"completion":8918,"start":8919,"enrollment":8920,"conditions":9330,"interventions":9331},[43],[8922],[7711,8852],{"nctId":9333,"briefTitle":9334,"status":75,"phases":9335,"primaryCompletion":9336,"completion":9336,"start":9337,"enrollment":1268,"conditions":9338,"interventions":9340},"NCT01917006","A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation",[43],"2017-08-15","2013-08-07",[9339],"Premature Ejaculation",[9327,6145],{"trials":9342,"activeCount":13},[9343,9354,9358,9362,9366,9373,9382,9386,9393,9397,9401,9405],{"nctId":9344,"briefTitle":9345,"status":61,"phases":9346,"primaryCompletion":9347,"completion":9348,"start":9349,"enrollment":9350,"conditions":9351,"interventions":9353},"NCT02261467","A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides",[44],"2015-06-04","2016-04-26","2014-10-21",421,[9352,9102],"Forehead Rhytides",[9327,6145],{"nctId":8947,"briefTitle":8948,"status":61,"phases":9355,"primaryCompletion":5730,"completion":8950,"start":8951,"enrollment":8952,"conditions":9356,"interventions":9357},[44],[8954,32,8955,7708],[7711,6145],{"nctId":8982,"briefTitle":8855,"status":75,"phases":9359,"primaryCompletion":1230,"completion":1230,"start":2503,"enrollment":8984,"conditions":9360,"interventions":9361},[44],[35],[7711,6145],{"nctId":8988,"briefTitle":8989,"status":61,"phases":9363,"primaryCompletion":8991,"completion":108,"start":89,"enrollment":8992,"conditions":9364,"interventions":9365},[44],[8994,372],[7711,6145],{"nctId":9367,"briefTitle":9368,"status":61,"phases":9369,"primaryCompletion":3306,"completion":3306,"start":1923,"enrollment":9370,"conditions":9371,"interventions":9372},"NCT00910520","Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence",[44],548,[35],[376,3917],{"nctId":9374,"briefTitle":9375,"status":61,"phases":9376,"primaryCompletion":227,"completion":9377,"start":9378,"enrollment":9379,"conditions":9380,"interventions":9381},"NCT02261493","A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides",[44],"2016-04-20","2014-10-27",787,[371,9102],[9327,6145],{"nctId":9021,"briefTitle":9022,"status":61,"phases":9383,"primaryCompletion":9024,"completion":9024,"start":9025,"enrollment":9026,"conditions":9384,"interventions":9385},[44],[8954,32,8955],[7711,6145],{"nctId":9387,"briefTitle":9388,"status":61,"phases":9389,"primaryCompletion":2221,"completion":2221,"start":1923,"enrollment":9390,"conditions":9391,"interventions":9392},"NCT00910845","Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence",[44],557,[35],[376,3917],{"nctId":3908,"briefTitle":3909,"status":61,"phases":9394,"primaryCompletion":3911,"completion":129,"start":3912,"enrollment":3913,"conditions":9395,"interventions":9396},[44],[371,372,373],[3897,3916,3917],{"nctId":3919,"briefTitle":3909,"status":61,"phases":9398,"primaryCompletion":345,"completion":1021,"start":77,"enrollment":3921,"conditions":9399,"interventions":9400},[44],[371,372,373],[3917,3916,3897],{"nctId":9056,"briefTitle":9057,"status":61,"phases":9402,"primaryCompletion":89,"completion":9059,"start":2718,"enrollment":9060,"conditions":9403,"interventions":9404},[44],[32],[7711,6145],{"nctId":9406,"briefTitle":9407,"status":61,"phases":9408,"primaryCompletion":9175,"completion":419,"start":9409,"enrollment":9410,"conditions":9411,"interventions":9412},"NCT01189747","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines",[44],"2010-10-01",446,[9038,372],[376,3917],{"trials":9414,"activeCount":13},[9415,9425,9432,9436],{"nctId":9416,"briefTitle":9417,"status":61,"phases":9418,"primaryCompletion":9419,"completion":9420,"start":9421,"enrollment":9422,"conditions":9423,"interventions":9424},"NCT01945489","OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder",[45],"2016-05-24","2017-01-05","2013-10-28",254,[35],[376,8852],{"nctId":9426,"briefTitle":9427,"status":61,"phases":9428,"primaryCompletion":4109,"completion":9429,"start":9035,"enrollment":3145,"conditions":9430,"interventions":9431},"NCT01777620","A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides",[45],"2013-07-31",[371],[376,6145],{"nctId":9125,"briefTitle":9126,"status":61,"phases":9433,"primaryCompletion":345,"completion":345,"start":204,"enrollment":1206,"conditions":9434,"interventions":9435},[45],[9129],[7711,3917],{"nctId":9437,"briefTitle":9438,"status":61,"phases":9439,"primaryCompletion":89,"completion":89,"start":9440,"enrollment":9441,"conditions":9442,"interventions":9443},"NCT01833130","Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)",[45],"2013-04",52,[2959],[9327,8852],{"trials":9445,"activeCount":13},[9446],{"nctId":9180,"briefTitle":9181,"status":61,"phases":9447,"primaryCompletion":9183,"completion":9184,"start":9185,"enrollment":9186,"conditions":9448,"interventions":9449},[46],[371,9129],[7711,6145],{"intervention":376,"totalTrials":9272,"cells":9451},{"EARLY_PHASE1":9452,"PHASE1":9454,"PHASE2":9456,"PHASE3":9474,"PHASE4":9540,"NA":9578},{"trials":9453,"activeCount":13},[],{"trials":9455,"activeCount":13},[],{"trials":9457,"activeCount":13},[9458,9462,9466,9470],{"nctId":9293,"briefTitle":9294,"status":61,"phases":9459,"primaryCompletion":9296,"completion":9297,"start":9298,"enrollment":9299,"conditions":9460,"interventions":9461},[43],[9301],[376,6145],{"nctId":9312,"briefTitle":9313,"status":61,"phases":9463,"primaryCompletion":8324,"completion":8324,"start":796,"enrollment":4745,"conditions":9464,"interventions":9465},[43],[8911],[376,6145],{"nctId":9318,"briefTitle":9319,"status":61,"phases":9467,"primaryCompletion":9321,"completion":9322,"start":9323,"enrollment":2102,"conditions":9468,"interventions":9469},[43],[9325],[9327,8852],{"nctId":9333,"briefTitle":9334,"status":75,"phases":9471,"primaryCompletion":9336,"completion":9336,"start":9337,"enrollment":1268,"conditions":9472,"interventions":9473},[43],[9339],[9327,6145],{"trials":9475,"activeCount":13},[9476,9483,9493,9500,9504,9508,9512,9521,9525,9536],{"nctId":9477,"briefTitle":9478,"status":214,"phases":9479,"primaryCompletion":9480,"completion":9480,"start":1076,"enrollment":13,"conditions":9481,"interventions":9482},"NCT02145689","Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity",[44],"2017-05",[32,7708],[376],{"nctId":9484,"briefTitle":9485,"status":61,"phases":9486,"primaryCompletion":9487,"completion":9488,"start":9489,"enrollment":9490,"conditions":9491,"interventions":9492},"NCT01852058","A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity",[44],"2018-11-22","2019-10-03","2014-01-11",95,[3574],[9327],{"nctId":9494,"briefTitle":9495,"status":75,"phases":9496,"primaryCompletion":88,"completion":88,"start":808,"enrollment":9497,"conditions":9498,"interventions":9499},"NCT02145676","OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity",[44],53,[32,7708],[376],{"nctId":9344,"briefTitle":9345,"status":61,"phases":9501,"primaryCompletion":9347,"completion":9348,"start":9349,"enrollment":9350,"conditions":9502,"interventions":9503},[44],[9352,9102],[9327,6145],{"nctId":9367,"briefTitle":9368,"status":61,"phases":9505,"primaryCompletion":3306,"completion":3306,"start":1923,"enrollment":9370,"conditions":9506,"interventions":9507},[44],[35],[376,3917],{"nctId":9374,"briefTitle":9375,"status":61,"phases":9509,"primaryCompletion":227,"completion":9377,"start":9378,"enrollment":9379,"conditions":9510,"interventions":9511},[44],[371,9102],[9327,6145],{"nctId":9513,"briefTitle":9514,"status":61,"phases":9515,"primaryCompletion":9516,"completion":9516,"start":9517,"enrollment":9518,"conditions":9519,"interventions":9520},"NCT01852045","Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients",[44],"2018-10-11","2013-07-02",114,[3574],[9327],{"nctId":9387,"briefTitle":9388,"status":61,"phases":9522,"primaryCompletion":2221,"completion":2221,"start":1923,"enrollment":9390,"conditions":9523,"interventions":9524},[44],[35],[376,3917],{"nctId":9526,"briefTitle":9527,"status":61,"phases":9528,"primaryCompletion":9529,"completion":9530,"start":9531,"enrollment":3050,"conditions":9532,"interventions":9535},"NCT01600716","Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)",[44],"2014-04-04","2015-03-27","2012-06-13",[3574,9533,9534],"Multiple Sclerosis","Neurogenic Bladder",[9327],{"nctId":9406,"briefTitle":9407,"status":61,"phases":9537,"primaryCompletion":9175,"completion":419,"start":9409,"enrollment":9410,"conditions":9538,"interventions":9539},[44],[9038,372],[376,3917],{"trials":9541,"activeCount":13},[9542,9546,9550,9554,9561,9565,9569],{"nctId":1395,"briefTitle":1396,"status":61,"phases":9543,"primaryCompletion":1398,"completion":1399,"start":1400,"enrollment":1401,"conditions":9544,"interventions":9545},[45],[37],[376,1382],{"nctId":9416,"briefTitle":9417,"status":61,"phases":9547,"primaryCompletion":9419,"completion":9420,"start":9421,"enrollment":9422,"conditions":9548,"interventions":9549},[45],[35],[376,8852],{"nctId":9426,"briefTitle":9427,"status":61,"phases":9551,"primaryCompletion":4109,"completion":9429,"start":9035,"enrollment":3145,"conditions":9552,"interventions":9553},[45],[371],[376,6145],{"nctId":9555,"briefTitle":9556,"status":61,"phases":9557,"primaryCompletion":9121,"completion":9121,"start":545,"enrollment":9558,"conditions":9559,"interventions":9560},"NCT01516892","A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine",[45],716,[37],[376],{"nctId":9437,"briefTitle":9438,"status":61,"phases":9562,"primaryCompletion":89,"completion":89,"start":9440,"enrollment":9441,"conditions":9563,"interventions":9564},[45],[2959],[9327,8852],{"nctId":364,"briefTitle":365,"status":61,"phases":9566,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":9567,"interventions":9568},[45],[371,372,373,374],[376,279],{"nctId":9570,"briefTitle":9571,"status":61,"phases":9572,"primaryCompletion":9573,"completion":9573,"start":9574,"enrollment":9575,"conditions":9576,"interventions":9577},"NCT03052764","Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence",[45],"2018-12-10","2016-12-12",120,[5692,3574],[376],{"trials":9579,"activeCount":13},[9580,9588,9598,9605,9612,9618],{"nctId":9581,"briefTitle":9582,"status":61,"phases":9583,"primaryCompletion":9584,"completion":9584,"start":9585,"enrollment":2948,"conditions":9586,"interventions":9587},"NCT01930786","An Adult Spasticity Registry of OnabotulinumtoxinA Treatment",[],"2017-10-09","2013-10-16",[32],[376],{"nctId":9589,"briefTitle":9590,"status":61,"phases":9591,"primaryCompletion":9592,"completion":9593,"start":9594,"enrollment":9595,"conditions":9596,"interventions":9597},"NCT03043287","Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)",[],"2019-09-09","2019-09-30","2017-05-12",420,[5692],[376],{"nctId":9599,"briefTitle":9600,"status":61,"phases":9601,"primaryCompletion":9602,"completion":9602,"start":407,"enrollment":8897,"conditions":9603,"interventions":9604},"NCT01655862","A Prospective, Observational Study of Patients With Cervical Dystonia (Dystonie) Treated With OnabotulinumtoxinA",[],"2017-02",[9152],[9327],{"nctId":9606,"briefTitle":9607,"status":214,"phases":9608,"primaryCompletion":506,"completion":506,"start":1231,"enrollment":13,"conditions":9609,"interventions":9611},"NCT01749423","A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines",[],[9610],"Chronic Migraine, Headache",[9327],{"nctId":9613,"briefTitle":9614,"status":61,"phases":9615,"primaryCompletion":8475,"completion":8475,"start":3271,"enrollment":3673,"conditions":9616,"interventions":9617},"NCT02557971","Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder",[],[5692],[376],{"nctId":9619,"briefTitle":9620,"status":61,"phases":9621,"primaryCompletion":808,"completion":808,"start":2545,"enrollment":9622,"conditions":9623,"interventions":9625},"NCT01749410","A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines",[],33,[9624],"Chronic Migraine, Headaches",[376],{"intervention":177,"totalTrials":8124,"cells":9627},{"EARLY_PHASE1":9628,"PHASE1":9630,"PHASE2":9632,"PHASE3":9642,"PHASE4":9644,"NA":9659},{"trials":9629,"activeCount":13},[],{"trials":9631,"activeCount":13},[],{"trials":9633,"activeCount":13},[9634,9638],{"nctId":7166,"briefTitle":7167,"status":61,"phases":9635,"primaryCompletion":344,"completion":1465,"start":308,"enrollment":2385,"conditions":9636,"interventions":9637},[42,43],[29,175],[7157,177],{"nctId":114,"briefTitle":115,"status":61,"phases":9639,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":9640,"interventions":9641},[43],[29],[122,49],{"trials":9643,"activeCount":13},[],{"trials":9645,"activeCount":13},[9646,9650],{"nctId":168,"briefTitle":169,"status":61,"phases":9647,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":9648,"interventions":9649},[45],[175,29],[177,49],{"nctId":9651,"briefTitle":9652,"status":61,"phases":9653,"primaryCompletion":9654,"completion":9654,"start":9655,"enrollment":752,"conditions":9656,"interventions":9657},"NCT03953807","A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated",[45],"2022-07-04","2019-09-05",[2678],[9658],"Dexamethasone Intravitreal Implant",{"trials":9660,"activeCount":13},[9661,9671,9679,9690,9697,9704],{"nctId":9662,"briefTitle":9663,"status":61,"phases":9664,"primaryCompletion":9665,"completion":9665,"start":9666,"enrollment":9667,"conditions":9668,"interventions":9669},"NCT03889444","Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)",[],"2019-06-07","2019-01-15",141,[2678],[9670],"Dexamethasone intravitreal implant",{"nctId":9672,"briefTitle":9673,"status":61,"phases":9674,"primaryCompletion":9675,"completion":9675,"start":5379,"enrollment":4535,"conditions":9676,"interventions":9678},"NCT02731911","Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study",[],"2018-10-22",[9677],"Diabetic Macular Oedema",[177],{"nctId":9680,"briefTitle":9681,"status":75,"phases":9682,"primaryCompletion":9683,"completion":9684,"start":9685,"enrollment":9686,"conditions":9687,"interventions":9689},"NCT02951975","Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye",[],"2018-11-28","2018-12-19","2017-01-25",246,[9688],"Non-infectious Uveitis",[177],{"nctId":9691,"briefTitle":9692,"status":61,"phases":9693,"primaryCompletion":9440,"completion":796,"start":7529,"enrollment":9694,"conditions":9695,"interventions":9696},"NCT01618266","Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion",[],375,[29,175],[177],{"nctId":9698,"briefTitle":9699,"status":61,"phases":9700,"primaryCompletion":9684,"completion":9684,"start":9701,"enrollment":206,"conditions":9702,"interventions":9703},"NCT03003416","Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)",[],"2017-10-19",[2678],[177],{"nctId":9705,"briefTitle":9706,"status":61,"phases":9707,"primaryCompletion":9708,"completion":9708,"start":9709,"enrollment":9067,"conditions":9710,"interventions":9711},"NCT01805323","A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema",[],"2013-04-15","2012-09-01",[29],[9658],{"intervention":800,"totalTrials":182,"cells":9713},{"EARLY_PHASE1":9714,"PHASE1":9716,"PHASE2":9718,"PHASE3":9720,"PHASE4":9730,"NA":9756},{"trials":9715,"activeCount":13},[],{"trials":9717,"activeCount":13},[],{"trials":9719,"activeCount":13},[],{"trials":9721,"activeCount":13},[9722],{"nctId":9723,"briefTitle":9724,"status":61,"phases":9725,"primaryCompletion":808,"completion":808,"start":544,"enrollment":9726,"conditions":9727,"interventions":9728},"NCT01830140","A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension",[44],466,[20,17],[9729,992],"Bimatoprost 0.01%",{"trials":9731,"activeCount":13},[9732,9736,9744,9748],{"nctId":793,"briefTitle":794,"status":61,"phases":9733,"primaryCompletion":796,"completion":796,"start":507,"enrollment":797,"conditions":9734,"interventions":9735},[45],[20,17],[800,801,779,802],{"nctId":9737,"briefTitle":9738,"status":61,"phases":9739,"primaryCompletion":466,"completion":466,"start":897,"enrollment":9740,"conditions":9741,"interventions":9743},"NCT01833741","A Study of LUMIGAN® RC in the Clinical Setting",[45],1137,[9742,17],"Glaucoma, Primary Open Angle",[9729],{"nctId":804,"briefTitle":805,"status":61,"phases":9745,"primaryCompletion":807,"completion":807,"start":808,"enrollment":809,"conditions":9746,"interventions":9747},[45],[20,17],[800,812,779,802],{"nctId":9749,"briefTitle":9750,"status":61,"phases":9751,"primaryCompletion":3179,"completion":3179,"start":9752,"enrollment":9753,"conditions":9754,"interventions":9755},"NCT01594970","A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)",[45],"2012-03",800,[23,17],[9729],{"trials":9757,"activeCount":13},[9758,9765,9772],{"nctId":9759,"briefTitle":9760,"status":61,"phases":9761,"primaryCompletion":1076,"completion":1076,"start":2545,"enrollment":9762,"conditions":9763,"interventions":9764},"NCT01814761","A Study of Bimatoprost 0.01% in the Clinical Setting",[],312,[9742,17],[9729],{"nctId":9766,"briefTitle":9767,"status":61,"phases":9768,"primaryCompletion":4152,"completion":4152,"start":6709,"enrollment":9769,"conditions":9770,"interventions":9771},"NCT01632423","A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",[],10337,[23,17],[800],{"nctId":9773,"briefTitle":9774,"status":61,"phases":9775,"primaryCompletion":523,"completion":523,"start":308,"enrollment":9776,"conditions":9777,"interventions":9778},"NCT01628588","Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",[],854,[23,17],[800],{"intervention":6478,"totalTrials":3157,"cells":9780},{"EARLY_PHASE1":9781,"PHASE1":9783,"PHASE2":9785,"PHASE3":9791,"PHASE4":9797,"NA":9817},{"trials":9782,"activeCount":13},[],{"trials":9784,"activeCount":13},[],{"trials":9786,"activeCount":13},[9787],{"nctId":6464,"briefTitle":6465,"status":61,"phases":9788,"primaryCompletion":6467,"completion":6468,"start":6469,"enrollment":6470,"conditions":9789,"interventions":9790},[42,43],[1731,17],[6455,6473,6474,6475,6476,6477,6478],{"trials":9792,"activeCount":13},[9793],{"nctId":9723,"briefTitle":9724,"status":61,"phases":9794,"primaryCompletion":808,"completion":808,"start":544,"enrollment":9726,"conditions":9795,"interventions":9796},[44],[20,17],[9729,992],{"trials":9798,"activeCount":13},[9799,9807,9811],{"nctId":9800,"briefTitle":9801,"status":61,"phases":9802,"primaryCompletion":9803,"completion":9803,"start":9804,"enrollment":4558,"conditions":9805,"interventions":9806},"NCT02061683","A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension",[45],"2011-06-24","2010-04-19",[23,17],[992],{"nctId":983,"briefTitle":984,"status":61,"phases":9808,"primaryCompletion":923,"completion":986,"start":987,"enrollment":988,"conditions":9809,"interventions":9810},[45],[990,17],[992,812,867],{"nctId":9812,"briefTitle":9813,"status":61,"phases":9814,"primaryCompletion":205,"completion":4744,"start":63,"enrollment":8897,"conditions":9815,"interventions":9816},"NCT01229423","Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects",[45],[311],[6478],{"trials":9818,"activeCount":13},[9819],{"nctId":9820,"briefTitle":9821,"status":61,"phases":9822,"primaryCompletion":129,"completion":129,"start":9823,"enrollment":9824,"conditions":9825,"interventions":9826},"NCT01623479","An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes",[],"2010-11-19",585,[311],[6478],{"intervention":610,"totalTrials":3157,"cells":9828},{"EARLY_PHASE1":9829,"PHASE1":9831,"PHASE2":9833,"PHASE3":9843,"PHASE4":9845,"NA":9851},{"trials":9830,"activeCount":13},[],{"trials":9832,"activeCount":13},[],{"trials":9834,"activeCount":13},[9835,9839],{"nctId":563,"briefTitle":564,"status":61,"phases":9836,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":9837,"interventions":9838},[43],[20,17],[571,554,572],{"nctId":574,"briefTitle":575,"status":61,"phases":9840,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":9841,"interventions":9842},[43],[20,17],[582,583,584,585,586],{"trials":9844,"activeCount":13},[],{"trials":9846,"activeCount":13},[9847],{"nctId":602,"briefTitle":603,"status":61,"phases":9848,"primaryCompletion":605,"completion":605,"start":606,"enrollment":607,"conditions":9849,"interventions":9850},[45],[20,17],[610,611],{"trials":9852,"activeCount":13},[9853,9860,9867],{"nctId":9854,"briefTitle":9855,"status":61,"phases":9856,"primaryCompletion":393,"completion":393,"start":345,"enrollment":9857,"conditions":9858,"interventions":9859},"NCT01568008","Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",[],933,[1731,17],[582],{"nctId":9861,"briefTitle":9862,"status":61,"phases":9863,"primaryCompletion":6901,"completion":6901,"start":3156,"enrollment":9864,"conditions":9865,"interventions":9866},"NCT01489670","Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension",[],387,[23,17],[610],{"nctId":9868,"briefTitle":9869,"status":61,"phases":9870,"primaryCompletion":1465,"completion":1465,"start":344,"enrollment":9871,"conditions":9872,"interventions":9873},"NCT01589510","A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",[],419,[23,17],[610],{"intervention":9875,"totalTrials":79,"cells":9876},"Bimatoprost",{"EARLY_PHASE1":9877,"PHASE1":9879,"PHASE2":9889,"PHASE3":9895,"PHASE4":9903,"NA":9905},{"trials":9878,"activeCount":13},[],{"trials":9880,"activeCount":13},[9881],{"nctId":9882,"briefTitle":9883,"status":75,"phases":9884,"primaryCompletion":9885,"completion":9886,"start":8324,"enrollment":9497,"conditions":9887,"interventions":9888},"NCT02676310","Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)",[42],"2017-01","2017-03",[395,396,397],[9875],{"trials":9890,"activeCount":13},[9891],{"nctId":3141,"briefTitle":3142,"status":61,"phases":9892,"primaryCompletion":345,"completion":345,"start":3144,"enrollment":3145,"conditions":9893,"interventions":9894},[43],[23,17],[3148,3149,3120],{"trials":9896,"activeCount":13},[9897],{"nctId":9898,"briefTitle":9899,"status":61,"phases":9900,"primaryCompletion":2503,"completion":2503,"start":5473,"enrollment":4941,"conditions":9901,"interventions":9902},"NCT00300443","Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension",[43,44],[17],[3149],{"trials":9904,"activeCount":13},[],{"trials":9906,"activeCount":13},[9907],{"nctId":9908,"briefTitle":9909,"status":61,"phases":9910,"primaryCompletion":9440,"completion":9440,"start":2718,"enrollment":9911,"conditions":9912,"interventions":9913},"NCT01646151","A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension",[],2580,[23,17],[9875],{"intervention":7251,"totalTrials":616,"cells":9915},{"EARLY_PHASE1":9916,"PHASE1":9918,"PHASE2":9920,"PHASE3":9930,"PHASE4":9932,"NA":9934},{"trials":9917,"activeCount":13},[],{"trials":9919,"activeCount":13},[],{"trials":9921,"activeCount":13},[9922,9926],{"nctId":201,"briefTitle":202,"status":61,"phases":9923,"primaryCompletion":77,"completion":204,"start":205,"enrollment":206,"conditions":9924,"interventions":9925},[43],[208],[210,181],{"nctId":7246,"briefTitle":7247,"status":61,"phases":9927,"primaryCompletion":888,"completion":761,"start":631,"enrollment":1048,"conditions":9928,"interventions":9929},[43],[26],[7251,7237],{"trials":9931,"activeCount":13},[],{"trials":9933,"activeCount":13},[],{"trials":9935,"activeCount":13},[9936],{"nctId":9937,"briefTitle":9938,"status":61,"phases":9939,"primaryCompletion":761,"completion":450,"start":3545,"enrollment":7103,"conditions":9940,"interventions":9941},"NCT00827255","Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%",[],[3664],[7251],{"intervention":9943,"totalTrials":616,"cells":9944},"dexamethasone intravitreal implant 0.7 mg",{"EARLY_PHASE1":9945,"PHASE1":9947,"PHASE2":9949,"PHASE3":9951,"PHASE4":9953,"NA":9955},{"trials":9946,"activeCount":13},[],{"trials":9948,"activeCount":13},[],{"trials":9950,"activeCount":13},[],{"trials":9952,"activeCount":13},[],{"trials":9954,"activeCount":13},[],{"trials":9956,"activeCount":13},[9957,9964,9970],{"nctId":9958,"briefTitle":9959,"status":61,"phases":9960,"primaryCompletion":9752,"completion":9752,"start":2221,"enrollment":9961,"conditions":9962,"interventions":9963},"NCT01411696","Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)",[],289,[175,29],[9943],{"nctId":9965,"briefTitle":9966,"status":61,"phases":9967,"primaryCompletion":1047,"completion":1047,"start":345,"enrollment":2222,"conditions":9968,"interventions":9969},"NCT01445626","A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)",[],[29],[9943],{"nctId":9971,"briefTitle":9972,"status":61,"phases":9973,"primaryCompletion":487,"completion":487,"start":9752,"enrollment":6687,"conditions":9974,"interventions":9976},"NCT01566526","Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion",[],[175,9975],"Macular Oedema",[9943],{"intervention":9978,"totalTrials":616,"cells":9979},"No Intervention",{"EARLY_PHASE1":9980,"PHASE1":9982,"PHASE2":9984,"PHASE3":9986,"PHASE4":9988,"NA":9990},{"trials":9981,"activeCount":13},[],{"trials":9983,"activeCount":13},[],{"trials":9985,"activeCount":13},[],{"trials":9987,"activeCount":13},[],{"trials":9989,"activeCount":13},[],{"trials":9991,"activeCount":13},[9992,9998,10004],{"nctId":9993,"briefTitle":9994,"status":61,"phases":9995,"primaryCompletion":3156,"completion":3156,"start":3306,"enrollment":508,"conditions":9996,"interventions":9997},"NCT01412086","Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale",[],[8326],[9978],{"nctId":9999,"briefTitle":10000,"status":61,"phases":10001,"primaryCompletion":407,"completion":407,"start":487,"enrollment":2125,"conditions":10002,"interventions":10003},"NCT01600729","Reliability of the Facial Wrinkle Scale in Japanese Subjects",[],[371],[9978],{"nctId":10005,"briefTitle":10006,"status":61,"phases":10007,"primaryCompletion":407,"completion":407,"start":2718,"enrollment":309,"conditions":10008,"interventions":10009},"NCT01636765","Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale",[],[3773,3774],[9978],{"intervention":10011,"totalTrials":780,"cells":10012},"Glycerin and Polysorbate 80 based artificial tear",{"EARLY_PHASE1":10013,"PHASE1":10015,"PHASE2":10017,"PHASE3":10019,"PHASE4":10021,"NA":10023},{"trials":10014,"activeCount":13},[],{"trials":10016,"activeCount":13},[],{"trials":10018,"activeCount":13},[],{"trials":10020,"activeCount":13},[],{"trials":10022,"activeCount":13},[],{"trials":10024,"activeCount":13},[10025,10035],{"nctId":10026,"briefTitle":10027,"status":61,"phases":10028,"primaryCompletion":64,"completion":64,"start":63,"enrollment":10029,"conditions":10030,"interventions":10032},"NCT01010282","Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects",[46],288,[10031],"Dry Eye Syndrome",[10011,10033,10034],"Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear","Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear",{"nctId":10036,"briefTitle":10037,"status":61,"phases":10038,"primaryCompletion":1923,"completion":1923,"start":476,"enrollment":2841,"conditions":10039,"interventions":10040},"NCT00932477","Safety and Tolerability of Artificial Tears in Dry Eye Subjects",[46],[10031],[10041,10042,10011],"Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear","Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear",{"intervention":10033,"totalTrials":780,"cells":10044},{"EARLY_PHASE1":10045,"PHASE1":10047,"PHASE2":10049,"PHASE3":10051,"PHASE4":10053,"NA":10055},{"trials":10046,"activeCount":13},[],{"trials":10048,"activeCount":13},[],{"trials":10050,"activeCount":13},[],{"trials":10052,"activeCount":13},[],{"trials":10054,"activeCount":13},[],{"trials":10056,"activeCount":13},[10057,10061],{"nctId":10026,"briefTitle":10027,"status":61,"phases":10058,"primaryCompletion":64,"completion":64,"start":63,"enrollment":10029,"conditions":10059,"interventions":10060},[46],[10031],[10011,10033,10034],{"nctId":10036,"briefTitle":10037,"status":61,"phases":10062,"primaryCompletion":1923,"completion":1923,"start":476,"enrollment":2841,"conditions":10063,"interventions":10064},[46],[10031],[10041,10042,10011],{"intervention":10066,"totalTrials":780,"cells":10067},"Carboxymethylcellulose and Glycerin based artificial tear",{"EARLY_PHASE1":10068,"PHASE1":10070,"PHASE2":10072,"PHASE3":10074,"PHASE4":10076,"NA":10078},{"trials":10069,"activeCount":13},[],{"trials":10071,"activeCount":13},[],{"trials":10073,"activeCount":13},[],{"trials":10075,"activeCount":13},[],{"trials":10077,"activeCount":13},[],{"trials":10079,"activeCount":13},[10080,10088],{"nctId":10081,"briefTitle":10082,"status":61,"phases":10083,"primaryCompletion":1553,"completion":1553,"start":987,"enrollment":10084,"conditions":10085,"interventions":10086},"NCT00544713","Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery",[46],228,[10031],[10066,10087],"Carboxymethylcellulose",{"nctId":10089,"briefTitle":10090,"status":61,"phases":10091,"primaryCompletion":2607,"completion":2607,"start":630,"enrollment":10092,"conditions":10093,"interventions":10094},"NCT00514852","Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye",[46],316,[10031],[10066,10087],{"intervention":10087,"totalTrials":780,"cells":10096},{"EARLY_PHASE1":10097,"PHASE1":10099,"PHASE2":10101,"PHASE3":10103,"PHASE4":10105,"NA":10107},{"trials":10098,"activeCount":13},[],{"trials":10100,"activeCount":13},[],{"trials":10102,"activeCount":13},[],{"trials":10104,"activeCount":13},[],{"trials":10106,"activeCount":13},[],{"trials":10108,"activeCount":13},[10109,10113],{"nctId":10081,"briefTitle":10082,"status":61,"phases":10110,"primaryCompletion":1553,"completion":1553,"start":987,"enrollment":10084,"conditions":10111,"interventions":10112},[46],[10031],[10066,10087],{"nctId":10089,"briefTitle":10090,"status":61,"phases":10114,"primaryCompletion":2607,"completion":2607,"start":630,"enrollment":10092,"conditions":10115,"interventions":10116},[46],[10031],[10066,10087],{"intervention":10118,"totalTrials":780,"cells":10119},"dexamethasone 700 ㎍ intravitreal implant",{"EARLY_PHASE1":10120,"PHASE1":10122,"PHASE2":10124,"PHASE3":10126,"PHASE4":10128,"NA":10130},{"trials":10121,"activeCount":13},[],{"trials":10123,"activeCount":13},[],{"trials":10125,"activeCount":13},[],{"trials":10127,"activeCount":13},[],{"trials":10129,"activeCount":13},[],{"trials":10131,"activeCount":13},[10132,10139],{"nctId":10133,"briefTitle":10134,"status":61,"phases":10135,"primaryCompletion":139,"completion":139,"start":466,"enrollment":10136,"conditions":10137,"interventions":10138},"NCT01976650","Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea",[],724,[175],[10118],{"nctId":10140,"briefTitle":10141,"status":61,"phases":10142,"primaryCompletion":10143,"completion":10143,"start":109,"enrollment":10144,"conditions":10145,"interventions":10146},"NCT02188173","An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)",[],"2016-05",200,[29],[10118],{"intervention":3161,"totalTrials":780,"cells":10148},{"EARLY_PHASE1":10149,"PHASE1":10151,"PHASE2":10153,"PHASE3":10155,"PHASE4":10161,"NA":10163},{"trials":10150,"activeCount":13},[],{"trials":10152,"activeCount":13},[],{"trials":10154,"activeCount":13},[],{"trials":10156,"activeCount":13},[10157],{"nctId":3153,"briefTitle":3154,"status":75,"phases":10158,"primaryCompletion":796,"completion":796,"start":3156,"enrollment":3157,"conditions":10159,"interventions":10160},[44],[20],[3160,3161,3120],{"trials":10162,"activeCount":13},[],{"trials":10164,"activeCount":13},[10165],{"nctId":10166,"briefTitle":10167,"status":61,"phases":10168,"primaryCompletion":3156,"completion":3156,"start":4744,"enrollment":10169,"conditions":10170,"interventions":10171},"NCT01229462","Safety and Efficacy of Brimonidine Tartrate\u002FTimolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",[46],238,[20,17],[10172,10173,3161],"brimonidine tartrate\u002Ftimolol fixed combination ophthalmic solution","brimonidine tartrate ophthalmic solution",{"intervention":10175,"totalTrials":10,"cells":10176},"Deoxycholic acid",{"EARLY_PHASE1":10177,"PHASE1":10179,"PHASE2":10181,"PHASE3":10183,"PHASE4":10185,"NA":10187},{"trials":10178,"activeCount":13},[],{"trials":10180,"activeCount":13},[],{"trials":10182,"activeCount":13},[],{"trials":10184,"activeCount":13},[],{"trials":10186,"activeCount":13},[],{"trials":10188,"activeCount":13},[10189],{"nctId":10190,"briefTitle":10191,"status":61,"phases":10192,"primaryCompletion":10193,"completion":10193,"start":1058,"enrollment":10194,"conditions":10195,"interventions":10197},"NCT03682471","Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)",[],"2013-12-13",201,[10196],"Subcutaneous Fat",[10175],{"intervention":10199,"totalTrials":10,"cells":10200},"Any Fixed Combination Therapy",{"EARLY_PHASE1":10201,"PHASE1":10203,"PHASE2":10205,"PHASE3":10207,"PHASE4":10209,"NA":10211},{"trials":10202,"activeCount":13},[],{"trials":10204,"activeCount":13},[],{"trials":10206,"activeCount":13},[],{"trials":10208,"activeCount":13},[],{"trials":10210,"activeCount":13},[],{"trials":10212,"activeCount":13},[10213],{"nctId":10214,"briefTitle":10215,"status":61,"phases":10216,"primaryCompletion":7529,"completion":7529,"start":477,"enrollment":10217,"conditions":10218,"interventions":10219},"NCT01637246","A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy",[],4385,[23,17],[10199],{"intervention":10221,"totalTrials":10,"cells":10222},"Fixed combination 0.3 mg bimatoprost and 5 mg timolol",{"EARLY_PHASE1":10223,"PHASE1":10225,"PHASE2":10227,"PHASE3":10229,"PHASE4":10231,"NA":10233},{"trials":10224,"activeCount":13},[],{"trials":10226,"activeCount":13},[],{"trials":10228,"activeCount":13},[],{"trials":10230,"activeCount":13},[],{"trials":10232,"activeCount":13},[],{"trials":10234,"activeCount":13},[10235],{"nctId":10236,"briefTitle":10237,"status":61,"phases":10238,"primaryCompletion":204,"completion":204,"start":5631,"enrollment":10239,"conditions":10240,"interventions":10241},"NCT01628601","GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy",[],392,[23,17],[10221],{"intervention":10243,"totalTrials":10,"cells":10244},"Ganforti",{"EARLY_PHASE1":10245,"PHASE1":10247,"PHASE2":10249,"PHASE3":10251,"PHASE4":10253,"NA":10255},{"trials":10246,"activeCount":13},[],{"trials":10248,"activeCount":13},[],{"trials":10250,"activeCount":13},[],{"trials":10252,"activeCount":13},[],{"trials":10254,"activeCount":13},[],{"trials":10256,"activeCount":13},[10257],{"nctId":10258,"briefTitle":10259,"status":61,"phases":10260,"primaryCompletion":5539,"completion":487,"start":5539,"enrollment":3180,"conditions":10261,"interventions":10263},"NCT01737853","Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)",[],[10262],"Glaucoma Primary Open Angle",[10243,10264],"Krytantek",{"intervention":10264,"totalTrials":10,"cells":10266},{"EARLY_PHASE1":10267,"PHASE1":10269,"PHASE2":10271,"PHASE3":10273,"PHASE4":10275,"NA":10277},{"trials":10268,"activeCount":13},[],{"trials":10270,"activeCount":13},[],{"trials":10272,"activeCount":13},[],{"trials":10274,"activeCount":13},[],{"trials":10276,"activeCount":13},[],{"trials":10278,"activeCount":13},[10279],{"nctId":10258,"briefTitle":10259,"status":61,"phases":10280,"primaryCompletion":5539,"completion":487,"start":5539,"enrollment":3180,"conditions":10281,"interventions":10282},[],[10262],[10243,10264],{"intervention":10284,"totalTrials":10,"cells":10285},"bimatoprost\u002Ftimolol",{"EARLY_PHASE1":10286,"PHASE1":10288,"PHASE2":10290,"PHASE3":10292,"PHASE4":10294,"NA":10296},{"trials":10287,"activeCount":13},[],{"trials":10289,"activeCount":13},[],{"trials":10291,"activeCount":13},[],{"trials":10293,"activeCount":13},[],{"trials":10295,"activeCount":13},[],{"trials":10297,"activeCount":13},[10298],{"nctId":10299,"briefTitle":10300,"status":61,"phases":10301,"primaryCompletion":10302,"completion":10302,"start":476,"enrollment":10303,"conditions":10304,"interventions":10305},"NCT01976624","Safety and Efficacy of Bimatoprost\u002FTimolol (Ganfort®) Ophthalmic Solution in Korea",[],"2014-01",756,[23,17],[10284],{"intervention":10307,"totalTrials":10,"cells":10308},"OPTIVE PLUS®",{"EARLY_PHASE1":10309,"PHASE1":10311,"PHASE2":10313,"PHASE3":10315,"PHASE4":10317,"NA":10319},{"trials":10310,"activeCount":13},[],{"trials":10312,"activeCount":13},[],{"trials":10314,"activeCount":13},[],{"trials":10316,"activeCount":13},[],{"trials":10318,"activeCount":13},[],{"trials":10320,"activeCount":13},[10321],{"nctId":10322,"briefTitle":10323,"status":61,"phases":10324,"primaryCompletion":6901,"completion":6901,"start":393,"enrollment":10325,"conditions":10326,"interventions":10327},"NCT01711424","An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease",[],1209,[26],[10307],{"intervention":10034,"totalTrials":10,"cells":10329},{"EARLY_PHASE1":10330,"PHASE1":10332,"PHASE2":10334,"PHASE3":10336,"PHASE4":10338,"NA":10340},{"trials":10331,"activeCount":13},[],{"trials":10333,"activeCount":13},[],{"trials":10335,"activeCount":13},[],{"trials":10337,"activeCount":13},[],{"trials":10339,"activeCount":13},[],{"trials":10341,"activeCount":13},[10342],{"nctId":10026,"briefTitle":10027,"status":61,"phases":10343,"primaryCompletion":64,"completion":64,"start":63,"enrollment":10029,"conditions":10344,"interventions":10345},[46],[10031],[10011,10033,10034],{"intervention":10347,"totalTrials":10,"cells":10348},"Fixed Combination Bimatoprost and Timolol",{"EARLY_PHASE1":10349,"PHASE1":10351,"PHASE2":10353,"PHASE3":10355,"PHASE4":10357,"NA":10359},{"trials":10350,"activeCount":13},[],{"trials":10352,"activeCount":13},[],{"trials":10354,"activeCount":13},[],{"trials":10356,"activeCount":13},[],{"trials":10358,"activeCount":13},[],{"trials":10360,"activeCount":13},[10361],{"nctId":10362,"briefTitle":10363,"status":61,"phases":10364,"primaryCompletion":10365,"completion":10365,"start":10366,"enrollment":10367,"conditions":10368,"interventions":10369},"NCT01999348","A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting",[],"2014-12-19","2013-11-25",1553,[9742,17],[10347],{"intervention":10371,"totalTrials":10,"cells":10372},"brimonidine tartrate\u002Ftimolol maleate Ophthalmic Solution",{"EARLY_PHASE1":10373,"PHASE1":10375,"PHASE2":10377,"PHASE3":10379,"PHASE4":10381,"NA":10383},{"trials":10374,"activeCount":13},[],{"trials":10376,"activeCount":13},[],{"trials":10378,"activeCount":13},[],{"trials":10380,"activeCount":13},[],{"trials":10382,"activeCount":13},[],{"trials":10384,"activeCount":13},[10385],{"nctId":10386,"briefTitle":10387,"status":61,"phases":10388,"primaryCompletion":7529,"completion":7529,"start":3545,"enrollment":10389,"conditions":10390,"interventions":10391},"NCT01987752","Safety and Efficacy of Combigan® Ophthalmic Solution in Korea",[],732,[23,17],[10371],{"intervention":10393,"totalTrials":10,"cells":10394},"Prostaglandin Analogue -Containing IOP-Lowering Therapy",{"EARLY_PHASE1":10395,"PHASE1":10397,"PHASE2":10399,"PHASE3":10401,"PHASE4":10403,"NA":10405},{"trials":10396,"activeCount":13},[],{"trials":10398,"activeCount":13},[],{"trials":10400,"activeCount":13},[],{"trials":10402,"activeCount":13},[],{"trials":10404,"activeCount":13},[],{"trials":10406,"activeCount":13},[10407],{"nctId":10408,"briefTitle":10409,"status":61,"phases":10410,"primaryCompletion":10411,"completion":10411,"start":10412,"enrollment":10413,"conditions":10414,"interventions":10415},"NCT01735214","An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments",[],"2014-04-10","2013-03-07",358,[23,17],[10393],{"intervention":10417,"totalTrials":10,"cells":10418},"Bimatoprost Ophthalmic Solution",{"EARLY_PHASE1":10419,"PHASE1":10421,"PHASE2":10423,"PHASE3":10425,"PHASE4":10427,"NA":10429},{"trials":10420,"activeCount":13},[],{"trials":10422,"activeCount":13},[],{"trials":10424,"activeCount":13},[],{"trials":10426,"activeCount":13},[],{"trials":10428,"activeCount":13},[],{"trials":10430,"activeCount":13},[10431],{"nctId":10432,"briefTitle":10433,"status":61,"phases":10434,"primaryCompletion":10435,"completion":10435,"start":10436,"enrollment":10437,"conditions":10438,"interventions":10439},"NCT01853085","A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons",[],"2014-03-01","2013-04-01",1830,[9742,17],[10417],{"intervention":10441,"totalTrials":10,"cells":10442},"bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%",{"EARLY_PHASE1":10443,"PHASE1":10445,"PHASE2":10447,"PHASE3":10449,"PHASE4":10451,"NA":10453},{"trials":10444,"activeCount":13},[],{"trials":10446,"activeCount":13},[],{"trials":10448,"activeCount":13},[],{"trials":10450,"activeCount":13},[],{"trials":10452,"activeCount":13},[],{"trials":10454,"activeCount":13},[10455],{"nctId":10456,"briefTitle":10457,"status":61,"phases":10458,"primaryCompletion":987,"completion":1923,"start":3103,"enrollment":10459,"conditions":10460,"interventions":10461},"NCT00716742","Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)",[],1099,[1731,17],[10441],{"intervention":10463,"totalTrials":10,"cells":10464},"Alcaftadine Ophthalmic Solution 0.25%",{"EARLY_PHASE1":10465,"PHASE1":10467,"PHASE2":10469,"PHASE3":10471,"PHASE4":10473,"NA":10475},{"trials":10466,"activeCount":13},[],{"trials":10468,"activeCount":13},[],{"trials":10470,"activeCount":13},[],{"trials":10472,"activeCount":13},[],{"trials":10474,"activeCount":13},[],{"trials":10476,"activeCount":13},[10477],{"nctId":10478,"briefTitle":10479,"status":61,"phases":10480,"primaryCompletion":10481,"completion":10481,"start":10482,"enrollment":10483,"conditions":10484,"interventions":10485},"NCT02555761","Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea",[],"2018-03-19","2015-10-19",3423,[1234],[10463],{"intervention":10042,"totalTrials":10,"cells":10487},{"EARLY_PHASE1":10488,"PHASE1":10490,"PHASE2":10492,"PHASE3":10494,"PHASE4":10496,"NA":10498},{"trials":10489,"activeCount":13},[],{"trials":10491,"activeCount":13},[],{"trials":10493,"activeCount":13},[],{"trials":10495,"activeCount":13},[],{"trials":10497,"activeCount":13},[],{"trials":10499,"activeCount":13},[10500],{"nctId":10036,"briefTitle":10037,"status":61,"phases":10501,"primaryCompletion":1923,"completion":1923,"start":476,"enrollment":2841,"conditions":10502,"interventions":10503},[46],[10031],[10041,10042,10011],{"intervention":10505,"totalTrials":10,"cells":10506},"Bimatoprost cutaneous solution 0.03%",{"EARLY_PHASE1":10507,"PHASE1":10509,"PHASE2":10511,"PHASE3":10513,"PHASE4":10515,"NA":10517},{"trials":10508,"activeCount":13},[],{"trials":10510,"activeCount":13},[],{"trials":10512,"activeCount":13},[],{"trials":10514,"activeCount":13},[],{"trials":10516,"activeCount":13},[],{"trials":10518,"activeCount":13},[10519],{"nctId":10520,"briefTitle":10521,"status":61,"phases":10522,"primaryCompletion":10523,"completion":10523,"start":10524,"enrollment":10525,"conditions":10526,"interventions":10527},"NCT02505776","Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan",[],"2018-05-21","2014-12-08",1699,[311],[10505],{"intervention":10529,"totalTrials":10,"cells":10530},"cyclosporine ophthalmic emulsion 0.05%, artificial tears",{"EARLY_PHASE1":10531,"PHASE1":10533,"PHASE2":10535,"PHASE3":10537,"PHASE4":10539,"NA":10541},{"trials":10532,"activeCount":13},[],{"trials":10534,"activeCount":13},[],{"trials":10536,"activeCount":13},[],{"trials":10538,"activeCount":13},[],{"trials":10540,"activeCount":13},[],{"trials":10542,"activeCount":13},[10543],{"nctId":10544,"briefTitle":10545,"status":61,"phases":10546,"primaryCompletion":854,"completion":863,"start":3103,"enrollment":10547,"conditions":10548,"interventions":10549},"NCT00717418","Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease",[],781,[754],[10529],{"intervention":10551,"totalTrials":10,"cells":10552},"4% Hydroquinone Topical Cream",{"EARLY_PHASE1":10553,"PHASE1":10555,"PHASE2":10557,"PHASE3":10559,"PHASE4":10561,"NA":10563},{"trials":10554,"activeCount":13},[],{"trials":10556,"activeCount":13},[],{"trials":10558,"activeCount":13},[],{"trials":10560,"activeCount":13},[],{"trials":10562,"activeCount":13},[],{"trials":10564,"activeCount":13},[10565],{"nctId":10566,"briefTitle":10567,"status":61,"phases":10568,"primaryCompletion":9584,"completion":9584,"start":249,"enrollment":7984,"conditions":10569,"interventions":10571},"NCT02977507","Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma",[46],[10570],"Melasma",[10551],{"intervention":10172,"totalTrials":10,"cells":10573},{"EARLY_PHASE1":10574,"PHASE1":10576,"PHASE2":10578,"PHASE3":10580,"PHASE4":10582,"NA":10584},{"trials":10575,"activeCount":13},[],{"trials":10577,"activeCount":13},[],{"trials":10579,"activeCount":13},[],{"trials":10581,"activeCount":13},[],{"trials":10583,"activeCount":13},[],{"trials":10585,"activeCount":13},[10586],{"nctId":10166,"briefTitle":10167,"status":61,"phases":10587,"primaryCompletion":3156,"completion":3156,"start":4744,"enrollment":10169,"conditions":10588,"interventions":10589},[46],[20,17],[10172,10173,3161],{"intervention":10173,"totalTrials":10,"cells":10591},{"EARLY_PHASE1":10592,"PHASE1":10594,"PHASE2":10596,"PHASE3":10598,"PHASE4":10600,"NA":10602},{"trials":10593,"activeCount":13},[],{"trials":10595,"activeCount":13},[],{"trials":10597,"activeCount":13},[],{"trials":10599,"activeCount":13},[],{"trials":10601,"activeCount":13},[],{"trials":10603,"activeCount":13},[10604],{"nctId":10166,"briefTitle":10167,"status":61,"phases":10605,"primaryCompletion":3156,"completion":3156,"start":4744,"enrollment":10169,"conditions":10606,"interventions":10607},[46],[20,17],[10172,10173,3161],{"intervention":10609,"totalTrials":10,"cells":10610},"dexamethasone 700 ug intravitreal implant",{"EARLY_PHASE1":10611,"PHASE1":10613,"PHASE2":10615,"PHASE3":10617,"PHASE4":10619,"NA":10621},{"trials":10612,"activeCount":13},[],{"trials":10614,"activeCount":13},[],{"trials":10616,"activeCount":13},[],{"trials":10618,"activeCount":13},[],{"trials":10620,"activeCount":13},[],{"trials":10622,"activeCount":13},[10623],{"nctId":10624,"briefTitle":10625,"status":61,"phases":10626,"primaryCompletion":127,"completion":368,"start":10627,"enrollment":3233,"conditions":10628,"interventions":10629},"NCT01571557","A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)",[],"2012-04-30",[29,175],[10609],{"intervention":10631,"totalTrials":10,"cells":10632},"Relestat Ophthalmic Solution 0.05%",{"EARLY_PHASE1":10633,"PHASE1":10635,"PHASE2":10637,"PHASE3":10639,"PHASE4":10641,"NA":10643},{"trials":10634,"activeCount":13},[],{"trials":10636,"activeCount":13},[],{"trials":10638,"activeCount":13},[],{"trials":10640,"activeCount":13},[],{"trials":10642,"activeCount":13},[],{"trials":10644,"activeCount":13},[10645],{"nctId":10646,"briefTitle":10647,"status":61,"phases":10648,"primaryCompletion":393,"completion":393,"start":3545,"enrollment":10649,"conditions":10650,"interventions":10651},"NCT01987765","Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea",[],847,[1234],[10631],{"intervention":10653,"totalTrials":10,"cells":10654},"0.03% Bimatoprost\u002F0.5% Timolol Ophthalmic Solution",{"EARLY_PHASE1":10655,"PHASE1":10657,"PHASE2":10659,"PHASE3":10661,"PHASE4":10663,"NA":10665},{"trials":10656,"activeCount":13},[],{"trials":10658,"activeCount":13},[],{"trials":10660,"activeCount":13},[],{"trials":10662,"activeCount":13},[],{"trials":10664,"activeCount":13},[],{"trials":10666,"activeCount":13},[10667],{"nctId":10668,"briefTitle":10669,"status":61,"phases":10670,"primaryCompletion":3912,"completion":3912,"start":8961,"enrollment":8952,"conditions":10671,"interventions":10672},"NCT01068964","Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension",[46],[1532,17],[10653,10673],"0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution",{"intervention":10673,"totalTrials":10,"cells":10675},{"EARLY_PHASE1":10676,"PHASE1":10678,"PHASE2":10680,"PHASE3":10682,"PHASE4":10684,"NA":10686},{"trials":10677,"activeCount":13},[],{"trials":10679,"activeCount":13},[],{"trials":10681,"activeCount":13},[],{"trials":10683,"activeCount":13},[],{"trials":10685,"activeCount":13},[],{"trials":10687,"activeCount":13},[10688],{"nctId":10668,"briefTitle":10669,"status":61,"phases":10689,"primaryCompletion":3912,"completion":3912,"start":8961,"enrollment":8952,"conditions":10690,"interventions":10691},[46],[1532,17],[10653,10673],{"intervention":10693,"totalTrials":10,"cells":10694},"Loteprednol etabonate ophthalmic suspension 0.5%",{"EARLY_PHASE1":10695,"PHASE1":10697,"PHASE2":10699,"PHASE3":10701,"PHASE4":10703,"NA":10705},{"trials":10696,"activeCount":13},[],{"trials":10698,"activeCount":13},[],{"trials":10700,"activeCount":13},[],{"trials":10702,"activeCount":13},[],{"trials":10704,"activeCount":13},[],{"trials":10706,"activeCount":13},[10707],{"nctId":10708,"briefTitle":10709,"status":61,"phases":10710,"primaryCompletion":897,"completion":897,"start":3545,"enrollment":1555,"conditions":10711,"interventions":10712},"NCT00834171","A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol\u002FTobramycin",[],[17],[10693,10713],"Loteprednol etabonate (0.5%) and tobramycin (0.3%).",{"intervention":10713,"totalTrials":10,"cells":10715},{"EARLY_PHASE1":10716,"PHASE1":10718,"PHASE2":10720,"PHASE3":10722,"PHASE4":10724,"NA":10726},{"trials":10717,"activeCount":13},[],{"trials":10719,"activeCount":13},[],{"trials":10721,"activeCount":13},[],{"trials":10723,"activeCount":13},[],{"trials":10725,"activeCount":13},[],{"trials":10727,"activeCount":13},[10728],{"nctId":10708,"briefTitle":10709,"status":61,"phases":10729,"primaryCompletion":897,"completion":897,"start":3545,"enrollment":1555,"conditions":10730,"interventions":10731},[],[17],[10693,10713],{"intervention":10733,"totalTrials":10,"cells":10734},"Anti-VEGF",{"EARLY_PHASE1":10735,"PHASE1":10737,"PHASE2":10739,"PHASE3":10741,"PHASE4":10743,"NA":10745},{"trials":10736,"activeCount":13},[],{"trials":10738,"activeCount":13},[],{"trials":10740,"activeCount":13},[],{"trials":10742,"activeCount":13},[],{"trials":10744,"activeCount":13},[],{"trials":10746,"activeCount":13},[10747],{"nctId":10748,"briefTitle":10749,"status":61,"phases":10750,"primaryCompletion":10751,"completion":10751,"start":10752,"enrollment":3517,"conditions":10753,"interventions":10754},"NCT01918371","A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema",[],"2014-09-04","2013-08-02",[175,29],[10733],{"intervention":10756,"totalTrials":10,"cells":10757},"BELKYRA Inj.",{"EARLY_PHASE1":10758,"PHASE1":10760,"PHASE2":10762,"PHASE3":10764,"PHASE4":10766,"NA":10768},{"trials":10759,"activeCount":13},[],{"trials":10761,"activeCount":13},[],{"trials":10763,"activeCount":13},[],{"trials":10765,"activeCount":13},[],{"trials":10767,"activeCount":13},[],{"trials":10769,"activeCount":13},[10770],{"nctId":10771,"briefTitle":10772,"status":75,"phases":10773,"primaryCompletion":10774,"completion":10774,"start":10775,"enrollment":358,"conditions":10776,"interventions":10778},"NCT03691415","Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea",[],"2020-04-14","2018-09-07",[10777],"Submental Fullness",[10756],{"intervention":10780,"totalTrials":10,"cells":10781},"dexamethasone 700 μg intravitreal implant",{"EARLY_PHASE1":10782,"PHASE1":10784,"PHASE2":10786,"PHASE3":10788,"PHASE4":10790,"NA":10792},{"trials":10783,"activeCount":13},[],{"trials":10785,"activeCount":13},[],{"trials":10787,"activeCount":13},[],{"trials":10789,"activeCount":13},[],{"trials":10791,"activeCount":13},[],{"trials":10793,"activeCount":13},[10794],{"nctId":10795,"briefTitle":10796,"status":61,"phases":10797,"primaryCompletion":8324,"completion":8324,"start":9752,"enrollment":10798,"conditions":10799,"interventions":10800},"NCT01539577","A Long-Term Safety Study of OZURDEX® in Clinical Practice",[],875,[175,29,7557],[10780]]